
<html lang="en"     class="pb-page"  data-request-id="e14b474b-80b9-4f0f-a8f5-bfa1bca951eb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-22;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b00796;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)" /></meta><meta name="dc.Creator" content="F. Anthony  Romero" /></meta><meta name="dc.Creator" content="Jeremy  Murray" /></meta><meta name="dc.Creator" content="Kwong Wah  Lai" /></meta><meta name="dc.Creator" content="Vickie  Tsui" /></meta><meta name="dc.Creator" content="Brian K.  Albrecht" /></meta><meta name="dc.Creator" content="Le  An" /></meta><meta name="dc.Creator" content="Maureen H.  Beresini" /></meta><meta name="dc.Creator" content="Gladys  de Leon Boenig" /></meta><meta name="dc.Creator" content="Sarah M.  Bronner" /></meta><meta name="dc.Creator" content="Emily W.  Chan" /></meta><meta name="dc.Creator" content="Kevin X.  Chen" /></meta><meta name="dc.Creator" content="Zhongguo  Chen" /></meta><meta name="dc.Creator" content="Edna F.  Choo" /></meta><meta name="dc.Creator" content="Kyle  Clagg" /></meta><meta name="dc.Creator" content="Kevin  Clark" /></meta><meta name="dc.Creator" content="Terry D.  Crawford" /></meta><meta name="dc.Creator" content="Patrick  Cyr" /></meta><meta name="dc.Creator" content="Denise  de Almeida Nagata" /></meta><meta name="dc.Creator" content="Karen E.  Gascoigne" /></meta><meta name="dc.Creator" content="Jane L.  Grogan" /></meta><meta name="dc.Creator" content="Georgia  Hatzivassiliou" /></meta><meta name="dc.Creator" content="Wei  Huang" /></meta><meta name="dc.Creator" content="Thomas L.  Hunsaker" /></meta><meta name="dc.Creator" content="Susan  Kaufman" /></meta><meta name="dc.Creator" content="Stefan G.  Koenig" /></meta><meta name="dc.Creator" content="Ruina  Li" /></meta><meta name="dc.Creator" content="Yingjie  Li" /></meta><meta name="dc.Creator" content="Xiaorong  Liang" /></meta><meta name="dc.Creator" content="Jiangpeng  Liao" /></meta><meta name="dc.Creator" content="Wenfeng  Liu" /></meta><meta name="dc.Creator" content="Justin  Ly" /></meta><meta name="dc.Creator" content="Jonathan  Maher" /></meta><meta name="dc.Creator" content="Colin  Masui" /></meta><meta name="dc.Creator" content="Mark  Merchant" /></meta><meta name="dc.Creator" content="Yingqing  Ran" /></meta><meta name="dc.Creator" content="Alexander M.  Taylor" /></meta><meta name="dc.Creator" content="John  Wai" /></meta><meta name="dc.Creator" content="Fei  Wang" /></meta><meta name="dc.Creator" content="Xiaocang  Wei" /></meta><meta name="dc.Creator" content="Dong  Yu" /></meta><meta name="dc.Creator" content="Bing-Yan  Zhu" /></meta><meta name="dc.Creator" content="Xiaoyu  Zhu" /></meta><meta name="dc.Creator" content="Steven  Magnuson" /></meta><meta name="dc.Description" content="Inhibition of the bromodomain of the transcriptional regulator CBP/P300 is an especially interesting new therapeutic approach in oncology. We recently disclosed in vivo chemical tool 1 (GNE-272) fo..." /></meta><meta name="Description" content="Inhibition of the bromodomain of the transcriptional regulator CBP/P300 is an especially interesting new therapeutic approach in oncology. We recently disclosed in vivo chemical tool 1 (GNE-272) fo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 21, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00796" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00796" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00796" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00796" /></link>
        
    
    

<title>GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00796" /></meta><meta property="og:title" content="GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0025.jpeg" /></meta><meta property="og:description" content="Inhibition of the bromodomain of the transcriptional regulator CBP/P300 is an especially interesting new therapeutic approach in oncology. We recently disclosed in vivo chemical tool 1 (GNE-272) for the bromodomain of CBP that was moderately potent and selective over BRD4(1). In pursuit of a more potent and selective CBP inhibitor, we used structure-based design. Constraining the aniline of 1 into a tetrahydroquinoline motif maintained potency and increased selectivity 2-fold. Structure–activity relationship studies coupled with further structure-based design targeting the LPF shelf, BC loop, and KAc regions allowed us to significantly increase potency and selectivity, resulting in the identification of non-CNS penetrant 19 (GNE-781, TR-FRET IC50 = 0.94 nM, BRET IC50 = 6.2 nM; BRD4(1) IC50 = 5100 nΜ) that maintained good in vivo PK properties in multiple species. Compound 19 displays antitumor activity in an AML tumor model and was also shown to decrease Foxp3 transcript levels in a dose dependent manner." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00796"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00796">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00796&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00796&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00796&amp;href=/doi/10.1021/acs.jmedchem.7b00796" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 9162-9183</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00797" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00941" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=F.+Anthony++Romero">F. Anthony Romero</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-7917-1459" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeremy++Murray">Jeremy Murray</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kwong+Wah++Lai">Kwong Wah Lai</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vickie++Tsui">Vickie Tsui</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+K.++Albrecht">Brian K. Albrecht</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Le++An">Le An</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maureen+H.++Beresini">Maureen H. Beresini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gladys++de+Leon+Boenig">Gladys de Leon Boenig</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+M.++Bronner">Sarah M. Bronner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emily+W.++Chan">Emily W. Chan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+X.++Chen">Kevin X. Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhongguo++Chen">Zhongguo Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Edna+F.++Choo">Edna F. Choo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-4200-8302" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kyle++Clagg">Kyle Clagg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Clark">Kevin Clark</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Terry+D.++Crawford">Terry D. Crawford</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-4663-4116" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Cyr">Patrick Cyr</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-5320-3483" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Denise++de+Almeida+Nagata">Denise de Almeida Nagata</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen+E.++Gascoigne">Karen E. Gascoigne</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jane+L.++Grogan">Jane L. Grogan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Georgia++Hatzivassiliou">Georgia Hatzivassiliou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Huang">Wei Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+L.++Hunsaker">Thomas L. Hunsaker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Kaufman">Susan Kaufman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan+G.++Koenig">Stefan G. Koenig</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-1878-614X" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ruina++Li">Ruina Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yingjie++Li">Yingjie Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaorong++Liang">Xiaorong Liang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiangpeng++Liao">Jiangpeng Liao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenfeng++Liu">Wenfeng Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Justin++Ly">Justin Ly</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan++Maher">Jonathan Maher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Colin++Masui">Colin Masui</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Merchant">Mark Merchant</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yingqing++Ran">Yingqing Ran</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander+M.++Taylor">Alexander M. Taylor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Wai">John Wai</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fei++Wang">Fei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaocang++Wei">Xiaocang Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dong++Yu">Dong Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bing-Yan++Zhu">Bing-Yan Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyu++Zhu">Xiaoyu Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Magnuson">Steven Magnuson</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Wuxi Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s Republic of China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Constellation Pharmaceuticals, Inc., 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States</span></div><div class="corresp-info"><strong>*</strong>For F.A.R. phone, (858) 349-6055; E-mail, <a href="/cdn-cgi/l/email-protection#97f6f9e3fff8f9eeb9e5f8faf2e5f8d7e2f9fee3eef5fef8e3f2f4fff9f8fbf8f0eeb9f4f8fa"><span class="__cf_email__" data-cfemail="cdaca3b9a5a2a3b4e3bfa2a0a8bfa28db8a3a4b9b4afa4a2b9a8aea5a3a2a1a2aab4e3aea2a0">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For S.M. E-mail, <a href="/cdn-cgi/l/email-protection#a5c8c4c2cbd0d6cacb8bd6d1c0d3c0cbe5c2c0cbc08bc6cac8"><span class="__cf_email__" data-cfemail="deb3bfb9b0abadb1b0f0adaabba8bbb09eb9bbb0bbf0bdb1b3">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00796&amp;href=/doi/10.1021%2Facs.jmedchem.7b00796" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 9162–9183</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 11, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 June 2017</li><li><span class="item_label"><b>Published</b> online</span>21 September 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 November 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00796" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00796</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9162%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DF.%2BAnthony%2BRomero%252C%2BJeremy%2BMurray%252C%2BKwong%2BWah%2BLai%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D22%26contentID%3Dacs.jmedchem.7b00796%26title%3DGNE-781%252C%2BA%2BHighly%2BAdvanced%2BPotent%2Band%2BSelective%2BBromodomain%2BInhibitor%2Bof%2BCyclic%2BAdenosine%2BMonophosphate%2BResponse%2BElement%2BBinding%2BProtein%252C%2BBinding%2BProtein%2B%2528CBP%2529%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9183%26publicationDate%3DNovember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00796"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5458</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">37</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00796" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;F.&quot;,&quot;last_name&quot;:&quot;Anthony Romero&quot;},{&quot;first_name&quot;:&quot;Jeremy&quot;,&quot;last_name&quot;:&quot;Murray&quot;},{&quot;first_name&quot;:&quot;Kwong&quot;,&quot;last_name&quot;:&quot;Wah Lai&quot;},{&quot;first_name&quot;:&quot;Vickie&quot;,&quot;last_name&quot;:&quot;Tsui&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;K. Albrecht&quot;},{&quot;first_name&quot;:&quot;Le&quot;,&quot;last_name&quot;:&quot;An&quot;},{&quot;first_name&quot;:&quot;Maureen&quot;,&quot;last_name&quot;:&quot;H. Beresini&quot;},{&quot;first_name&quot;:&quot;Gladys&quot;,&quot;last_name&quot;:&quot;de Leon Boenig&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;M. Bronner&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;W. Chan&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;X. Chen&quot;},{&quot;first_name&quot;:&quot;Zhongguo&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Edna&quot;,&quot;last_name&quot;:&quot;F. Choo&quot;},{&quot;first_name&quot;:&quot;Kyle&quot;,&quot;last_name&quot;:&quot;Clagg&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Clark&quot;},{&quot;first_name&quot;:&quot;Terry&quot;,&quot;last_name&quot;:&quot;D. Crawford&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Cyr&quot;},{&quot;first_name&quot;:&quot;Denise&quot;,&quot;last_name&quot;:&quot;de Almeida Nagata&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;E. Gascoigne&quot;},{&quot;first_name&quot;:&quot;Jane&quot;,&quot;last_name&quot;:&quot;L. Grogan&quot;},{&quot;first_name&quot;:&quot;Georgia&quot;,&quot;last_name&quot;:&quot;Hatzivassiliou&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;L. Hunsaker&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Kaufman&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;G. Koenig&quot;},{&quot;first_name&quot;:&quot;Ruina&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yingjie&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Xiaorong&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Jiangpeng&quot;,&quot;last_name&quot;:&quot;Liao&quot;},{&quot;first_name&quot;:&quot;Wenfeng&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Justin&quot;,&quot;last_name&quot;:&quot;Ly&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;Maher&quot;},{&quot;first_name&quot;:&quot;Colin&quot;,&quot;last_name&quot;:&quot;Masui&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Merchant&quot;},{&quot;first_name&quot;:&quot;Yingqing&quot;,&quot;last_name&quot;:&quot;Ran&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;M. Taylor&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Wai&quot;},{&quot;first_name&quot;:&quot;Fei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xiaocang&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Dong&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Bing-Yan&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Xiaoyu&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Magnuson&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;9162-9183&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00796&quot;},&quot;abstract&quot;:&quot;Inhibition of the bromodomain of the transcriptional regulator CBP/P300 is an especially interesting new therapeutic approach in oncology. We recently disclosed in vivo chemical tool 1 (GNE-272) for the bromodomain of CBP that was moderately potent and selective over BRD4(1). In pursuit of a more potent and selective CBP inhibitor, we used structure-based design. Constraining the aniline of 1 into a tetrahydroquinoline motif maintained potency and increased selectivity 2-fold. Structure–activity relationship studies coupled with further structure-based design targeting the LPF shelf, BC loop, and KAc regions allowed us to significantly increase potency and selectivity, resulting in the identification of non-CNS penetrant 19 (GNE-781, TR-FRET IC50 = 0.94 nM, BRET IC50 = 6.2 nM; BRD4(1) IC50 = 5100 nΜ) that maintained good in vivo PK properties in multiple species. Compound 19 displays antitumor activity in an AML tumor model and was also shown to decrease Foxp3 transcript levels in a dose dependent manner.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00796&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00796" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00796&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00796" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00796&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00796" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00796&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00796&amp;href=/doi/10.1021/acs.jmedchem.7b00796" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00796" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00796" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00796%26sid%3Dliteratum%253Aachs%26pmid%3D28892380%26genre%3Darticle%26aulast%3DRomero%26date%3D2017%26atitle%3DGNE-781%252C%2BA%2BHighly%2BAdvanced%2BPotent%2Band%2BSelective%2BBromodomain%2BInhibitor%2Bof%2BCyclic%2BAdenosine%2BMonophosphate%2BResponse%2BElement%2BBinding%2BProtein%252C%2BBinding%2BProtein%2B%2528CBP%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D22%26spage%3D9162%26epage%3D9183%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292271" title="Urea">Urea</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/jmcmar.2017.60.issue-22/20171122/jmcmar.2017.60.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibition of the bromodomain of the transcriptional regulator CBP/P300 is an especially interesting new therapeutic approach in oncology. We recently disclosed in vivo chemical tool <b>1</b> (GNE-272) for the bromodomain of CBP that was moderately potent and selective over BRD4(1). In pursuit of a more potent and selective CBP inhibitor, we used structure-based design. Constraining the aniline of <b>1</b> into a tetrahydroquinoline motif maintained potency and increased selectivity 2-fold. Structure–activity relationship studies coupled with further structure-based design targeting the LPF shelf, BC loop, and KAc regions allowed us to significantly increase potency and selectivity, resulting in the identification of non-CNS penetrant <b>19</b> (GNE-781, TR-FRET IC<sub>50</sub> = 0.94 nM, BRET IC<sub>50</sub> = 6.2 nM; BRD4(1) IC<sub>50</sub> = 5100 nΜ) that maintained good in vivo PK properties in multiple species. Compound <b>19</b> displays antitumor activity in an AML tumor model and was also shown to decrease Foxp3 transcript levels in a dose dependent manner.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45645" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45645" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The histone acetyl transferase (HAT) cAMP response element binding protein, binding protein (CREBBP, CBP), and highly homologous paralogue, adenoviral E1A binding protein of 300 kDa (EP300, P300) are large, multidomain proteins that each contain a single bromodomain and contribute to transcriptional regulation.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> CBP/P300 (hereafter together referred to as “CBP”) bind to chromatin via their bromodomain. Once associated with chromatin, CBP modifies chromatin through its HAT activity, leading to the recruitment of various transcriptional proteins to modulate gene expression. CBP has been shown to bind nonhistone proteins and to recognize acetylated p53 at K382 following DNA damage.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> There have been several studies that have implicated CBP in the development, maintenance, or progression of cancer and tumor immunity.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7 ref8">(4-8)</a> Studies have shown that inhibition of the bromodomain of CBP regulates <i>MYC</i><a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> (a regulator gene that plays a role in cell cycle progression and that is amplified in many cancers). Other studies have demonstrated that CBP bromodomain inhibition impairs differentiation of regulatory T cells (T<sub>regs</sub>) and immunosuppressive function.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> To help understand the physiological implications of CBP in disease states, much work has centered around discovering novel chemical tools that inhibit the bromodomain of CBP.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19">(11-19)</a> These studies have revealed that inhibition of the CBP bromodomain is a promising new therapeutic approach in oncology and immuno-oncology.</div><div class="NLM_p">We recently reported an in vivo chemical tool (<b>1</b>, GNE-272, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) as an inhibitor of the bromodomain of CBP that was potent and 650-fold selective over the bromodomain 1 of the bromodomain-containing protein 4 [BRD4(1)] (BET bromodomain surrogate). We demonstrated through in vivo studies that <b>1</b> is able to modulate CBP <i>MYC</i> expression that corresponds with antitumor activity in a <i>MYC</i>-dependent acute myeloid leukemia (AML) model. While <b>1</b> is a promising in vivo tool to investigate CBP biology, we wished to extend our efforts to develop a more drug-like compound with improved cell potency and increased bromodomain selectivity, particularly over the bromodomain and extraterminal (BET) family.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Here we describe the design of <b>19</b> (GNE-781; 3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-<i>N</i>-methyl-1-tetrahydropyran-4-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5-carboxamide), a highly potent and selective CBP inhibitor that is efficacious in a MOLM-16 AML xenograft model. Additionally, in vitro studies show that <b>19</b> reduces FOXP3 (forkhead box P3) transcript levels, confirming earlier studies,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> with a less optimal chemical probe and suggesting that inhibition of the CBP bromodomain may provide a novel small molecule therapeutic approach for cancer immunotherapy.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. In vivo chemical tool <b>1</b> and potency data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Co-crystal structures of <b>1</b> bound to both CBP and BRD4(1) provided insight toward understanding the selectivity preference of this compound for CBP over BRD4(1) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Previously, we have shown that <b>1</b> binds to CBP and BRD4(1) in different conformations.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> While <b>1</b> binds in a lower energy conformation in CBP, this compound binds at a higher energy conformation in BRD4(1) due to a residue difference in the WPF motif: Trp81, Pro82, and Phe83 for BRD4(1), and Leu1109, Pro1110, and Phe1111 for CBP (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Upon binding to BRD4(1), the fluorophenylpyrazole arm of <b>1</b> is pushed into a strained conformation in-plane with the pyrazolopiperidine core to avoid clashing with Trp81.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> With this in mind, we hypothesized that selectivity could be increased further on this scaffold by constraining the aniline nitrogen of <b>1</b> in a bicycle, thus limiting the ability of the fluorophenylpyrazole to become coplanar with the pyrazolopiperidine core in the BRD4(1) binding site. Accordingly, we explored three saturated ring-size analogues (5-, 6-, or 7-membered) of <b>1</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). While indoline <b>2</b> had a slight decrease in CBP potency and selectivity compared to parent <b>1</b>, tetrahydroquinoline (THQ) <b>3</b> maintained CBP potency and improved selectivity by nearly 2-fold. Expanding the ring further to a 7-membered ring (<b>4</b>) resulted in a significant loss in CBP potency, indicating the preferred conformations of the 7-membered ring are not accommodated in the binding site of CBP. We therefore used <b>3</b> as a template from which to further improve potency and selectivity. Because inhibition of the BET family bromodomains produces profound phenotypes, we were particularly focused on selectivity over BRD4(1) (our surrogate for BET bromodomains).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. . (A) A co-crystal structure of <b>1</b> (green) in the CBP bromodomain (yellow, 1.23 Å resolution, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KTX">5KTX</a>) highlighting hydrogen bond interactions between the ligand and receptor. Water molecules are shown as small red spheres. (B) A co-crystal structure of <b>1</b> (green) and BRD4(1) (cyan, 1.14 Å resolution, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KU3">5KU3</a>), highlighting hydrogen bond interactions between the ligand and receptor. Water molecules are shown as small red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Constrained Analogues of <b>1</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0020.gif" alt="" id="GRAPHIC-d215e795-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="."><i>n</i></th><th class="colsep0 rowsep0" align="center" char=".">CBP IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">BRD4(1) IC<sub>50</sub>(nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">fold selectivity<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">12000</td><td class="colsep0 rowsep0" align="char" char=".">387</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">20000</td><td class="colsep0 rowsep0" align="char" char=".">1250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">1800</td><td class="colsep0 rowsep0" align="char" char=".">>20000</td><td class="colsep0 rowsep0" align="char" char=".">>11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">All IC<sub>50</sub> values are reported as the geometric mean from at least two determinations. TR-FRET assay with the isolated CBP or BRD4(1) bromodomain.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Fold selectivity is defined by [BRD4(1) IC<sub>50</sub> (nM)/CBP IC<sub>50</sub> (nM)]</p></div></div></div><div class="NLM_p">We obtained a co-crystal structure of <b>3</b> with the bromodomain of CBP (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). As observed with <b>1</b>, the amide of <b>3</b> binds in the acetylated lysine (KAc) binding site, with the amide carbonyl making a canonical hydrogen bond to Asn1168 and additional water-mediated hydrogen bond interactions to Tyr1125. The pyrazolopiperidine core is sandwiched between the gatekeeper (Val1174) and Leu1120. The THQ ring makes van der Waals interactions with Pro1110 and Leu1120. The <i>N</i>-methylpyrazole packs along the lipophilic surface defined by the LPF shelf (Leu1109, Pro1110, Phe1111). Examination of the <b>3</b>-CBP co-crystal structure revealed several areas in the binding site that could be explored to potentially improve potency. Initially, we examined structure–activity relationships (SAR) targeting Arg1173, the BC loop, and the KAc binding pocket.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. A co-crystal structure of <b>3</b> in the CBP (cyan) bromodomain (yellow, 1.6 Å resolution, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0F">5W0F</a>) displaying important contacts between the ligand and receptor. Water molecules are shown as small red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We sought to improve the affinity of <b>3</b> by making favorable interactions with residues in the LPF shelf and Arg1173 through the introduction of various substituents to the 7-position of the THQ ring (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> To explore potential hydrophobic interactions with the methylene side chain of Arg1173 and to test the feasibility of disrupting the planarity between the <i>N</i>-methyl pyrazole and the phenyl ring of the THQ, methyl (<b>5</b>), chloro (<b>6</b>), and methoxy (<b>7</b>) substitutions were evaluated, resulting in each case in a 3.4–3.7-fold increase in CBP potency. The selectivity of <b>5</b> and <b>6</b> for CBP over BRD4(1) was comparable to parent <b>3</b>, while <b>7</b> had reduced (∼3-fold) selectivity for CBP. To further increase van der Waals interactions with residues in the LPF shelf and potentially interact with the guanidine atoms of Arg1173, fluorine atoms were added to the 7-methyl of <b>5</b>. Notably, difluoro <b>8</b> demonstrated an 11-fold increase in CBP inhibitory potency compared to <b>3</b> and exhibited selectivity (BRD4/CBP) substantially exceeding that of <b>3</b>. Additionally, <b>8</b> had significantly improved cell potency (CBP BRET IC<sub>50</sub> = 37 nM). Trifluoro analogue <b>9</b> was also quite potent but had lower selectivity compared to <b>8</b>. While <b>9</b> was potentially an interesting compound itself to follow up, we chose <b>8</b> to further examine SAR because it had a more favorable lipophilic ligand efficiency (cLogP<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> = 2.1; LLE<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> = 6.9) compared to <b>9</b> (cLogP = 3.6; LLE = 5.4). To further understand the increased CBP potency of <b>8</b>, we obtained a co-crystal structure of <b>8</b> and the CBP bromodomain (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). The crystal structure revealed that while <b>8</b> had a similar binding mode compared to <b>3</b>, additional favorable dipolar interactions between the partial negative charge on the fluorines of the 7-difluoromethyl and the positively charged guanidine on Arg1173 were observed. Relative to <b>3</b>, the <i>N</i>-methylpyrazole is rotated and lies out of plane by ∼30°, as expected due to the CF<sub>2</sub>H substitution (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_001.pdf" class="ext-link">Supporting Information</a> for torsion scan plot). As a result, the <i>N</i>-methylpyrazole sits in a shallow crevice on the surface of CBP that is formed by the side chains of Leu1109, Val1174, and Phe1177 of the LPF shelf and the Cβ of Arg1173.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Substitution at the 7-Position of the THQ</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0021.gif" alt="" id="GRAPHIC-d215e1059-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">CBP IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">BRD4(1) IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">CBP BRET IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">fold selectivity<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">20000</td><td class="colsep0 rowsep0" align="char" char=".">320</td><td class="colsep0 rowsep0" align="char" char=".">1250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="char" char=".">7300</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">1659</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">4800</td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="char" char=".">1116</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">2200</td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">468</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">CF<sub>2</sub>H</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">5600</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">4000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">4400</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">2933</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">All IC<sub>50</sub> values are reported as the geometric mean from at least two determinations.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">BRET assay in HEK293 cells transiently transfected with CBP-Nanoluc and histone H3.3-Halo tag constructs.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Fold selectivity is defined by [BRD4(1) IC<sub>50</sub> (nM)/CBP IC<sub>50</sub> (nM)].</p></div></div></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Co-crystal structure of <b>8</b> (orange) in the CBP bromodomain (yellow, 1.43 Å resolution, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0I">5W0I</a>) displaying important contacts between the ligand and receptor. Water molecules are shown as small red spheres. (B) The solvent accessible surface of the CBP bromodomain colored to highlight hydrophobicity and charge where hydrocarbon groups are white, atoms with a partial negative charge are red, and atoms with partial positive charge are blue. Bound ligand <b>8</b> is shown in stick representation (orange). Water molecules are shown as small red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further inspection of the co-crystal structure of <b>8</b> and CBP suggested that we could explore N1-substitution of the pyrazolopiperidine might increase hydrophobic interactions with residues in the BC and ZA loops. <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B displays the surface of the protein around the THF moiety of <b>8</b> and indicates that expanding the THF to a 6-membered ring could increase van der Waals interactions with Leu1120 and Ile1122. Tetrahydropyran (THP) <b>10</b> resulted in an increase in both biochemical and cell potency (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>; it should be noted that the effective lower limit of the CBP TR-FRET assay is 1 nM, as the CBP concentration is 2 nM). Additionally, the stability of <b>10</b> in liver microsomes (LM) increased compared to <b>8</b>. A co-crystal structure of <b>10</b> with CBP shows similar interactions to those described for <b>3</b> and <b>8</b> with the exception of the THP ring (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Rather than pointing toward Arg1173 as observed with the THF moiety, the oxygen atom of the THP pointed out toward solvent in the BC loop region and suggested that this region would enable us to tune physicochemical properties. To reduce the cLogP<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> of <b>10</b>, we investigated the addition of polar substituents to this area of the binding site. The structure suggested that these modifications would have minimal effect on the biochemical potency and potentially would increase LM stability. Removing the oxygen atom of the THP ring of <b>10</b> afforded cyclohexane <b>11</b> that had decreased CBP inhibitory potency. To further investigate polar atoms in this area, the oxygen atom of <b>10</b> was replaced with a nitrogen to make piperidines <b>12</b> and <b>13</b>. While the biochemical potency of <b>12</b> only decreased slightly compared to <b>10</b>, there was a significant decrease in cell potency presumably that may indicate poor permeability of this compound. The <i>N</i>-methyl piperidine <b>13</b> rescues the cell potency of <b>12</b> but leads to increased cLogP. The decrease in LM stability observed for <b>13</b> may be attributed to the increased cLogP. To lower cLogP and increase LM stability, we evaluated analogues <b>14</b>, <b>15</b>, and <b>16</b>. This afforded compounds with reduced cellular potency compared to <b>10</b> but limited increase in LM stability. Ultimately, <b>10</b> (GNE-049) was selected for further profiling as it had the best balance of LM stability, selectivity, and cellular potency (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Furthermore, <b>10</b> demonstrated acceptable PK in mouse, rat, dog, and monkey. Determination of potency versus a selection of bromodomains revealed that this compound is selective for CBP/P300 (full bromodomain selectivity profile provided in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_001.pdf" class="ext-link">Supporting Information</a>) and, importantly, quite selective (3820-fold) over BRD4(1). The compound had excellent potency in the BRET cellular assay and, in an orthogonal measure of the target engagement, <b>10</b> was shown to inhibit the expression of <i>MYC</i><a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> (MV4-11 cell line) with an EC<sub>50</sub> of 14 nM. Compound <b>10</b> was further evaluated in a rat single dose (30–250 mg/kg QD) toxicokinetic study (data not shown). Adverse central nervous system (CNS)-related signs (e.g., marked hyperactivity and vocalization) were observed in several of the rats at the 250 mg/kg dose level. Furthermore, at the 250 mg/kg dose level, the ratio of the unbound drug concentration in brain to unbound drug concentration in plasma (<i>K</i><sub>p,uu</sub>) 3 h post dose was determined to be 0.43, indicating that compound was penetrating into the CNS and potentially resulting in the observed toxicity.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Exploration of SAR in the BC Loop Region of CBP</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0022.gif" alt="" id="gr20" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0023.gif" alt="" id="GRAPHIC-d215e1416-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tefn1"><div class="footnote" id="tefn1"><sup>Table a</sup><p class="last">All IC<sub>50</sub> values are reported as the geometric mean from at least two determinations.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Fold selectivity is defined by [BRD4(1) IC<sub>50</sub> (nM)/CBP IC<sub>50</sub> (nM)].</p></div><div class="footnote" id="t3fn1"><sup>Table c</sup><p class="last">Mouse (M), rat (R), and human (H) liver microsome-predicted hepatic clearance (mL/min/kg).</p></div></div><div></div></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Co-crystal structure of <b>10</b> (purple) in the CBP bromodomain (yellow, 1.55 Å resolution, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0L">5W0L</a>) displaying important contacts between the ligand and receptor. Water molecules are shown as small red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Summary of potency, selectivity, and DMPK properties of <b>10</b>. <sup><i>a</i></sup>All IC<sub>50</sub> values are reported as the geometric mean from at least two determinations. <sup><i>b</i></sup>MDCK cell line: apical-to-basolateral; units = × 10<sup>–6</sup> cm s<sup>–1</sup>. <sup><i>c</i></sup>Mouse (M), rat (R), dog (D), cynomolgus monkey (C), and human (H) plasma protein binding. <sup><i>d</i></sup>Liver microsome-predicted hepatic clearance (mL/min/kg). <sup><i>e</i></sup>Hepatocyte-predicted hepatic clearance (mL/min/kg). <sup><i>f</i></sup>Compound was dosed iv (1 mg/kg) as PEG400/H<sub>2</sub>O (35/65) solution and po (5 mg/kg) as an aqueous suspension with 0.5% methylcellulose and 0.2% Tween 80. <sup><i>g</i></sup>Compound was dosed iv (1 mg/kg) as EtOH/PEG400/H<sub>2</sub>O (20/15/65) solution and po (5 mg/kg) as an aqueous suspension with 0.5% methylcellulose and 0.2% Tween 80.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In pursuit of a more drug-like CBP inhibitor, we sought a compound with a similar profile to <b>10</b> but with limited CNS penetration. To do this, we targeted a molecule with increased total polar surface area (<i>t</i>PSA) (<b>10</b><i>t</i>PSA = 68) and containing an additional H-bond donor. Previously, as part of our screening efforts, we had run a high-concentration fragment screen attempting to find alternative and novel Asn1168 binding chemotypes (not shown) and identified a highly ligand efficient<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> fragment, <b>17</b> (CBP IC<sub>50</sub> = 18 μM, LE = 0.41), that displayed >6-fold selectivity for CBP over BRD4 (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A). A co-crystal structure of this compound bound to the CBP bromodomain (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B) revealed the methyl urea moiety to be occupying the KAc binding pocket. The NH of the urea makes a hydrogen bond with the backbone of Pro1110, with the methyl group of the urea making van der Waals interactions with Phe1111. Interestingly, the phenyl ring of Phe1111 is rotated slightly such that the Cδ1 and Cε1 atoms are 0.8 and 0.9 Å from their positions when bound to <b>10</b> (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>C). From the structure of <b>10</b> overlaid with <b>17</b>, it appeared that the key Asn-binding acetamide of <b>10</b> could be replaced with a urea moiety. We therefore explored a small set of substituted urea analogues of <b>10</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Primary urea <b>18</b> matched the biochemical potency of <b>10</b> and displayed a remarkable 9600-fold selectivity for CBP over BRD4(1). Methyl urea <b>19</b>, the same group present in fragment hit <b>17</b>, afforded subnanomolar biochemical potency, 5425-fold selectivity for CBP over BRD4(1), and <10 nM cellular potency. To further probe the KAc pocket, we made ethyl urea <b>20</b> and <i>N</i>,<i>N</i>-dimethyl urea <b>21</b>, but these resulted in 33-fold and 330-fold losses in potency, respectively, compared to <b>19</b>. The significant loss in potency observed with <b>21</b> was expected because it was assumed that the NH of the urea was participating in a H-bond with the backbone of Pro1110 similar to that observed with the <b>17</b>-CBP crystal structure.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) CBP-selective fragment screening hit <b>17</b>. (B) Co-crystal structure of <b>17</b> (aqua) and the CBP bromodomain (yellow, 1.7 Å resolution; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0Q">5W0Q</a>). Residues engaging in important contacts between the ligand and receptor are shown in stick representation. Water molecules are shown as small red spheres. (C) Compound <b>17</b> (aqua) overlaid with <b>10</b> (purple) in the CBP binding site (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Exploring the KAc Binding Site with Urea Substitution</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0024.gif" alt="" id="GRAPHIC-d215e1629-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">CBP<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">BRD4(1)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">CBP BRET<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">fold selectivity<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">4200</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">3818</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">9600</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">8727</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">NHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.94</td><td class="colsep0 rowsep0" align="char" char=".">5100</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">5425</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">NHCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">>20000</td><td class="colsep0 rowsep0" align="char" char=".">530</td><td class="colsep0 rowsep0" align="char" char=".">>645</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">N(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">310</td><td class="colsep0 rowsep0" align="char" char=".">15000</td><td class="colsep0 rowsep0" align="char" char=".">3700</td><td class="colsep0 rowsep0" align="char" char=".">48</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">All IC<sub>50</sub> values are reported as the geometric mean from at least two determinations.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Fold selectivity is defined by [BRD4(1) IC<sub>50</sub> (nM)/CBP IC<sub>50</sub> (nM)].</p></div></div></div><div class="NLM_p">To further understand the selectivity of <b>19</b>, we obtained co-crystal structures of this compound with CBP and BRD4(1) (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). In the <b>19</b>-CBP co-crystal structure, similar interactions with the binding site are observed as seen in the <b>10</b>-CBP co-crystal crystal structure, with an additional interaction provided by the methyl urea of <b>19</b> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A). As observed in the <b>17</b>-CBP co-crystal structure, the urea NH of <b>19</b> makes a hydrogen bond with the backbone of Pro1110 and the methyl group of the urea makes van der Waals interactions with Phe1111. Unsurprisingly, the Cδ1 and Cε1 atoms of Phe1111 shifted by 0.8 and 1.0 Å, respectively, relative to the <b>10</b> structure, consistent with the shifts observed in the <b>17</b>-CBP co-crystal structure. In BRD4, Trp81 from the WPF shelf served as a lipophilic “protrusion” compared to CBP’s LPF “wall” (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B). As a result, the THQ of <b>19</b> is rotated in BRD4(1) such that the phenyl ring makes van der Waals contacts with Leu92 from the BC loop while the <i>N</i>-methylpyrazole is completely solvent-exposed. The ligand–receptor complementarity of <b>19</b> in BRD4 is less optimal relative to <b>19</b> bound to CBP, providing an explanation for the selectivity.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Co-crystal structure of <b>19</b> (pink) and the CBP bromodomain (yellow, 1.41 Å resolution; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0E">5W0E</a>). Residues engaging in important contacts between the ligand and receptor are shown in stick representation. Water molecules are shown as small red spheres. (B) Co-crystal structure of <b>19</b> (pink) and the BRD4(1) bromodomain (cyan, 1.71 Å resolution; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VZS">5VZS</a>). Residues engaging in important contacts between the ligand and receptor are shown in stick representation. Water molecules are shown as small red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the cell potency and selectivity of <b>19</b>, we further profiled this compound (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>). Compound <b>19</b> showed moderate to low clearance in vivo in all species evaluated, with acceptable oral bioavailability. Examination of a subset of bromodomains revealed that this compound is exquisitely selective for CBP/P300 (full bromodomain selectivity profile provided in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_001.pdf" class="ext-link">Supporting Information</a>) and is remarkably selective for CBP (5425-fold) and P300 (4250-fold). When tested (full details in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_001.pdf" class="ext-link">Supporting Information</a>) in an Invitrogen kinase panel (1 μM, 220 kinases), <b>19</b> did not inhibit any target at >10%, and in a Cerep off-target screening panel (10 μM, 43 receptors), <b>19</b> did not inhibit any target at >39%. In addition, <b>19</b> did not inhibit (>10 μM, top concentration) several cytochrome P450s (3A4, 1A2, 2C9, 2C19, 2D6). The compound had excellent and comparable potency (<10 nM) between the BRET and <i>MYC</i> cellular assays. Furthermore, when <b>19</b> was dosed in a rat at 250 mg/kg, the <i>K</i><sub>p,uu</sub> (3 h post dose) was determined to be 0.02 (compared to 0.43 for <b>10</b>), indicating that there was little brain penetration of this compound, and no adverse CNS-related signs were observed.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Summary of potency, selectivity, and DMPK properties of <b>19</b>. <sup><i>a</i></sup>All IC<sub>50</sub> values are reported as the geometric mean from at least two determinations. <sup><i>b</i></sup>MDCK cell line: apical-to-basolateral; units = × 10<sup>–6</sup> cm s<sup>–1</sup>. <sup><i>c</i></sup>Mouse (M), rat (R), dog (D), cynomolgus monkey (C), and human (H) plasma protein binding. <sup><i>d</i></sup>Liver microsome-predicted hepatic clearance (mL/min/kg). <sup><i>e</i></sup>Hepatic clearance (mL/min/kg). <sup><i>f</i></sup>Compound was dosed iv (1 mg/kg) as PEG400/H<sub>2</sub>O (35/65) solution and po (5 mg/kg) as an aqueous suspension with 0.5% methylcellulose and 0.2% Tween 80. <sup><i>g</i></sup>Compound was dosed iv (1 mg/kg) as EtOH/PEG400/H<sub>2</sub>O (20/15/65) solution and po (5 mg/kg) as an aqueous suspension with 0.5% methylcellulose and 0.2% Tween 80.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next determined the effect of <b>19</b> in an in vivo PK/PD experiment using a MOLM-16 (adult AML cell line) xenograft mouse model. Single doses of <b>19</b> were given at dose levels between 3 and 30 mg/kg in MOLM-16 tumor-bearing animals, and samples were collected at time points covering 2–24 h. Tumor RNA was generated and used to assess <i>MYC</i> transcript by quantitative RT-PCR relative to vehicle-treated animals. Suppression of <i>MYC</i> was observed at doses as low as 3 mg/kg at 2 and 8 h, with maximal suppression observed at 10 and 30 mg/kg at 2 h (87% and 88% inhibition, respectively; <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>A). It should be noted that suppression of <i>MYC</i> at the 3, 10, and 30 mg/kg doses was seen without tumor or plasma levels of <b>19</b> reaching the BRD4(1) IC<sub>50</sub> (5.1 μM), and thus results observed are clearly not from BET inhibition. Consistent with previous results,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> inhibition of <i>MYC</i>-transcript was transient over the 24 h window with an apparent rebound effect at the 3 mg/kg dose level, rising to about 150% of vehicle control at the 16 h time point. Increasing suppression of <i>MYC</i> transcript level correlated with increasing plasma and tumor drug levels (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>A).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. In vivo evaluation of <b>19</b>. (A) Effect on <b>19</b> treatment on <i>MYC</i> transcript levels in MOLM-16 xenograft tumors with single doses of <b>19</b> (<i>n</i> = 3/group; mean ± SEM plotted). Plasma and tumor levels were adjusted for PPB and tissue binding, respectively, and mean plasma and tumor unbound drug levels (±SD) are displayed. (B) Antitumor efficacy of <b>19</b> at 3, 10, and 30 mg/kg in the MOLM-16 AML xenograft tumor model and effect on body weight (<i>n</i> = 10/group; tumor volume, mean ± SEM plotted; body weight, group fitted % body weight loss plotted).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To evaluate the in vivo efficacy of <b>19</b>, MOLM-16 AML xenografts were established in SCID beige mice. Upon tumor establishment, dosing of compound <b>19</b> was initiated with po doses of 3–30 mg/kg, twice daily (BID). Single-agent efficacy was observed at all doses, as evidenced by inhibition of MOLM-16 tumor growth (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>B). Tumor growth inhibition (%TGI) was 73%, 71%, and 89% at 3, 10, and 30 mg/kg, respectively. All doses of <b>19</b> were well tolerated over the 21-day dosing window, with a maximal body weight loss of 3.7%. There was a lack of dose proportionality observed between the 3 and 10 mg/kg doses for <b>19</b>, resulting in comparable exposures and suppression of <i>MYC</i> transcript levels, corresponding to comparable efficacy for these two doses in the efficacy study. At a dose of 30 mg/kg, we observed higher exposures of <b>19</b>, resulting in more durable suppression of <i>MYC</i> transcript levels, which corresponded to an increase in antitumor activity. These data suggest that there is a dose-proportional PK–PD efficacy relationship where more durable suppression of <i>MYC</i> transcript results in better suppression of MOLM-16 tumor growth. Previously, we had evaluated <b>1</b> in this same xenograft model.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Compound <b>19</b>, possessing greater cell potency than <b>1</b>, exhibited approximately the same %TGI at 3 mg/kg as <b>1</b> does at 25 mg/kg (65% TGI). Taken together, these results demonstrate that <b>19</b> is highly active in vivo and capable of modulating CBP-dependent <i>MYC</i> transcription, which corresponds with antitumor activity in a <i>MYC</i>-dependent AML tumor model.</div><div class="NLM_p">In addition to studying the effect of <b>19</b> in a hematologic antitumor xenograft model, we also explored the ability of this compound to impair T<sub>reg</sub> differentiation and immunosuppressive function. CBP can interact with multiple transcription factors.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> One of them is FOXP3, the master transcription factor defining T<sub>regs</sub>. FOXP3 is essential for immune homeostasis, preventing autoimmunity, limiting chronic inflammation, and hampering effective immunity against tumors.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30">(27-30)</a> Inhibition of the histone acetyltransferase domain of CBP has been shown to decrease the expression of FOXP3, leading to reduced tumor growth in mouse models of cancer.<a onclick="showRef(event, 'ref8 ref31'); return false;" href="javascript:void(0);" class="ref ref8 ref31">(8, 31)</a> More recently, inhibition of the CBP bromodomain was also reported to impair <i>FOXP3</i> expression and T<sub>reg</sub> function, suggesting that bromodomain inhibition could impact optimal acetylation of chromatin associated transcription factors, including FOXP3 itself.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> To determine whether <b>19</b> would affect in vitro generation of inducible T<sub>regs</sub> (iT<sub>regs</sub>) and <i>FOXP3</i> expression, human naïve CD4+T cells were differentiated toward T<sub>regs</sub> using anti-CD3, anti-CD28, rIL-2, and rTGFβ in the presence of increasing concentrations of <b>19</b> (0.001 to 2 μM), using DMSO as a control. At day 4 postdifferentiation, cells were harvested, mRNA was extracted, and <i>FOXP3</i> gene expression was assessed by quantitative reverse transcriptase polymerase chain reaction (q-RT-PCR). <a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>A shows that <b>19</b> decreases <i>FOXP3</i> transcripts in a dose-dependent manner (IC<sub>50</sub> = 17 nM) consistent with the cellular potency in our <i>MYC</i> RNA assay. Moreover, the reduction in <i>FOXP3</i> mRNA corresponded to a reduction in FOXP3 protein as determined in fixed and permeabilized CD4<sup>+</sup>CD25<sup>+</sup> cells by fluorescence-activated cell sorting. Compound <b>19</b> did not affect cell viability (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>B), and a dose-dependent decrease in FOXP3 staining was observed (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>C), corroborating the gene expression data. Taken together with our previous work,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> these data suggest that inhibition of the CBP bromodomain may provide a novel small molecule approach for cancer immunotherapy.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compound <b>19</b> decreased the generation of iT<sub>regs</sub> in vitro without affecting cell viability. Human iT<sub>reg</sub> cells were differentiated in vitro from naïve CD4+T cells derived from peripheral blood mononuclear cells (PBMCs) of a healthy donor in the presence of <b>19</b> or DMSO as control. On day 4, cells were harvested. (A) <i>FOXP3</i> expression was assessed by q-RT-PCR and normalized with <i>B2M</i>. (B) Cell viability was assessed by flow cytometry using a fixable viability dye. (C) T<sub>reg</sub> cells were also fixed, permeabilized, and intracellular FOXP3 protein assessed in CD4<sup>+</sup>CD25<sup>+</sup> by flow cytometry. Graph shows % FOXP3+iTregs cells out of total CD4+T cells. Data are representative of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Chemistry</h3><div class="NLM_p">Intermediates <b>27</b>–<b>35</b> were prepared according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Conjugate addition of ethyl 3-aminopropanoate (<b>22</b>) to acrylonitrile followed by Boc protection yielded <b>23</b>. Compound <b>23</b> was treated with sodium hydride and cyclized to give <b>24</b>. The pyrazolopiperidine core (<b>25</b>) was formed by treatment of <b>24</b> with hydrazine, and subsequent conversion of the amino function of <b>25</b> to the bromide under Sandmeyer conditions afforded <b>26</b>. Alkylation of the pyrazole <b>26</b> with the appropriate alkyl methanesulfonate yielded <b>27</b>–<b>31</b>. Deprotection of the Boc group with TFA followed by acylation with acetic anhydride afforded <b>32</b>–<b>34</b>. Intermediate sulfone <b>35</b> was formed by oxidation of thioether <b>31</b> with oxone.</div><figure id="sch1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediates <b>27</b>–<b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) NaOH, acrylonitrile, MeOH, 70 °C, (ii) di-<i>tert</i>-butyl dicarbonate, 0 °C, 99%; (b) NaH, toluene, 100 °C, 100%; (c) hydrazine monohydrate, EtOH, 60 °C, 70%; (d) isopentyl nitrite, MeCN, CuBr<sub>2</sub>, 60 °C, 34%; (e) R-OMs, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 28–71%; (f) (i) TFA, DCM, rt, (ii) Ac<sub>2</sub>O, TEA, DMF, rt, 77–87%; (g) oxone, THF, H<sub>2</sub>O, rt, 98%.</p></p></figure><div class="NLM_p">The synthesis of <b>2</b> and <b>3</b> is outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Suzuki coupling of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole with commercially available <b>36</b> or <b>37</b> afforded <b>38</b> and <b>39</b>, respectively. Buchwald coupling of racemate <b>32</b> and <b>38</b> followed by chiral chromatography yielded <b>2</b>. (We have observed from evaluating analogues from the synthesis of enantiopure starting material that the (<i>R</i>)-isomer is always less potent than the (<i>S</i>)-isomer. Compound <b>2</b> was assumed to be the (<i>S</i>)-isomer as this was more potent than the (<i>R</i>)-isomer.) Buchwald coupling of optically pure <b>33</b> with <b>39</b> afforded <b>3</b>.</div><figure id="sch2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>2</b> and <b>3</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 120 °C, 47–86%; (b) <b>32</b>, RuPhos Pd G1, RuPhos, <i>t</i>-BuONa, dioxane, 120 °C, supercritical fluid chromatography (SFC) chiral resolution, 16%; (c) <b>33</b>, RuPhos Pd G1, RuPhos, <i>t</i>-BuONa, dioxane,120 °C, 34%</p></p></figure><div class="NLM_p">Buchwald coupling of commercially available <b>40</b> or <b>41</b> with intermediate <b>33</b> yielded <b>42</b> and <b>43</b>, respectively (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Bromination of <b>42</b> and <b>43</b> with <i>N</i>-bromosuccinimide (NBS) gave bromides <b>44</b> and <b>45</b>, respectively. Subsequent Suzuki coupling with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole provided analogues <b>4</b> and <b>7</b>, respectively.</div><figure id="sch3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>4</b> and <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>33</b>, RuPhos Pd G1, RuPhos, <i>t</i>-BuONa, dioxane, 120 °C, 26–39%; (b) NBS, DCM, 0 °C to rt 90–97%; (c) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 110 °C, 23–24%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> shows the synthesis of compounds <b>5</b>, <b>6</b>, <b>8</b>, and <b>9</b>. Appropriately substituted THQs (<b>46</b>–<b>48</b>) were treated with NBS, yielding the brominated intermediates <b>49</b>–<b>51</b>. Suzuki coupling of <b>49</b>–<b>51</b> with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole provided <b>52</b>–<b>54</b>. Buchwald coupling of intermediate <b>33</b> with <b>52</b> or <b>54</b> provided compounds <b>6</b> and <b>9</b>, respectively. Buchwald coupling of racemic intermediate <b>32</b> with <b>53</b> followed by chiral chromatography yielded <b>8</b>. Chloride <b>6</b> was converted directly to methyl analogue <b>5</b> via palladium coupling with potassium methyltrifluoroborate.</div><figure id="sch4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>5</b>, <b>6</b>, <b>8</b>, and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NBS, DCM, 0 °C to rt, 36–60%; (b) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub> or Na<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 110 °C, 86–95%; (c) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, XPhos Pd G2, XPhos, Na<sub>2</sub>CO<sub>3</sub>, THF, H<sub>2</sub>O, 80 °C, 70%; (d) <b>33</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, <i>t</i>-BuONa, dioxane, toluene, 90 °C, 50%; (e) <b>32</b>, RuPhos Pd G1, RuPhos, <i>t</i>-BuONa, dioxane, 130 °C, SFC chiral resolution, 16%; (f) <b>33</b>, Pd-PEPPSI-IPent, <i>t</i>-BuONa, dioxane, 150 °C, 21%; (g) <b>6</b>, Ad<sub>2</sub>PBu, MeBF<sub>3</sub>K, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, toluene, H<sub>2</sub>O, 100 °C, 15%.</p></p></figure><div class="NLM_p">Buchwald coupling of intermediate <b>34</b> with THQ <b>53</b> afforded <b>10</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>53</b>, XPhos Pd G3, K<sub>3</sub>PO<sub>4</sub>, <i>t</i>-amyl alcohol, 95 °C, 74%.</p></p></figure><div class="NLM_p">The syntheses of <b>11</b>–<b>13</b> and <b>15</b> are shown in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Treatment of intermediate <b>26</b> with SEM-Cl followed by Buchwald coupling with <b>53</b> provided <b>56</b>. Removal of the SEM and Boc protecting groups yielded <b>58</b>. Acetylation of the piperidine with acetic anhydride afforded the key intermediate <b>59</b>. Alkylation of <b>59</b> with the corresponding bromide or mesylate yielded <b>11</b>, <b>15</b>, and <b>60</b>. Compound <b>60</b> was further converted to <b>13</b> by first removing the Boc group followed by reductive amination with formaldehyde.</div><figure id="sch6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>11</b>–<b>13</b> and <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, SEM-Cl, THF, 0 °C to rt, 83%; (b) <b>53</b>, RuPhos Pd G2, RuPhos, <i>t</i>-BuONa, dioxane, 120 °C, 20%; (c) TBAF, THF, 60 °C, 66%; (d) TFA, DCM, rt, 100%; (e) Ac<sub>2</sub>O, TEA, DMF, rt, 14%; (f), R<sub>2</sub>-Br or R<sub>2</sub>-OMs, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 5–17%; (g) <b>60</b>, TFA, DCM, 0 °C to rt, 49%; (h) aq CH<sub>2</sub>O, CH<sub>3</sub>CO<sub>2</sub>H, NaBH(OAc)<sub>3</sub>, DCE, rt, 23%.</p></p></figure><div class="NLM_p">Outlined in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a> is the synthesis of <b>14</b> and <b>16</b>. Buchwald coupling of <b>30</b> or <b>35</b> with THQ <b>53</b> provided <b>61</b> and <b>62</b>, respectively. Deprotection of the Boc group with TFA followed by acetylation with acetic anhydride afforded candidate compounds <b>14</b> and <b>16</b>.</div><figure id="sch7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>14</b> and <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>53</b>, Pd-PEPPSi-IPent, <i>t</i>-BuONa, dioxane, 120 °C, 42–46%; (b) TFA, DCM, rt, 100%; (c) Ac<sub>2</sub>O, TEA, DCM, 0 °C to rt, 40–52%.</p></p></figure><div class="NLM_p">Buchwald coupling of THQ <b>53</b> with <b>29</b> to form <b>65</b>, followed by deprotection of the Boc group with TFA, yielded key intermediate <b>66</b> from which urea analogues <b>18</b>–<b>21</b> could be synthesized (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>). Compound <b>66</b> was treated with (trimethylsilyl)isocyanate to afford the unsubstituted urea <b>18</b>. Monomethyl urea <b>19</b> was formed from treatment of <b>66</b> with <i>N</i>-methyl-1<i>H</i>-imidazole-1-carboxamide. Intermediate <b>66</b> was first treated with 4-nitrophenyl chloroformate then with ethylamine to yield <b>20</b>. Dimethyl urea <b>21</b> was synthesized by treatment of <b>66</b> with dimethylcarbamoyl chloride.</div><figure id="sch8" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>18</b>–<b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>53</b>, RuPhos Pd G1, RuPhos, <i>t</i>-BuONa, dioxane, 120 °C, 73%; (b) TFA, DCM, rt; (c) TMSNCO, DCM, rt, 20%; (d) <i>N</i>-methyl-1<i>H</i>-imidazole-1-carboxamide, DCM, rt, 22%; (e) (i) 4-nitrophenyl chloroformate, pyridine, DMF, rt, (ii) EtNH<sub>2</sub>, THF, rt, 14%; (f) dimethylcarbamyl chloride, TEA, DMF, rt, 22%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03500" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03500" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have identified a highly potent and selective in vivo probe (<b>19</b>) of the CBP bromodomain that is suitable to interrogate the biology of CBP without the complication of BET inhibition. Our studies began with recently disclosed <b>1</b> (TR-FRET IC<sub>50</sub> = 20 nM, BRET IC<sub>50</sub> = 410 nM, BRD4(1) IC<sub>50</sub> = 13,000 nΜ) that was moderately potent for the bromodomain of CBP and 650-fold selective over BRD4(1). Constraining the aniline of <b>1</b> into tetrahydroquinoline <b>3</b> maintained potency and increased selectivity by 2-fold over <b>1</b>. Structure–activity relationship studies coupled with structure-based design targeting the LPF shelf, BC loop, and KAc regions allowed us to identify <b>10</b> (TR-FRET IC<sub>50</sub> = 1.1 nM, BRET IC<sub>50</sub> = 12 nM, BRD4(1) IC<sub>50</sub> = 4200 nΜ). Further profiling of this compound revealed that it penetrated into the CNS, resulting in adverse CNS effects. Subsequent optimization focused on increasing <i>t</i>PSA with the addition of a hydrogen bond donor. This was accomplished with conversion of the Asn-binding acetamide of <b>10</b> to a methyl urea, enabling identification of non-CNS penetrant <b>19</b> (TR-FRET IC<sub>50</sub> = 0.94 nM, BRET IC<sub>50</sub> = 6.2 nM, BRD4(1) IC<sub>50</sub> = 5100 nΜ) that demonstrated an appropriate balance of cell potency, selectivity (5425-fold over BRD4(1)), and in vivo PK. The exquisite potency and selectivity of <b>19</b> enables the clear delineation of pharmacological effects from the inhibition of CBP over the BET bromodomains. In vivo, <b>19</b> modulates <i>MYC</i> expression that corresponds with antitumor activity in an AML tumor model. Additional in vitro studies with <b>19</b> showed that this compound impaired <i>FOXP3</i> expression and T<sub>reg</sub> function, further suggesting CBP bromodomain inhibition as a novel small molecule approach for cancer immunotherapy.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Procedures</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78768" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78768" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Methods</h3><div class="NLM_p last">All solvents and reagents were used as obtained. NMR analysis performed in a deuterated solvent with a Varian Avance 300 MHz or Bruker Avance 400 or 500 MHz NMR spectrometers, referenced to trimethylsilane (TMS). Chemical shifts are expressed as δ units using TMS as the external standard (in NMR description, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad peak). All coupling constants (<i>J</i>) are reported in hertz. Compounds with the acetamide moiety (e.g., compound <b>10</b>) exhibited rotamers in the NMR, and thus in many cases coupling constants were not reported and generally characterized as multiplets. In addition, the <sup>13</sup>C of compound <b>10</b> was run at elevated temperature in order to coalesce the mutiple rotamer peaks into a single peak. Mass spectra were measured with a Finnigan SSQ710C spectrometer using an ESI source coupled to a Waters 600MS high performance liquid chromatography (HPLC) system operating in reverse-phase mode with an X-bridge phenyl column of dimensions 150 mm by 2.6 mm, with 5 μm sized particles. Preparatory-scale silica gel chromatography was performed using medium-pressure liquid chromatography (MPLC) on a CombiFlash Companion (Teledyne ISCO) with RediSep normal phase silica gel (35–60 μm) columns and UV detection at 254 nm. Reverse-phase (HPLC) was used to purify compounds as needed by elution from a Phenomenex Gemini-NX C18 column (20.2 mm × 50 mm, 5 μm) as stationary phase using mobile phase indicated and operating at a 35 mL/min flow rate on a Waters 3100 mass-directed prep instrument. Chemical purities were >95% for all final compounds as assessed by LC/MS analysis. The following analytical method was used to determine chemical purity of final compounds: HPLC-Agilent 1200, water with 0.05% TFA, acetonitrile with 0.05% TFA (buffer B), Agilent SB-C18, 1.8 μM, 2.1 mm × 30 mm, 25 °C, 3–95% buffer B in 8.5 min, 95% in 2.5 min, 400 μL/min, 220 and 254 nm, equipped with Agilent quadrupole 6140, ESI positive, 90–1300 amu.</div></div><div id="sec4-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>tert</i>-Butyl 3-Bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>27</b>)</h3><div id="sec4-2-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Step 1: Ethyl 3-((<i>tert</i>-Butoxycarbonyl)(2-cyanoethyl)amino)propanoate (<b>23</b>)</h4><div class="NLM_p last">To a solution of ethyl 3-aminopropanoate hydrochloride (<b>22</b>, 367 g, 2.39 mol) in MeOH (1.2 L) at room temperature was added NaOH (95.6 g, 2.39 mol) portionwise. The mixture was heated to 70 °C, acrylonitrile (158 g, 2.98 mol) was added dropwise, and the reaction mixture was stirred for 6 h. The solution was cooled to 0 °C before di-<i>tert</i>-butyl dicarbonate (521 g, 2.39 mol) was added. The reaction was stirred at room temperature for 6 h, filtered, and washed with MeOH (200 mL). The filtrate was concentrated in vacuo to give a yellow oily residue that was redissolved in EtOAc and water (500 mL). The aqueous layer was extracted with EtOAc (800 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give the title compound (<b>23</b>, 638 g, 99%) as a light-yellow oil that required no further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.17 (q, <i>J</i> = 7.2 Hz, 2H), 3.68–3.62 (m, 4H), 2.57–2.53 (m, 4H), 1.49 (s, 9H), 1.29 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4-2-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Step 2: <i>tert</i>-Butyl 3-Cyano-4-oxopiperidine-1-carboxylate (<b>24</b>)</h4><div class="NLM_p last">To toluene (2.7 L) at 25 °C was added NaH (80 g, 2.0 mol) portionwise, and the suspension was heated to 80 °C. Ethyl 3-((<i>tert</i>-butoxycarbonyl)(2-cyanoethyl)amino)propanoate (<b>23</b>, 270 g, 1.00 mol) in anhydrous toluene (270 mL) was added dropwise. The mixture was heated to 100 °C and stirred for 5 h. The mixture was cooled to room temperature, quenched with satd aq ammonium chloride (800 mL), and washed with hexanes (800 mL). The aqueous phase was acidified with HCl (2N) to pH 6, and the mixture was extracted with EtOAc (1 L × 2). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give <i>tert</i>-butyl 3-cyano-4-oxopiperidine-1-carboxylate (<b>24</b>, 310 g, 100%) as yellow oil that required no further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.17–4.14 (m, 1H), 3.59–3.56 (m, 2H), 3.43–3.41 (m, 2H), 2.70–2.66 (m, 2H), 1.51 (s, 9H).</div></div><div id="sec4-2-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Step 3: <i>tert</i>-Butyl 3-Amino-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>25</b>)</h4><div class="NLM_p last">A mixture of <i>tert</i>-butyl 3-cyano-4-oxopiperidine-1-carboxylate (<b>24</b>, 310 g, 1.38 mol) and hydrazine monohydrate (140 mL, 2.08 mol) in EtOH (1.5 L) was heated to 60 °C for 2 h. The mixture was concentrated in vacuo to give the crude product that was dissolved in EtOAc (1 L) and washed with water (1 L × 2). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to afford <i>tert</i>-butyl 3-amino-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>25</b>, 230 g, 70%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 4.28 (s, 2H), 3.66–3.63 (m, 2H), 2.62–2.59 (m, 2H), 1.49 (s, 9H).</div></div><div id="sec4-2-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Step 4: <i>tert</i>-Butyl 3-Bromo-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>26</b>)</h4><div class="NLM_p last">To a stirred mixture of <i>tert</i>-butyl 3-amino-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>25</b>, 120 g, 504 mmol), CuBr<sub>2</sub> (112.5 g, 503.6 mmol), and MeCN (1.2 L) at 0 °C was added isopentyl nitrite (76.7 g, 655 mmol), and the reaction mixture stirred for 20 min. The temperature was raised to 60 °C, and the reaction mixture was stirred for an additional 5 h. After cooling the reaction to room temperature, the reaction mixture was quenched with water (1 L) and the mixture was extracted with EtOAc (1 L × 2). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 4:1) to afford <i>tert</i>-butyl 3-bromo-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>26</b>, 52 g, 34%) as light-yellow solid. LCMS <i>m</i>/<i>z</i> (M + H) 302.</div></div><div id="sec4-2-5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Step 5: <i>tert</i>-Butyl 3-Bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>27</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-bromo-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>26</b>, 20.0 g, 66.0 mmol) in DMF (100 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (40.0 g, 123 mmol) and tetrahydrofuran-3-yl methanesulfonate (16.0 g, 98.0 mmol). The mixture was heated to 80 °C for 12 h. The solution was concentrated in vacuo, and the crude residue was purified by silica gel chromatography (eluent from petroleum ether/EtOAc = 10:1 to 3:1) to give the title compound (<b>27</b>, 17 g, 69%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.78–4.69 (m, 1 H), 4.26 (s, 2 H), 4.18–3.86 (m, 4 H), 3.72 (s, 2 H), 2.72–2.62 (m, 2H), 2.44–2.22 (m, 2H), 1.48 (s, 9H).</div></div></div><div id="sec4-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>S</i>)-<i>tert</i>-Butyl 3-Bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>28</b>)</h3><div class="NLM_p last">In a similar manner to <b>27</b>, compound <b>28</b> was prepared from (<i>R</i>)-tetrahydrofuran-3-yl methanesulfonate to provide the title compound (71%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.97–4.78 (m, 1H), 4.13 (s, 2H), 3.98–3.86 (m, 2H), 3.81–3.67 (m, 2H), 3.56 (t, <i>J</i> = 5.6 Hz, 2H), 2.68 (t, <i>J</i> = 5.6 Hz, 2H), 2.33–2.08 (m, 2H), 1.38 (s, 9H).</div></div><div id="sec4-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>tert</i>-Butyl 3-Bromo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>29</b>)</h3><div class="NLM_p last">In a similar manner to <b>27</b>, compound <b>29</b> was prepared from tetrahydro-2<i>H</i>-pyran-4-yl methanesulfonate to provide the title compound (47%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.35–4.25 (m, 1H), 4.17 (s, 2H), 3.95–3.93 (m, 2H), 3.62–3.57 (m, 2H), 3.42 (t, <i>J</i> = 11.2 Hz, 2H), 2.74–2.73 (m, 2H), 1.98–1.89 (m, 2H), 1.80–1.77 (m, 2H), 1.41 (s, 9H).</div></div><div id="sec4-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>tert</i>-Butyl 1-(1-Acetylpiperidin-4-yl)-3-bromo-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>30</b>)</h3><div class="NLM_p last">In a similar manner to <b>27</b>, compound <b>30</b> was prepared from 1-acetylpiperidin-4-yl methanesulfonate to provide the title compound (28%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.50–4.41 (m, 1H), 4.38–4.29 (m, 1H), 4.16 (s, 2H), 3.94–3.85 (m, 1H), 3.64–3.57 (m, 2H), 3.21–3.09 (m, 1H), 2.75–2.58 (m, 3H), 2.03 (s, 3H), 1.91–1.80 (m, 3H), 1.73–1.61 (m, 1H), 1.41 (s, 9H).</div></div><div id="sec4-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>tert</i>-Butyl 3-Bromo-1-(1,1-dioxidotetrahydro-2<i>H</i>-thiopyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>35</b>)</h3><div id="sec4-6-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Step 1: <i>tert</i>-Butyl 3-Bromo-1-(tetrahydro-2<i>H</i>-thiopyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>31</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-bromo-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>26</b>, 10.0 g, 33.1 mmol) in DMF (50 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (27.0 g, 82.7 mmol) and tetrahydro-2<i>H</i>-thiopyran-4-yl methanesulfonate (8.4 g, 43.0 mmol). The mixture was heated to 80 °C for 16 h under a nitrogen atmosphere. After cooling the reaction to room temperature, the mixture was filtered. The mixture was diluted with EtOAc (100 mL) and washed with brine (100 mL × 2). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (eluent from petroleum ether/<i>tert</i>-butyl methyl ether/THF = from 10:1:1 to 3:1:1) to give the title compound (<b>31</b>, 5.9 g, 44%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.17 (s, 2H), 4.09–4.04 (m, 1H), 3.62–3.59 (m, 2H), 2.83–2.77 (m, 2H), 2.71–2.68 (m, 4H), 2.13–2.10 (m, 2H), 2.03–1.93 (m, 2H), 1.44 (s, 9H).</div></div><div id="sec4-6-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Step 2: <i>tert</i>-Butyl 3-Bromo-1-(1,1-dioxidotetrahydro-2<i>H</i>-thiopyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>35</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-bromo-1-(tetrahydro-2<i>H</i>-thiopyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>31</b>, 2.0 g, 5.0 mmol) in THF (10 mL) and water (2 mL) at 0 °C was added oxone (3.1 g, 5 mmol) portionwise. The mixture was stirred at room temperature for 2 h. The reaction was quenched by satd aq Na<sub>2</sub>SO<sub>3</sub> and extracted with DCM (20 mL × 3). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give the title compound (<b>35</b>, 2.1 g, 98%) as a white solid that required no further purification. LCMS <i>m</i>/<i>z</i> (M + H) 436.</div></div></div><div id="sec4-7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 1-(3-Bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>32</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo [4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>27</b>, 17.0 g, 45.0 mmol) in DCM (60 mL) was added TFA (30 mL) dropwise. The reaction solution was stirred at room temperature for 2 h. The solvent was removed by evaporation, and the crude product was redissolved in DMF (50 mL). The mixture was cooled to 0 °C before TEA (41.0 g, 40.5 mmol) and acetic anhydride (7.00 g, 68.0 mmol) were added dropwise. The ice bath was removed, and the reaction was stirred at room temperature for additional 2 h. Water (50 mL) was added, and the solution was extracted with EtOAc (150 mL × 3). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (DCM/MeOH = 30:1) to give the title compound (<b>32</b>, 12.0 g, 82%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.96–4.92 (m 1H), 4.28 (s, 2H), 3.99–3.95 (m, 2H), 3.80–3.68 (m, 4H), 2.82–2.70 (m, 2H), 2.29–2.19 (m, 2H), 2.10–2.08 (m, 3H).</div></div><div id="sec4-8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>S</i>)-1-(3-Bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>33</b>)</h3><div class="NLM_p last">In a similar manner to <b>32</b>, compound <b>33</b> was prepared from (<i>S</i>)-<i>tert</i>-butyl 3-bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>28</b>) to provide the title compound (87%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.78–4.67 (m, 1H), 4.45–4.29 (m, 2H), 4.15–4.06 (m, 2H), 3.96–3.92 (m, 2H), 3.88–3.70 (m, 2H), 2.71–2.67 (m, 2H), 2.38–2.34 (m, 2H), 2.16 (s, 3H).</div></div><div id="sec4-9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 1-(3-Bromo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (34)</h3><div class="NLM_p last">In a similar manner to <b>32</b>, compound <b>34</b> was prepared from <i>tert</i>-butyl 3-bromo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-6,7-dihydro-1<i>H</i>- pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>29</b>) to provide the title compound (77%) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.33–4.29 (m, 1H), 4.28 (s 2H), 3.95–3.92 (m, 2H), 3.70–3.67 (m, 2H), 3.43–3.36 (m, 2H), 2.84–2.69 (m, 2H), 2.09–2.08 (m, 3H), 1.96–1.91 (m, 2H), 1.80–1.76 (m, 2H).</div></div><div id="sec4-10" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 1-[3-[5-(1-Methylpyrazol-4-yl)indolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>2</b>)</h3><div id="sec4-10-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step 1: 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)indoline (<b>38</b>)</h4><div class="NLM_p last">To a solution of 5-bromoindoline (<b>36</b>, 500 mg, 2.52 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (630 mg, 3.03 mmol), and Na<sub>2</sub>CO<sub>3</sub> (535 mg, 5.05 mmol) in dioxane (20 mL) and H<sub>2</sub>O (5 mL) was added [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (184 mg, 0.250 mmol). The mixture was heated to 120 °C for 12 h under a nitrogen atmosphere. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 1:1) to give the presumed title compound (<b>38</b>, 430 mg, 86%) as a light yellow solid.</div></div><div id="sec4-10-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step 2: 1-[3-[5-(1-Methylpyrazol-4-yl)indolin-1-yl]-1-tetrahydrofuran-3-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone</h4><div class="NLM_p last">To a solution of 1-(3-bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>32</b>, 500 mg, 1.59 mmol), 5-(1-methyl-1<i>H</i>-pyrazol-4-yl)indoline (<b>38</b>, 371 mg, 1.59 mmol), and <i>t-</i>BuONa (458 mg, 4.77 mmol) in 1,4-dioxane (10 mL) was added chloro(2-dicyclohexylphosphino-2′,6′-di-<i>I</i>-propoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II), methyl-<i>tert</i>-butylether adduct (130 mg, 0.160 mmol) and 2-dicyclohexylphosphino-2′,6′-di-<i>I</i>-propoxy-1,1′-biphenyl (74 mg, 0.16 mmol). The mixture was heated to 120 °C for 12 h under a nitrogen atmosphere. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated in vacuo. The crude residue was purified by reverse phase chromatography (acetonitrile 32–62%/0.1% NH<sub>4</sub>OH in water) to give the title compound (112 mg, 16%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.69 (s, 1H), 7.51 (s, 1H), 7.41–7.13 (m, 3H), 4.74–4.71 (m, 1H), 4.68–4.48 (m, 2H), 4.12–4.06 (m, 2H), 4.04–4.01 (m, 4H), 3.99 (s, 3H), 3.93–3.75 (m, 2H), 3.21–3.17 (m, 2H), 2.73–2.70 (m, 2H), 2.45–2.32 (m, 2H), 2.20–2.15 (m, 3). LCMS <i>m</i>/<i>z</i> (M + H) 433.</div></div><div id="sec4-10-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step 3: 1-[3-[5-(1-Methylpyrazol-4-yl)indolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>2</b>)</h4><div class="NLM_p last">Racemic 1-[3-[5-(1-methylpyrazol-4-yl)indolin-1-yl]-1-tetrahydrofuran-3-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (100 mg) was separated by using chiral SFC (Chiralcel OJ 250 mm × 30 mm I.D., 10 μm; Supercritical CO<sub>2</sub>/MeOH (0.1% NH<sub>3</sub> H<sub>2</sub>O) = 50/50 at 70 mL/min) to give 1-[3-[5-(1-methylpyrazol-4-yl)indolin-1-yl]-1-[(3<i>R</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (26 mg, first peak) and 1-[3-[5-(1-methylpyrazol-4-yl)indolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (29 mg, second peak). Absolute configuration was arbitrarily assigned to each enantiomer. Isomer A: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.94 (s, 1H), 7.72 (s, 1H), 7.42–7.32 (m, 2H), 7.26–7.23 (m, 1H), 4.89–4.83 (m, 1H), 4.55–4.53 (m, 2H), 4.05–3.97 (m, 4H), 3.86–3.70 (m, 7H), 3.14–3.10 (m, 2H), 2.80–2.67 (m, 2H), 2.26–2.23 (m, 2H), 2.10–2.28 (m, 3H). LCMS <i>m</i>/<i>z</i> (M + H) 433. Isomer B (<b>2</b>): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.94 (s, 1H), 7.72 (s, 1H), 7.42–7.32 (m, 2H), 7.26–7.23 (m, 1H), 4.88–4.86 (m, 1H), 4.55–4.53 (m, 2H), 4.03–3.96 (m, 4H), 3.86–3.70 (m, 7H), 3.14–3.10 (m, 2H), 2.80–2.67 (m, 2H), 2.26–2.24 (m, 2H), 2.10–2.28 (m, 3H). LCMS <i>m</i>/<i>z</i> (M+H) 433.</div></div></div><div id="sec4-11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 1-[3-[6-(1-Methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>3</b>)</h3><div id="sec4-11-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Step 1: 6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline (<b>39</b>)</h4><div class="NLM_p last">To a solution of 6-bromo-1,2,3,4-tetrahydroquinoline (<b>37</b>, 17.0 g, 80.2 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (25.0 g, 120.2 mmol), and K<sub>2</sub>CO<sub>3</sub> (33.2 g, 240 mmol) in dioxane/H<sub>2</sub>O (5:1, 150 mL) was added [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (5.80 g, 8.02 mmol). The mixture was heated to 120 °C for 16 h under a nitrogen atmosphere. After cooling the reaction to room temperature, the mixture was filtered and the filtrate was concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 1:1) to give the title compound (<b>39</b>, 8.0 g, 47%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.71 (s, 1H), 7.62 (s, 1H), 7.07 (d, <i>J</i> = 6.0 Hz, 2H), 6.50 (d, <i>J</i> = 8.4 Hz, 1H), 3.87 (s, 3H), 3.23 (t, <i>J</i> = 5.2 Hz, 2H), 2.75 (t, <i>J</i> = 6.4 Hz, 2H), 1.94–1.88 (m, 2H).</div></div><div id="sec4-11-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Step 2: 1-[3-[6-(1-Methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>3</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-1-(3-bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>33</b>, 300 mg, 0.96 mmol), 6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline (<b>39</b>, 127 mg, 0.960 mmol), and <i>t</i>-BuONa (123 mg, 1.28 mmol) in 1,4-dioxane (3.0 mL) was added chloro(2-dicyclohexylphosphino-2′,6′-di-<i>I</i>-propoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(ii), methyl-<i>tert</i>-butylether adduct (78 mg, 0.096 mmol), and 2-dicyclohexylphosphino-2′,6′-di-<i>I</i>-propoxy-1,1′-biphenyl (45 mg, 0.096 mmol). The mixture was heated to 120 °C for 12 h under a nitrogen atmosphere. After cooling the reaction to room temperature, the mixture was filtered and the filtrate was concentrated in vacuo. The crude residue was purified by reverse phase chromatography (acetonitrile 38–68%/0.2% formic acid in water) to give the title compound (<b>3</b>, 145 mg, 34%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.92 (s, 1H), 7.68 (s, 1H), 7.20 (s, 1H), 7.15–7.06 (m, 1H), 6.49–6.37 (m, 1 H), 4.93–4.85 (m, 1H), 4.14–4.06 (m, 2H), 4.05–3.92 (m, 2H), 3.87–3.65 (m, 7H), 3.62–3.48 (m, 2H), 2.83–2.78 (m, 4H), 2.37–2.18 (m, 2H), 2.06–1.94 (m, 5H). LCMS <i>m</i>/<i>z</i> (M + H) 447.</div></div></div><div id="sec4-12" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 1-[3-[7-(1-Methylpyrazol-4-yl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>4</b>)</h3><div id="sec4-12-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Step 1: (<i>S</i>)-1-(3-(2,3,4,5-Tetrahydro-1<i>H</i>-benzo[<i>b</i>]azepin-1-yl)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>42</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-1-(3-bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>33</b>, 500 mg, 1.6 mmol), 2,3,4,5-tetrahydro-1<i>H</i>-benzo[<i>b</i>]azepine (<b>40</b>, 235 mg, 1.60 mmol), and <i>t</i>-BuONa (461 mg, 4.80 mmol) in 1,4-dioxane (5.0 mL) was added chloro(2-dicyclohexylphosphino-2′,6′-di-<i>i</i>-propoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(ii), methyl-<i>tert</i>-butylether adduct (131 mg, 0.160 mmol) and 2-dicyclohexylphosphino-2′,6′-di-<i>i</i>-propoxy-1,1′-biphenyl (75 mg, 0.16 mmol). The mixture was heated to 110 °C for 16 h under a nitrogen atmosphere. After cooling the reaction to room temperature, the mixture was filtered and the filtrate was concentrated in vacuo. The crude residue was purified by Prep-TLC (DCM/MeOH = 25:1) to give the presumed title compound (<b>42</b>, 400 mg, 60% purity) as a light-yellow solid.</div></div><div id="sec4-12-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Step 2: (<i>S</i>)-1-(3-(7-Bromo-2,3,4,5-tetrahydro-1<i>H</i>-benzo[<i>b</i>]azepin-1-yl)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>44</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-1-(3-(2,3,4,5-tetrahydro-1<i>H</i>-benzo[<i>b</i>]azepin-1-yl)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>42</b>, 400 mg, 60% purity) in DCM (3 mL) at 0 °C was added <i>N</i>-bromosuccinimide (154 mg, 0.860 mmol) portionwise. The mixture was stirred at room temperature for 16 h. The mixture was washed with water (40 mL × 2). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (DCM/MeOH = 20:1) to give the title compound (<b>44</b>, 280 mg, 97%) as a yellow solid. LCMS <i>m</i>/<i>z</i> (M + H) 459.</div></div><div id="sec4-12-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Step 3: 1-[3-[7-(1-Methylpyrazol-4-yl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>4</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-1-(3-(7-bromo-2,3,4,5-tetrahydro-1<i>H</i>-benzo[<i>b</i>]azepin-1-yl)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>44</b>, 350 mg, 0.760 mmol) in dioxane (5 mL) and water (3 mL) was added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (175 mg, 0.840 mmol), K<sub>2</sub>CO<sub>3</sub> (210 mg, 1.52 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (56 mg, 0.076 mmol). The mixture was heated to 110 °C for 18 h under a nitrogen atmosphere. After cooling the reaction to room temperature, the mixture was concentrated in vacuo. The residue was purified by reverse phase chromatography (acetonitrile 23–53%/0.2% formic acid in water) to give the title compound (<b>4</b>, 82 mg, 23%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.06–8.05 (m, 1H), 8.00–7.79 (m, 1H), 7.44–7.42 (m, 1H), 7.31–7.26 (m, 1H), 6.90–6.77 (m, 1H), 4.81–4.78 (m, 1H), 4.03–3.98 (m, 2H), 3.84–3.78 (m, 5H), 3.55–3.43 (m, 6H), 2.77–2.55 (m, 4H), 2.25–2.22 (m, 2H), 1.97–1.62 (m, 7H). LCMS <i>m</i>/<i>z</i> (M + H) 483.</div></div></div><div id="sec4-13" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 1-[3-[7-Methoxy-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>7</b>)</h3><div class="NLM_p last">In a similar manner to <b>4</b>, compound <b>7</b> was prepared from 7-methoxy-1,2,3,4-tetrahydroquinoline (<b>41</b>) to provide the title compound (<b>7</b>, 24%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.90 (s, 1H), 7.72 (s, 1H), 7.19 (s, 1H), 6.29 (s, 1H), 4.95–4.86 (m, 1H), 4.19–4.22 (m, 2H), 4.00–3.92 (m, 2H), 3.82–3.55 (m, 6H), 3.80 (s, 3H), 3.61 (s, 3H), 2.83–2.72 (m, 4H), 2.38–2.12 (m, 2H), 2.07–1.91 (m, 5H). LCMS <i>m</i>/<i>z</i> (M + H) 477.</div></div><div id="sec4-14" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 1-[3-[7-Chloro-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>6</b>)</h3><div id="sec4-14-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Step 1: 6-Bromo-7-chloro-1,2,3,4-tetrahydroquinoline (<b>49</b>)</h4><div class="NLM_p last">To a solution of 7-chloro-1,2,3,4-tetrahydroquinoline (<b>46</b>, 14 g, 80 mmol) in DCM (100 mL) at 0 °C was added <i>N</i>-bromosuccinimide (14.8 g, 80.0 mmol). The mixture was stirred at room temperature for 1 h. Water (100 mL) was added, and the mixture was extracted with DCM (100 mL × 2). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 100:1) to give the title compound (<b>49</b>, 7.1 g, 36%) as a light-yellow solid. LCMS <i>m</i>/<i>z</i> (M + H) 246.</div></div><div id="sec4-14-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Step 2: 7-Chloro-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline (<b>52</b>)</h4><div class="NLM_p last">To a solution of 6-bromo-7-chloro-1,2,3,4-tetrahydroquinoline (<b>49</b>, 2.1 g, 8.5 mmol) in dioxane/H<sub>2</sub>O (60 mL, 5:1) was added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (1.9 g, 9.4 mmol), Na<sub>2</sub>CO<sub>3</sub> (1.8 g, 17 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (622 mg, 0.900 mmol). The mixture was heated to 110 °C for 12 h under a nitrogen atmosphere. After cooling the reaction to room temperature, the mixture was concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 4:1) to give the title compound (<b>52</b>, 2.0 g, 95%) as yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.88–7.85 (m, 1H), 7.61 (s, 1H), 7.01 (s, 1H), 6.53 (s, 1H), 5.95 (s, 1H), 3.86–3.84 (m, 3H), 3.38–3.16 (m, 2 H), 2.65–2.62 (m, 2 H), 1.80–1.74 (m, 2 H).</div></div><div id="sec4-14-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Step 3:1-[3-[7-Chloro-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>6</b>)</h4><div class="NLM_p last">To a solution of 7-chloro-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline (<b>52</b>, 247 mg, 1.0 mmol) in dioxane (3 mL) and toluene (3 mL) was added <i>t</i>-BuONa (288 mg, 3.00 mmol), tris(dibenzylideneacetone)dipalladium (46 mg, 0.050 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (59 mg, 0.10 mmol), and (<i>S</i>)-1-(3-bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>33</b>, 313 mg, 1.00 mmol). The mixture was heated to 90 °C for 16 h under a nitrogen atmosphere. After cooling the reaction to room temperature, the mixture was concentrated in vacuo. The crude residue was purified by Prep-TLC (DCM/MeOH = 20:1) to give the title compound (<b>6</b>, 240 mg, 50%) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.97 (s, 1H), 7.68 (s, 1H), 7.21–7.20 (m, 1H), 6.54–6.50 (m, 1H), 4.95–4.89 (m, 1H), 4.18–4.15 (m, 2H), 4.03–3.98 (m, 2H), 3.85–3.71 (m, 7H), 3.54–3.50 (m, 2H), 2.86–2.77 (m, 4H), 2.33–2.27 (m, 2H), 2.08–1.94 (m, 5H). LCMS <i>m</i>/<i>z</i> (M + H) 481.</div></div></div><div id="sec4-15" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 1-[3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>8</b>)</h3><div id="sec4-15-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Step 1: Quinoline-7-carbaldehyde</h4><div class="NLM_p last">To a solution of 7-methylquinoline (27.0 g, 189 mmol) at 160 °C was added SeO<sub>2</sub> (21.0 g, 189 mmol) portionwise over 5 min. The mixture was stirred at 160 °C for 8 h. After cooling the reaction to room temperature, DCM (400 mL) was added and the mixture was filtered though Celite. The organic layer was concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 10:1) to give the title compound (14.0 g, 47%) as yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.23 (s, 1H), 9.03 (d, <i>J</i> = 2.8 Hz, 1H), 8.56 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 1H), 8.04 (d, <i>J</i> = 8.4 Hz, 1H), 7.93 (d, <i>J</i> = 8.4 Hz, 1H), 7.55–7.52 (m, 1H).</div></div><div id="sec4-15-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Step 2: 7-(Difluoromethyl)quinoline</h4><div class="NLM_p last">To a solution of quinoline-7-carbaldehyde (14.0 g, 89.2 mmol) in DCM (150 mL) 0 °C was added diethylaminosulfurtrifluoride (65.0 g, 446 mmol) dropwise over 20 min. The mixture was stirred at room temperature for 16 h. The mixture was poured into satd aq NaHCO<sub>3</sub> (1 L) at 0 °C and extracted with DCM (200 mL × 2). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 5:1) to give the title compound (13.0 g, 81%) as yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.92 (d, <i>J</i> = 2.8 Hz, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 (d, <i>J</i> = 8.4 Hz, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 1H), 7.44–7.41 (m, 1H), 6.78 (t, <i>J</i> = 56.0 Hz, 1H).</div></div><div id="sec4-15-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Step 3: 7-(Difluoromethyl)-1,2,3,4-tetrahydroquinoline (<b>47</b>)</h4><div class="NLM_p last">To a solution of 7-(difluoromethyl)quinoline (13.0 g, 72.6 mmol) and NaBH<sub>3</sub>CN (23.0 g, 363 mmol) in MeOH (150 mL) at 0 °C was added boron trifluoride diethyl etherate (17.9 mL, 145 mmol) dropwise over 20 min. The mixture was heated to 90 °C for 24 h. After cooling the reaction to room temperature, the mixture was poured into satd aq NaHCO<sub>3</sub> (1 L) at 0 °C and extracted with DCM (200 mL × 2). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>,filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 20:1) to give the title compound (<b>47</b>, 8.0 g, 56%) as brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.00 (d, <i>J</i> = 7.2 Hz, 1H), 6.71 (d, <i>J</i> = 8.0 Hz, 1H), 6.59 (s, 1H), 6.50 (t, <i>J</i> = 56.8 Hz, 1H), 3.33 (t, <i>J</i> = 5.6 Hz, 2H), 2.79 (t, <i>J</i> = 6.4 Hz, 2H), 1.98–1.92 (m, 2H).</div></div><div id="sec4-15-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Step 4: 6-Bromo-7-(difluoromethyl)-1,2,3,4-tetrahydroquinoline (<b>50</b>)</h4><div class="NLM_p last">To a solution of 7-(difluoromethyl)-1,2,3,4-tetrahydroquinoline (<b>47</b>, 7.00 g, 38.3 mmol) in DCM (100 mL) at 0 °C was added <i>N</i>-bromosuccinimide (6.90 g, 38.3 mmol) portionwise over 20 min. The mixture was stirred at room temperature for 16 h. The mixture was poured into water (100 mL) and extracted with DCM (200 mL × 2). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 300:1) to give the title compound (<b>50</b>, 6.0 g, 60%) as light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.13 (s, 1H), 6.78 (t, <i>J</i> = 55.2 Hz, 1H), 6.72 (s, 1H), 3.31 (t, <i>J</i> = 5.2 Hz, 2H), 2.74 (t, <i>J</i> = 6.0 Hz, 2H), 1.95–1.87 (m, 2H).</div></div><div id="sec4-15-5" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Step 5: 7-(Difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline (<b>53</b>)</h4><div class="NLM_p last">To a solution of 6-bromo-7-(difluoromethyl)-1,2,3,4-tetrahydroquinoline (<b>50</b>, 600 mg, 2.30 mmol) in dioxane (8 mL) and H<sub>2</sub>O (2 mL) was added K<sub>2</sub>CO<sub>3</sub> (635 mg, 4.6 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (169 mg, 0.23 mmol), and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (478 mg, 2.30 mmol). The mixture was heated to 110 °C for 18 h under a nitrogen atmosphere. After cooling the reaction to room temperature, the mixture was concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 40:1) to give the title compound (<b>53</b>, 520 mg, 86%) as yellow oil. LCMS <i>m</i>/<i>z</i> (M + H) 264.</div></div><div id="sec4-15-6" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Step 6: 1-[3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-tetrahydrofuran-3-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone</h4><div class="NLM_p last">To a solution of 1-(3-bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>32</b>, 313 mg, 1.0 mmol), 7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline (<b>53</b>, 263 mg, 1.0 mmol), and <i>t</i>-BuONa (288 mg, 3.0 mmol) in 1,4-dioxane (10 mL) was added chloro(2-dicyclohexylphosphino-2′,6′-di-<i>i</i>-propoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II), methyl-<i>tert</i>-butylether adduct (82 mg, 0.10 mmol), and 2-dicyclohexylphosphino-2′,6′-di-<i>I</i>-propoxy-1,1′-biphenyl (47 mg, 0.10 mmol). The mixture was irradiated in a microwave at 130 °C for 45 min. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated in vacuo. The crude residue was purified by Prep-TLC (DCM/MeOH = 20:1) to give the title compound (76 mg, 16%) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.76 (s, 1H), 7.50 (s, 1H), 7.11 (s, 1H), 6.94–6.65 (m, 2H), 4.94–4.88 (m, 1H), 4.16–4.12 (m, 2H), 4.03–3.90 (m, 2H), 3.86 (s, 3H), 3.82–3.79 (m, 4H), 3.70–3.56 (m, 2H), 2.86–2.74 (m, 4H), 2.29–2.22 (m, 2H), 2.07–1.96 (m, 5H). LCMS <i>m</i>/<i>z</i> (M + H) 497.</div></div><div id="sec4-15-7" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Step 7: 1-[3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>8</b>)</h4><div class="NLM_p last">Racemic 1-[3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-tetrahydrofuran-3-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (50 mg) was separated by using chiral SFC (cellulose-3 150 mm × 21.2 mm I.D.; Supercritical CO<sub>2</sub>/MeOH (0.1% NH<sub>4</sub>OH) = 20/80 at 70 mL/min) to give 1-[3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>R</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (22 mg, second peak) and 1-[3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>8</b>, 17 mg, first peak). <i>R</i>-isomer: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.75 (s, 1H), 7.51 (s, 1H), 7.11 (s, 1H), 6.94–6.64 (m, 2H), 4.95–4.88 (m, 1H), 4.17–4.12 (m, 2H), 4.04–3.91 (m, 2H), 3.86 (s, 3H), 3.82–3.80 (m, 4H), 3.70–3.56 (m, 2H), 2.87–2.74 (m, 4H), 2.29–2.22 (m, 2H), 2.07–1.97 (m, 5H). LCMS <i>m</i>/<i>z</i> (M + H) 497. <i>S</i>-isomer (<b>8</b>): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.76 (s, 1H), 7.49 (s, 1H), 7.10 (s, 1H), 6.93–6.64 (m, 2H), 4.94–4.88 (m, 1H), 4.16–4.12 (m, 2H), 4.03–3.90 (m, 2H), 3.86 (s, 3H), 3.82–3.79 (m, 4H), 3.69–3.56 (m, 2H), 2.86–2.73 (m, 4H), 2.30–2.20 (m, 2H), 2.06–1.96 (m, 5H). LCMS <i>m</i>/<i>z</i> (M + H) 497.</div></div></div><div id="sec4-16" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 1-[3-[6-(1-Methylpyrazol-4-yl)-7-(trifluoromethyl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>9</b>)</h3><div id="sec4-16-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Step 1: 6-Bromo-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline (<b>51</b>)</h4><div class="NLM_p last">To a solution of 7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline (<b>48</b>, 800 mg, 3.98 mmol) in DCM (50 mL) at 0 °C was added <i>N</i>-bromosuccinimide (637 mg, 3.58 mmol) portionwise over 20 min. The mixture was stirred at room temperature for 1 h. The reaction was concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 10:1) to give the presumed title compound (<b>51</b>, 430 mg, 39%) as yellow oil.</div></div><div id="sec4-16-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Step 2: 6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline (<b>54</b>)</h4><div class="NLM_p last">To a solution of 6-bromo-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline (<b>51</b>, 430 mg, 1.54 mmol) in dioxane (20 mL) and H<sub>2</sub>O (4 mL) was added Na<sub>2</sub>CO<sub>3</sub> (488 mg, 4.61 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-tri-<i>i</i>-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl) palladium(II) (121 mg, 0.150 mmol), 2-(dicyclohexylphosphino)-2′,4′,6′-triisopropylbiphenyl (73 mg, 0.15 mmol), and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (383 mg, 1.84 mmol). The mixture was heated to 80 °C for 3 h under a nitrogen atmosphere. After cooling to room temperature, the mixture was concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 3:1) to give the presumed title compound (<b>54</b>, 300 mg, 70%) as a white solid.</div></div><div id="sec4-16-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Step 3: 1-[3-[6-(1-Methylpyrazol-4-yl)-7-(trifluoromethyl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>9</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-1-(3-bromo-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>33</b>, 112 mg, 0.360 mmol), 6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline (<b>54</b>, 100 mg, 0.36 mmol), and <i>t</i>-BuONa (103 mg, 1.07 mmol) in 1,4-dioxane (2 mL) was added dichloro[1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) (28 mg, 0.040 mmol). The mixture was irradiated in a microwave at 150 °C for 1 h. After cooling to room temperature, water (40 mL) was added and extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by reverse phase chromatography (acetonitrile 40–70%/0.225% formic acid in water) to give the title compound (<b>9</b>, 39 mg, 21%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.53 (d, <i>J</i> = 2.8 Hz, 1H), 7.41 (d, <i>J</i> = 7.2 Hz, 1H), 7.07–7.02 (m, 1H), 6.90 (d, <i>J</i> = 7.6 Hz, 1H), 4.78–4.76 (m, 1H), 4.27–4.13 (m, 4H), 4.00–3.91 (m, 3H), 3.93 (s, 3H), 3.76–3.70 (m, 3H), 2.88–2.84 (m, 4H), 2.43–2.39 (m, 2H), 2.18–2.06 (m, 5H). LCMS <i>m</i>/<i>z</i> (M + H) 515.</div></div></div><div id="sec4-17" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 1-[3-[7-Methyl-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>5</b>)</h3><div class="NLM_p last">To a solution of 1-[3-[7-chloro-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-[(3<i>S</i>)-tetrahydrofuran-3-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>6</b>, 150 mg, 0.313 mmol) in toluene (3 mL) and H<sub>2</sub>O (1 mL) was added MeBF<sub>3</sub>K (116 mg, 0.939 mmol), palladium(II) acetate (7 mg, 0.03 mmol), Cs<sub>2</sub>CO<sub>3</sub> (612 mg, 0.626 mmol), and di(adamantan-1-yl)(butyl)phosphine (23 mg, 0.0616 mmol). The mixture was heated to 100 °C for 18 h under a nitrogen atmosphere. After cooling the reaction to room temperature, the mixture was concentrated in vacuo. The crude residue was purified by Prep-TLC (DCM/MeOH = 20:1) to give the title compound (<b>5</b>, 21 mg, 15%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.76 (s, 1H), 7.52 (s, 1H), 6.99–6.98 (m, 1H), 6.36–6.34 (m, 1H), 4.90–4.85 (m, 1H), 4.14–4.05 (m, 2H), 4.04–3.93 (m, 2H), 3.87–3.66 (m, 7H), 3.58–3. 52 (m, 2H), 2.84–2.67 (m, 4H), 2.34–2.21 (m, 2H), 2.15 (s, 3H), 2.09–1.81 (m, 5H). LCMS <i>m</i>/<i>z</i> (M + H) 461.</div></div><div id="sec4-18" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 1-(3-(7-(Difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1,4,6,7-tetrahydro-5<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl)ethan-1-one (<b>10</b>)</h3><div class="NLM_p last">To a solution of 7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline (<b>53</b>, 251 mg, 0.950 mmol) in 2-methyl-2-butanol (8 mL) was added 1-(3-bromo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>34</b>, 500 mg, 1.52 mmol), (2-dicyclohexylphosphino-2,4,6-triisopropyl-1,1-biphenyl)[2-(2-amino-1,1-biphenyl)]palladium(II) methanesulfonate (129 mg, 0.150 mmol), and K<sub>3</sub>PO<sub>4</sub> (971 mg, 4.60 mmol). The mixture was heated to 95 °C for 42 h under an argon atmosphere. After cooling the reaction to room temperature, the mixture was concentrated in vacuo. The crude residue was purified by silica gel chromatography (DCM/MeOH = 50:1) to give 1-[3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-tetrahydrofuran-3-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>10</b>, 360 mg, 74%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.75 (s, 1H), 7.50 (s, 1H), 7.10 (s, 1H), 6.96–6.63 (m, 2H), 4.33–4.25 (m, 1H), 4.20–4.09 (m, 2H), 3.99–3.90 (m, 2H), 3.86 (s, 3H), 3.78–3.66 (m, 2H), 3.63–3.55 (m, 2H), 3.49–3.41 (m, 2H), 2.89–2.66 (m, 4H), 2.11–1.90 (m, 7H), 1.85–1.80 (m, 2H). <sup>13</sup>C NMR (101 MHz, 360 K, DMSO-<i>d</i><sub>6</sub>) δ 169.3, 148.4, 142.7, 138.3, 137.7, 131.1, 129.7, 129.2 (t, <i>J</i> = 20.8 Hz), 126.4, 121.4, 119.1, 114.3 (t, <i>J</i> = 235.3 Hz), 110.7, 106.5, 66.5, 54.5, 49.6, 43.4, 39.0, 38.7, 32.8, 27.4, 22.5, 22.3, 21.7; HRMS <i>m</i>/<i>z</i> 511.2628 (M + H<sup>+</sup>, C<sub>27</sub>H<sub>33</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub>, requires 511.2633).</div></div><div id="sec4-19" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 1-[1-Cyclohexyl-3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>11</b>)</h3><div id="sec4-19-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Step 1: <i>tert</i>-Butyl 3-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>55</b>) and <i>tert</i>-Butyl 3-Bromo-2-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-2<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-bromo-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>26</b>, 80.0 g, 265 mmol) in THF (1.5 L) at 0 °C was added sodium hydride (60%, 12.71 g, 317.7 mmol) portionwise. The mixture was stirred at room temperature for 0.5 h. 2-(Trimethylsilyl)ethoxymethyl chloride (52.97 g, 317.7 mmol) was added dropwise and the mixture stirred at room temperature for an additional 16 h. The mixture was quenched with water (1 L) and extracted with EtOAc (500 mL × 3). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (petroleum ether/EtOAc = 5:1) to give a mixture of the title compounds (<b>55</b>, 95 g, 83%) as yellow oil. LCMS <i>m</i>/<i>z</i> (M + H) 434.</div></div><div id="sec4-19-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Step 2: <i>tert</i>-Butyl 3-(7-(Difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>56</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate and <i>tert</i>-butyl 3-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-2<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>55</b>, 65.7 g, 152 mmol) in 1,4-dioxane (200 mL) was added chloro(2-dicyclohexylphosphino-2′,6′-di-<i>i</i>-propoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (5.9 g, 7.6 mmol), 2-dicyclohexylphosphino-2′,6′-di-<i>i</i>-propoxy-1,1′-biphenyl (3.54 g, 7.6 mmol), 7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline (20 g, 75.96 mmol), and <i>t</i>-BuONa (21.9 g, 227.89 mmol). The mixture was heated to 120 °C for 16 h under an argon atmosphere. After cooling the reaction to room temperature, water (800 mL) was added and extracted with EtOAc (500 mL × 3). The combined organic layers were washed with brine (500 mL × 3), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (DCM/MeOH = 50:1) to give the title compound (<b>56</b>, 9.1 g, 20%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.54 (s, 1H), 7.41 (s, 1H), 7.03 (s, 1H), 6.88 (s, 1H), 6.52 (t, <i>J</i> = 55.6 Hz, 1H), 5.33 (s, 2H), 4.10 (s, 2H), 3.96 (s, 3H), 3.73–3.70 (m, 4H), 3.64 (t, <i>J</i> = 8.0 Hz, 2H), 2.87–2.80 (m. 4H), 2.09–2.07 (m, 2H), 1.45 (s, 9H), 0.93 (t, <i>J</i> = 8.0 Hz, 2H), 0.00 (s, 9H). LCMS <i>m</i>/<i>z</i> (M + H) 615.</div></div><div id="sec4-19-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Step 3: <i>tert</i>-Butyl 3-(7-(Difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>57</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-(7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>56</b>, 8.5 g, 14 mmol) in THF (50 mL) was added tetrabutylammonium fluoride (1.0 M in THF, 40 mL, 40 mmol). The mixture was heated to 60 °C for 16 h under a nitrogen atmosphere. After cooling the reaction to room temperature, EtOAc (200 mL) was added and washed with brine (100 mL × 3). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (DCM/MeOH = 20:1) to give the title compound (<b>57</b>, 4.4 g, 66%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.54 (s, 1H), 7.42 (s, 1H), 7.03 (s, 1H), 6.87 (s, 1H), 6.52 (t, <i>J</i> = 55.6 Hz, 1H), 4.12 (s, 2H), 3.96 (s, 3H), 3.72–3.69 (m, 4H), 2.86–2.76 (m. 4H), 2.08–2.05 (m, 2H), 1.45 (s, 9H). LCMS <i>m</i>/<i>z</i> (M + H) 485.</div></div><div id="sec4-19-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Step 4: 7-(Difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-(4,5,6,7-tetrahydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (<b>58</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-(7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>57</b>, 2.0 g, 4.13 mmol) in DCM (5 mL) at 0 °C was added trifluoroacetic acid (4.0 mL, 4.13 mmol). The mixture was stirred at 20 °C for 16 h and concentrated in vacuo to give the title compound (<b>58</b>, 2.0 g, crude) as brown oil that required no further purification. LCMS <i>m</i>/<i>z</i> (M + H) 385.</div></div><div id="sec4-19-5" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Step 5: 1-[3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1,4,6,7-tetrahydropyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>59</b>)</h4><div class="NLM_p last">To a solution of 7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-(4,5,6,7-tetrahydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (<b>58</b>, 120 mg, 0.310 mmol) in DCM (5 mL) at 0 °C was added triethylamine (0.09 mL, 0.6 mmol) and acetic anhydride (0.04 mL, 0.62 mmol). The mixture was stirred at 20 °C for 1 h. DCM (50 mL) was added and washed with water (30 mL × 3) and brine (30 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by reverse phase chromatography (acetonitrile 26–56%/0.05% NH<sub>4</sub>OH in water) to give the title compound (<b>59</b>, 19 mg, 14%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.42–12.31 (m, 1H), 7.75 (s, 1H), 7.50 (s, 1H), 7.10 (s, 1H), 6.96–6.62 (m, 1H), 6.73 (s, 1H), 4.21–4.04 (m, 2H), 3.86 (s, 3H), 3.76–3.51 (m, 4H), 2.88–2.66 (m, 4H), 2.07–1.87 (m, 5H). LCMS <i>m</i>/<i>z</i> (M + H) 427.</div></div><div id="sec4-19-6" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Step 6: 1-[1-Cyclohexyl-3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>11</b>)</h4><div class="NLM_p last">To a solution of 1-[3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1,4,6,7-tetrahydropyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>59</b>, 50 mg, 0.12 mmol) in DMF (5 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (69 mg, 0.21 mmol) and bromocyclohexane (0.03 mL, 0.23 mmol). The mixture was heated to 80 °C for 24 h. After cooling to room temperature, the mixture was filtered and concentrated in vacuo. The crude residue was purified by reverse phase chromatography (acetonitrile 42–72%/0.2% formic acid in water) to give the title compound (<b>11</b>, 3 mg, 5%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.52 (d, <i>J</i> = 5.6 Hz, 1H), 7.40 (d, <i>J</i> = 6.4 Hz, 1H), 7.06–6.96 (m, 1H), 6.86 (d, <i>J</i> = 2.4 Hz, 1H), 6.68–6.34 (m, 1H), 4.30–4.10 (m, 2H), 3.96 (s, 3H), 3.92–3.83 (m, 2H), 3.76–3.66 (m, 3H), 2.90–2.72 (m, 4H), 2.19–2.02 (m, 7H), 1.96–1.88 (m, 6H), 1.44–1.22 (m, 2H). LCMS <i>m</i>/<i>z</i> (M + H) 509.</div></div></div><div id="sec4-20" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 1-[3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-(1-methylsulfonyl-4-piperidyl)-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>15</b>)</h3><div class="NLM_p last">In a similar manner to <b>11</b>, compound <b>15</b> was prepared from 1-(methylsulfonyl)piperidin-4-yl methanesulfonate to provide the title compound (<b>15</b>, 7%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.57–7.54 (m, 1H), 7.44–7.39 (m, 1H), 7.07–7.01 (m, 1H), 6.90–6.87 (m, 1H), 6.71–6.37 (m, 1H), 4.28–4.13 (m, 2H), 4.10–4.02 (m, 1H), 3.99–3.91 (m, 3H), 3.96 (s, 3H), 3.75–3.69 (m, 3H), 3.02–2.92 (m, 2H), 2.90–2.83 (m, 5H), 2.81–2.71 (m, 2H), 2.39–2.24 (m, 2H), 2.17–2.05 (m, 7H). LCMS <i>m</i>/<i>z</i> (M + H) 588.</div></div><div id="sec4-21" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 1-[3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-(4-piperidyl)-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>13</b>)</h3><div id="sec4-21-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Step 1: <i>tert</i>-Butyl 4-(5-Acetyl-3-(7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-4,5,6,7-tetrahydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-1-yl)piperidine-1-carboxylate (<b>60</b>)</h4><div class="NLM_p last">In a similar manner to <b>11</b>, compound <b>60</b> was prepared from <i>tert</i>-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate to provide the title compound (<b>60</b>, 17%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.55–7.53 (m, 1H), 7.42–7.40 (m, 1H), 7.06–7.00 (m, 1H), 6.86 (s, 1H), 6.68–6.37 (m, 1H), 4.38–4.12 (m, 3H), 4.08–3.99 (m, 1H), 3.96 (s, 3H), 3.95–3.89 (m, 2H), 3.75–3.67 (m, 3H), 2.89–2.70 (m, 6H), 2.17–2.03 (m, 7H), 1.92–1.88 (m, 2H), 1.48 (s, 9H). LCMS <i>m</i>/<i>z</i> (M + H) 610.</div></div><div id="sec4-21-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Step 2: 1-[3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-(4-piperidyl)-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>12</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-(5-acetyl-3-(7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-4,5,6,7-tetrahydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-1-yl)piperidine-1-carboxylate (<b>60</b>, 50 mg, 0.090 mmol) in DCM (2 mL) at 0 °C was added trifluoroacetic acid (0.07 mL, 0.9 mmol). The mixture was stirred at room temperature for 1 h and concentrated in vacuo. The mixture was diluted with DCM (10 mL) and washed with satd aq NaHCO<sub>3</sub> (10 mL × 2) and brine (10 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was resolved in MeOH (1 mL), water added (10 mL), and lyophilized to give the title compound (<b>12</b>, 22 mg, 49%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.54 (d, <i>J</i> = 6.0 Hz, 1H), 7.41 (d, <i>J</i> = 6.8 Hz, 1H), 7.08–6.97 (m, 1H), 6.88 (d, <i>J</i> = 3.6 Hz, 1H), 6.68–6.37 (m, 1H), 4.27–4.11 (m, 2H), 4.10–4.01 (m, 1H), 3.96 (s, 3H), 3.93–3.87 (m, 1H), 3.79–3.68 (m, 3H), 3.37–3.26 (m, 2H), 2.93–2.71 (m, 6H), 2.19–1.93 (m, 9H). LCMS <i>m</i>/<i>z</i> (M + H) 510.</div></div></div><div id="sec4-22" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 1-[3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-(1-methyl-4-piperidyl)-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>13</b>)</h3><div class="NLM_p last">To a solution of 1-(3-(7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-1-(piperidin-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5(4<i>H</i>)-yl)ethanone (<b>12</b>, 80 mg, 0.16 mmol) in DCE (2 mL) was added sodium cyanoborohydride (30 mg, 0.47 mmol), AcOH (0.05 mL, 0.9 mmol), and formaldehyde (37% in water, 0.035 mL, 0.47 mmol). The mixture was stirred at room temperature for 1 h. The reaction was quenched with satd aq NaHCO<sub>3</sub> (10 mL) and extracted with DCM (10 mL × 3). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by reverse phase chromatography (acetonitrile 24–54%/0.05% NH<sub>4</sub>OH in water) to give the title compound (<b>13</b>, 19 mg, 23%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.73 (s, 1H), 7.48 (s, 1H), 7.08 (s, 1H), 6.92–6.62 (m, 2H), 4.15–4.10 (m, 2H), 4.02–3.94 (m, 1H), 3.85 (s, 3H), 3.72–3.65 (m, 2H), 3.60–3.55 (m, 2H), 2.83–2.71 (m, 6H), 2.18 (s, 3H), 2.05–1.90 (m, 9H), 1.84–1.75 (m, 2H). LCMS <i>m</i>/<i>z</i> (M + H) 524.</div></div><div id="sec4-23" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 1-[4-[5-Acetyl-3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-1-yl]-1-piperidyl]ethanone (<b>14</b>)</h3><div id="sec4-23-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Step 1: <i>tert</i>-Butyl 1-(1-Acetylpiperidin-4-yl)-3-(7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>61</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 1-(1-acetylpiperidin-4-yl)-3-bromo-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>30</b>, 500 mg, 1.20 mmol) in 1,4-dioxane (3 mL) was added 7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline (<b>53</b>, 370 mg, 1.40 mmol), <i>t</i>-BuONa (562 mg, 5.9 mmol), and dichloro[1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) (93 mg, 0.12 mmol). The mixture was heated to 120 °C for 12 h under a nitrogen atmosphere. After cooling the reaction to room temperature, DCM (50 mL) was added and washed with water (40 mL × 2) and brine (40 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (DCM/MeOH = 20:1) to give the title compound (<b>61</b>, 300 mg, 42%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.75 (s, 1H), 7.49 (s, 1H), 7.10 (s, 1H), 6.79 (s, 1H), 6.78 (t, <i>J</i> = 55.2 Hz, 1 H), 4.48–4.41 (m, 1H), 4.39–4.28 (m, 2H), 4.08–3.98 (m, 2H), 3.94–3.90 (m, 1H), 3.86 (s, 3H), 3.61–3.56 (m, 2H), 3.24–3.09 (m, 1H), 2.84–2.74 (m, 4H), 2.74–2.63 (m, 2H), 2.02 (s, 3H), 1.98–1.85 (m, 6H), 1.41–1.37 (m, 9H). LCMS <i>m</i>/<i>z</i> (M + H) 610.</div></div><div id="sec4-23-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Step 2: 1-(4-(3-(7-(Difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-4,5,6,7-tetrahydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-1-yl)piperidin-1-yl)ethanone (<b>63</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 1-(1-acetylpiperidin-4-yl)-3-(7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>61</b>, 300 mg, 0.500 mmol) in DCM (2 mL) was added trifluoroacetic acid (0.4 mL, 5 mmol). The reaction was stirred at room temperature for 1 h and concentrated in vacuo. The crude residue was diluted with DCM (50 mL) and washed with satd aq NaHCO<sub>3</sub> (30 mL × 2) and water (30 mL) and brine (40 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give the title compound (<b>63</b>, 200 mg, crude) as a white solid that required no further purification. LCMS <i>m</i>/<i>z</i> (M + H) 510.</div></div><div id="sec4-23-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Step 3: 1-[4-[5-Acetyl-3-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-1-yl]-1-piperidyl]ethanone (<b>14</b>)</h4><div class="NLM_p last">To a solution of 1-(4-(3-(7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-4,5,6,7-tetrahydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-1-yl)piperidin-1-yl)ethanone (<b>63</b>, 100 mg, 0.17 mmol) in DCM (2 mL) at 0 °C was added triethylamine (0.07 mL, 0.5 mmol) and acetic anhydride (0.02 mL, 0.2 mmol). The mixture was stirred at room temperature for 1 h. DCM (50 mL) was added and washed with water (40 mL) and brine (40 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by Prep-TLC (DCM/MeOH = 20:1) to give the title compound (<b>14</b>, 53 mg, 52%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.75 (s, 1H), 7.50 (s, 1H), 7.10 (s, 1H), 6.94–6.64 (m, 2H), 4.46–4.42 (m, 1H), 4.39–4.26 (m, 1H), 4.21–4.08 (m, 2H), 3.93–3.89 (m, 1H), 3.86 (s, 3H), 3.79–3.65 (m, 2H), 3.63–3.52 (m, 2H), 3.25–3.11 (m, 1H), 2.90–2.83 (m, 3H), 2.80–2.64 (m, 2H), 2.08–1.96 (m, 6H), 1.95–1.83 (m, 5H), 1.80–1.67 (m, 1H). LCMS <i>m</i>/<i>z</i> (M + H) 552.</div></div></div><div id="sec4-24" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 1-[3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-(1,1-dioxothian-4-yl)-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-5-yl]ethanone (<b>16</b>)</h3><div class="NLM_p last">In a similar manner to <b>14</b>, compound <b>16</b> was prepared from <i>tert</i>-butyl 3-bromo-1-(1,1-dioxidotetrahydro-2<i>H</i>-thiopyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>35</b>) to provide the title compound (<b>16</b>, 40%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.76 (s, 1H), 7.50 (s, 1H), 7.11 (s, 1H), 6.94–6.65 (m, 2H), 4.52–4.48 (m, 1H), 4.16–4.11 (m, 2H), 3.86 (s, 3H), 3.75–3.69 (m, 2H), 3.60–3.58 (m, 2H), 3.35–3.30 (m, 2H), 3.25–3.22 (m, 2H), 2.84–2.73 (m, 4H), 2.43–2.41 (m, 2H), 2.23–2.20 (m, 2H), 2.07–1.96 (m, 5H). LCMS <i>m</i>/<i>z</i> (M + H) 559.</div></div><div id="sec4-25" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-tetrahydropyran-4-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5-carboxamide (<b>18</b>)</h3><div id="sec4-25-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Step 1: <i>tert</i>-Butyl 3-(7-(Difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>65</b>)</h4><div class="NLM_p last">To a solution of 7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline (<b>53</b>, 3.41 g, 13 mmol) in dioxane (100 mL) was added <i>tert</i>-butyl 3-bromo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>29</b>, 5.0 g, 12.9 mmol), chloro(2-dicyclohexylphosphino-2′,6′-di-<i>i</i>-propoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II), methyl-<i>tert</i>-butylether adduct (1.01 g, 1.30 mmol), 2-dicyclohexylphosphino-2′,6′-di-<i>i</i>-propoxy-1,1′-biphenyl (0.60 g, 1.3 mmol) ,and <i>t</i>-BuONa (3.70 g, 38.8 mmol). The mixture was heated to 120 °C for 16 h under an argon atmosphere. After cooling the reaction to room temperature, the mixture was concentrated in vacuo. The crude residue was purified by silica gel chromatography (DCM/MeOH = 100:1) to give the title compound (<b>65</b>, 5.4 g, 73%) as a light-yellow soild. LCMS <i>m</i>/<i>z</i> (M + H) 569.</div></div><div id="sec4-25-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Step 2: 7-(Difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-4,5,6,7-tetrahydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (<b>66</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-(7-(difluoromethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinolin-1(2<i>H</i>)-yl)-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-6,7-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxylate (<b>65</b>, 6.3 g, 11 mmol) in DCM (20 mL) was added trifluoroacetic acid (20 mL). The mixture was stirred at 30 °C for 3 h. The reaction was concentrated in vacuo to give the title compound (<b>66</b>, 10.8 g, crude) as brown oil which was used to the next step without further purification. LCMS <i>m</i>/<i>z</i> (M + H) 469.</div></div><div id="sec4-25-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Step 3: 3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-1-tetrahydropyran-4-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5-carboxamide (<b>18</b>)</h4><div class="NLM_p last">To a solution of 7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-1-(1-tetrahydropyran-4-yl-4,5,6,7-tetrahydropyrazolo[4,3-<i>c</i>]pyridin-3-yl)-3,4-dihydro-2<i>H</i>-quinoline (<b>66</b>, 200 mg, 0.430 mmol) in DCM (2 mL) was added trimethylsilyl isocyanate (0.12 mL, 0.85 mmol). The mixture was stirred at room temperature for 3 h and concentrated in vacuo. The crude residue was purified by reverse phase chromatography (acetonitrile 18–48%/0.1% NH<sub>4</sub>OH in water) to give the title compound (<b>18</b>, 44 mg, 20%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.75 (s, 1H), 7.50 (s, 1H), 7.09 (s, 1H), 6.83 (s, 1H), 6.78 (t, <i>J</i> = 55.2 Hz, 1H), 6.08 (s, 2H), 4.31–4.26 (m, 1H), 4.02 (s, 2H), 3.97–3.94 (m, 2H), 3.86 (s, 3H), 3.60–3.55 (m, 4H), 3.48–3.42 (m, 2H), 2.84–2.67 (m, 4H), 2.00–1.94 (m, 4H), 1.83–1.80 (m, 2H). LCMS <i>m</i>/<i>z</i> (M + H) 512.</div></div></div><div id="sec4-26" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-<i>N</i>-methyl-1-tetrahydropyran-4-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5-carboxamide (<b>19</b>)</h3><div class="NLM_p last">To a solution of 7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-1-(1-tetrahydropyran-4-yl-4,5,6,7-tetrahydropyrazolo[4,3-<i>c</i>]pyridin-3-yl)-3,4-dihydro-2<i>H</i>-quinoline (<b>66</b>, 10.8 g, 23.0 mmol) and triethylamine (8.1 g, 80 mmol) in DCM (20 mL) was added <i>N</i>-methylimidazole-1-carboxamide (4.0 g, 32 mmol). The reaction was stirred at 25 °C for 36 h. Water (20 mL) was added and extracted with DCM (20 mL × 3). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (DCM/MeOH = 100:1) to give the title compound (<b>19</b>, 2.7 g, 22%) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.76–7.75 (m, 1H), 7.49 (s, 1H), 7.10 (s, 1H), 6.83 (s, 1H), 6.92–6.78 (t, <i>J</i> = 55.2 Hz, 1H), 6.65–6.53 (m, 1H), 4.31–4.28 (m, 1H), 4.13–3.93 (m, 4H), 3.86 (s, 3H), 3.69–3.58 (m, 4H), 3.48–3.42 (m, 2H), 2.84–2.74 (m, 4H), 2.54–2.53 (m, 3H), 1.97–1.80 (m, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.3, 148.0, 142.5, 138.2, 137.9, 131.0, 129.7, 128.9 (t, <i>J</i> = 20.5 Hz), 126.0, 121.0 (t, <i>J</i> = 5.1 Hz), 119.0, 114.2 (t, <i>J</i> = 235.8 Hz), 110.2 (t, <i>J</i> = 6.1 Hz), 106.8, 66.5, 54.0, 49.4, 40.8, 40.7, 39.0, 32.8, 27.6, 27.4, 22.1, 21.9. HRMS <i>m</i>/<i>z</i> 526.2718 (M + H<sup>+</sup>, C<sub>27</sub>H<sub>34</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, requires 526.2742).</div></div><div id="sec4-27" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-<i>N</i>-ethyl-1-tetrahydropyran-4-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5-carboxamide (<b>20</b>)</h3><div class="NLM_p last">To a solution of pyridine (0.37 mL, 4.6 mmol) and 7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-1-(1-tetrahydropyran-4-yl-4,5,6,7-tetrahydropyrazolo[4,3-<i>c</i>]pyridin-3-yl)-3,4-dihydro-2<i>H</i>-quinoline (<b>66</b>, 362 mg, 0.770 mmol) in DMF (5 mL) was added 4-nitrophenyl chloroformate (467 mg, 2.32 mmol). The reaction was stirred at room temperature for 2 h. Ethanamine (12 mL, 24 mmol) was added to the reaction mixture. The reation was heated to 80 °C for 12 h in a sealed tube. After cooling to room temperature, the reaction mixture was concentrated in vacuo. The crude residue was purified by reverse phase chromatography (acetonitrile 33–51%/0.2% formic acid in water) to give the title compound (<b>20</b>, 57 mg, 14%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.75 (s, 1H), 7.49 (s, 1H), 7.09 (s, 1H), 6.83 (s, 1H), 6.78 (t, <i>J</i> = 55.6 Hz, 1H), 6.60 (t, <i>J</i> = 5.6 Hz, 1H), 4.37–4.20 (m, 1H), 4.01 (s, 2H), 4.00–3.91 (m, 2H), 3.86 (s, 3H), 3.66–3.56 (m, 4H), 3.51–3.39 (m, 2H), 3.02 (q, <i>J</i> = 6.8 Hz, 2H), 2.88–2.82 (m, 2H), 2.77–2.72 (m, 2H), 2.07–1.89 (m, 4H), 1.86–1.78 (m, 2H), 0.97 (t, <i>J</i> = 6.8 Hz, 3H). LCMS <i>m</i>/<i>z</i> (M + H) 540.</div></div><div id="sec4-28" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2<i>H</i>-quinolin-1-yl]-<i>N</i>,<i>N</i>-dimethyl-1-tetrahydropyran-4-yl-6,7-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-5-carboxamide (<b>21</b>)</h3><div class="NLM_p last">To a solution of triethylamine (0.31 mL, 2.3 mmol) and 7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-1-(1-tetrahydropyran-4-yl-4,5,6,7-tetrahydropyrazolo[4,3-<i>c</i>]pyridin-3-yl)-3,4-dihydro-2<i>H</i>-quinoline (<b>66</b>, 211 mg, 0.450 mmol) in DMF (2 mL) was added dimethylcarbamyl chloride (0.04 mL, 0.45 mmol). The reaction was stirred at room temperature for 16 h. EtOAc (5 mL) was added and washed with water (5 mL). The organic layer was concentrated in vacuo. The crude residue was purified by reverse phase chromatography (acetonitrile 30–60%/0.2% formic acid in water) to give the title compound (<b>21</b>, 55 mg, 22%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.76 (s, 1H), 7.50 (s, 1H), 7.10 (s, 1H), 6.81 (s, 1H), 6.79 (t, <i>J</i> = 55.2 Hz, 1H), 4.38–4.20 (m, 1H), 4.02–3.90 (m, 2H), 3.87 (s, 3H), 3.84–3.79 (m, 2H), 3.62–3.54 (m, 2H), 3.49–3.42 (m, 2H), 3.41–3.36 (m, 2H), 2.91–2.79 (m, 4H), 2.70 (s, 6H), 2.05–1.91 (m, 4H), 1.88–1.76 (m, 2H). LCMS <i>m</i>/<i>z</i> (M + H) 540.</div></div><div id="sec4-29" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Modeling Methods</h3><div class="NLM_p last">All crystal structure figures were made using PyMOL Molecular Graphics System, version 1.8, Schrödinger, LLC.</div></div><div id="sec4-30" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Expression and Purification of Bromodomain Proteins</h3><div class="NLM_p last">The expression and purification of bromodomain proteins was carried out as previously described.<a onclick="showRef(event, 'ref11 ref32'); return false;" href="javascript:void(0);" class="ref ref11 ref32">(11, 32)</a></div></div><div id="sec4-31" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Expression and Purification of Bromodomain Proteins for Crystallography</h3><div class="NLM_p last">The expression and purification of CRBP and BRD4 bromodomains for crystallography have been previously described.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div></div><div id="sec4-32" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Time-Resolved Fluorescence Resonance Energy Transfer Assays</h3><div class="NLM_p last">Compound potencies were evaluated in a panel of biochemical bromodomain binding assays. Binding of biotinylated small-molecule ligands to recombinant His-tagged bromodomains was assessed by time-resolved fluorescence resonance energy transfer (TR-FRET). Test compounds that compete with the biotinylated ligand for bromodomain binding reduce the TR-FRET signal. All biochemical assay protocols were carried out as previously described.<a onclick="showRef(event, 'ref11 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref11 ref32 ref33">(11, 32, 33)</a></div></div><div id="sec4-33" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Cellular Assay Protocols</h3><div class="NLM_p last">The CBP BRET assay was carried out as previously described.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> To determine the inhibition of <i>MYC</i> expression, MV-4-11 cells (ATCC) were plated at 10000 cells per well in 96-well plates in RPMI1640 media supplemented with 10% fetal bovine serum and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine. Test compounds diluted in DMSO were transferred to the cell plates, keeping final DMSO concentration consistent at 0.1%, and incubated for 4 h at 37 °C. Lysis and analysis for <i>MYC</i> expression were carried out using QuantiGene 2.0 reagents (Affymetrix/eBioscience, probe set cat. no. SA-50182) and following the vendor’s instructions. Luminescence was read using an EnVision plate reader (PerkinElmer) and EC<sub>50</sub>s generated in XLFit using a four-parameter nonlinear regression fit.</div></div><div id="sec4-34" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> In Vitro Metabolic Stability Experiments, MDCK Permeability Experiments, Protein Binding Experiments, and CYP Inhibition Assessment</h3><div class="NLM_p">Experiments were carried out as previously described.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div id="sec4-34-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> In Vivo PK of <b>10</b> and <b>19</b></h4><div class="NLM_p">Mouse PK: Twelve female CD-1 mice were obtained from Vital River Laboratory Animal Co., Ltd., Beijing, P.R. China. All animals were 6–9 weeks old at the time of study and weighed between 20 and 35 g. Animals (<i>n</i> = 3 per dosing route) were dosed with <b>10</b> or <b>19</b> at 1 mg/kg iv (in propyl ethylene glycol 400 (35% v/v) and water (65% v/v)) or 5 mg/kg po (suspended in 0.5% w/v methylcellulose, 0.2% w/v Tween 80). Food and water were available ad libitum to all animals. Serial blood samples (15 μL) were collected by tail nick at 0.033, 0.083, 0.25, 0.5, 1, 3, 8, and 24 h after the intravenous administration and 0.083, 0.25, 0.5, 1, 3, 8, and 24 h after the oral administration. All blood samples were diluted with 60 μL of water containing 1.7 mg/mL EDTA and kept at −80 °C until analysis.</div><div class="NLM_p">Rat PK: Twelve male Sprague–Dawley rats were obtained from Shanghai SLAC Laboratory Animal Co. Ltd., Shanghai, P.R. China. All animals were 6–9 weeks old at the time of study and weighed between 200 and 300 g. Animals (<i>n</i> = 3 per dosing route) were dosed with <b>10</b> or <b>19</b> at 1 mg/kg iv (in propyl ethylene glycol 400 (35% v/v) and water (65% v/v)) or 5 mg/kg po (suspended in 0.5% w/v methylcellulose, 0.2% w/v Tween 80). Food and water were available ad libitum to animals in the iv groups. Animals in po groups were fasted overnight and food withheld until 4 h postdose. Approximately 250 μL of blood were collected via the catheter at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h after the intravenous or oral administration. All blood samples were collected into tubes containing 5 μL of 0.5 M K<sub>2</sub>EDTA and processed for plasma. Samples were centrifuged (2500<i>g</i> for 15 min at 4 °C) within 1 h of collection, and plasma samples were kept at −80 °C until analysis.</div><div class="NLM_p">Dog PK: Twelve non-naïve male beagle dogs were obtained from Marshall Bioresources, Beijing, P.R. China. All animals were 6 months to 2 years old at the time of study and weighed between 6 and 10 kg. Animals (<i>n</i> = 3 per dosing route) were dosed with <b>10</b> or <b>19</b> at 1 mg/kg iv (in ethanol (20% v/v), propyl ethylene glycol 400 (15% v/v) and water (65% v/v)) or 5 mg/kg po (suspended in 0.5% w/v methylcellulose, 0.2% w/v Tween 80). Food and water were available ad libitum to animals in the iv groups. Animals in po groups were fasted overnight and food withheld until 4 h postdose. Approximately 800 μL of blood was collected from a peripheral vessel at predose, 0.033, 0.083, 0.25, 0.5, 1, 3, 6, 9, and 24 h after the intravenous administration and predose, 0.083, 0.25, 0.5, 1, 3, 6, 9, and 24 h after the oral administration. All blood samples were collected into tubes containing 10 μL of 0.5 M K<sub>2</sub>EDTA and processed for plasma. Samples were centrifuged (3000<i>g</i> for 10 min at 4 °C) within 1 h of collection, and plasma samples were kept at −80 °C until analysis.</div><div class="NLM_p">Monkey PK: Twelve non-naïve male cynomolgus monkeys were obtained from Hainan Jingang Laboratory Animal Co. Ltd., Haikou Hainan Province, P.R. China. All animals were at least 2 years old at the time of study and weighed between 2 and 5 kg. Animals (<i>n</i> = 3 per dosing route) were dosed with <b>10</b> or <b>19</b> 1 mg/kg iv (in ethanol (20% v/v), propyl ethylene glycol 400 (15% v/v) and water (65% v/v)) or 5 mg/kg po (suspended in 0.5% w/v methylcellulose, 0.2% w/v Tween 80). Food and water were available ad libitum to animals in the iv groups. Animals in po groups were fasted overnight and food withheld until 4 h postdose. Approximately 800 μL of blood was collected from a peripheral vessel at predose, 0.033, 0.083, 0.25, 0.5, 1, 3, 6, 9, and 24 h after the intravenous administration and predose, 0.083, 0.25, 0.5, 1, 3, 6, 9, and 24 h after the oral administration. All blood samples were collected into tubes containing 10 μL of 0.5 M K<sub>2</sub>EDTA and processed for plasma. Samples were centrifuged (3000<i>g</i> for 10 min at 4 °C) within 1 h of collection, and plasma samples were kept at −80 °C until analysis.</div><div class="NLM_p last">Bio-analytical method of PK samples: Concentrations of <b>10</b> and <b>19</b> were determined by a nonvalidated LC-MS/MS assay. The diluted blood samples were prepared for analysis by placing a 25 μL aliquot into a 96-well plate followed by the addition of 200 μL of acetonitrile containing an internal standard mixture (0.1 μg/mL indomethacin). The samples were vortexed and centrifuged at 4000 rpm for 10 min at 4 °C; 50 μL of the supernatant was diluted with 150 μL of water, and 10 μL of the solution was injected onto an analytical column. An Acquity UPLC system (Waters) coupled with an API 4000 mass spectrometer (AB Sciex, Foster City, CA) was used for sample analysis. The mobile phases were 0.025% FA and 1 mM NH<sub>4</sub>OAc in water/ACN (v:v, 95:5) (A) and 0.025% FA and 1 mM NH<sub>4</sub>OAc in ACN/water (v:v, 95:5) (B). The gradient was as follows: starting at 10% B and increased to 65% B for 1.2 min, then to 95% for 0.6 min, maintained at 95% B for 0.2 min, then decreased to 10% B within 0.01 min. The total flow rate was 0.6 mL/min, and samples were injected onto an ACE 3 AQ (2.1 mm × 100 mm, 3 μm) analytical column with a total run time of 2 min. Data were acquired using multiple reactions monitoring (MRM) in positive ion electrospray mode with an operating source temperature of 550 °C. The MRM transition was <i>m</i>/<i>z</i> 511.400 → 471.400 for <b>10</b>, 526.400 → 486.400 for <b>19</b>, and 357.900 → 139.000 for indomethacin. The lower and upper limits of quantitation of the assay for <b>10</b> were 0.002 and 13.1 μM, respectively. The lower and upper limits of quantitation of the assay for <b>19</b> were 0.002 and 12.7 μM, respectively.</div></div><div id="sec4-35" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> In Vivo Evaluation of <b>19</b> in MOLM-16 AML PK/PD and Antitumor Efficacy Model</h4><div class="NLM_p">RT-PCR was performed using TaqMan RNA-to-Ct 1-Step Kit and Taqman Gene Expression Assays (Applied Biosystems, Carlsbad, CA, USA). The comparative Ct method was used to estimate relative changes in gene expression using <i>MYC</i> Taqman assay (Hs00153408_m1) and <i>ACTB</i> TaqMan assay (Hs01060665_g1) as housekeeping gene.</div><div class="NLM_p">All procedures were approved by and conformed to the guidelines and principles set by the Institutional Animal Care and Use Committee of Genentech and were carried out in an Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility. Female C.B-17 SCID.bg mice that were 8–9 weeks old and weighed 20–24 g were obtained from Charles River Lab. They were inoculated with five million MOLM-16 leukemia acute myelogenic cells (suspended in a 1:1 mixture of Hank’s Balanced Salt Solution containing Matrigel at a 1:1 ratio) in the right flank subcutaneously. Tumors were monitored until they reached a mean tumor volume of 130–300 mm<sup>3</sup>. The mean tumor volume across all eight groups was 260 ± 34.5 mm<sup>3</sup> (mean ± SD) at the initiation of dosing. Mice were given 0 (vehicle–0.5% methylcellulose, 0.2% Tween-80), 3, 10, and 30 mg/kg of compound <b>19</b> by gavage, twice daily (BID) for 21 days in a volume of 100 μL. Tumor volumes were measured in two dimensions (length and width) using Ultra Cal-IV calipers (model 54-10-111; Fred V. Fowler Co., Newton, MA) and analyzed using Excel, version 11.2 (Microsoft Corporation; Redmond WA). The tumor volume was calculated with the following formula: tumor size (mm<sup>3</sup>) = (longer measurement × shorter measurement<sup>2</sup>) × 0.5. Animal body weights were measured using an Adventura Pro AV812 scale (Ohaus Corporation; Pine Brook, NJ). Percent weight change was calculated using the following formula: group percent weight change = (new weight – initial weight)/initial weight) × 100. Plasma, tumor, and brain samples were collected at 2 h postdose. To analyze the repeated measurement of tumor volumes from the same animals over time, a mixed-modeling approach was used. This approach addresses both repeated measurements and modest dropouts due to any nontreatment related removal of animals before the end of study. Cubic regression splines were used to fit a nonlinear profile to the time courses of log 2 tumor volume at each dose level. The nonlinear profiles were then related to dose within the mixed model. Tumor growth inhibition as a percentage of vehicle was calculated as the percentage of the area under the fitted tumor volume–time curve (AUC) per day for each dose group in relation to the vehicle, using the following formula: %TGI = 100 × [1 – (AUC<sub>dose</sub> per day/AUC<sub>vehicle</sub> per day)].</div><div class="NLM_p last">Concentrations of <b>19</b> were determined by a nonvalidated LC-MS/MS assay. The plasma samples were prepared for analysis by placing a 25 μL aliquot into a 96-well plate. The tumor samples were collected and weighed. Four volume of water by tissue weight was added. Using a bead beating homogenizer, the tissue samples were homogenized and 25 μL of each was aliquoted into a 96-well plate. A volume of 200 μL of acetonitrile containing an internal standard (labetalol) was added to the sample. The samples were vortexed and centrifuged at 4000 rpm for 10 min, and 50 μL of the supernatant was diluted with 150 μL of water. A 10 μL injection volume was used for analysis on a SIL-30ACMP autosampler system (Shimadzu, Columbia, MD) was linked to LC-30AD pumps (Shimadzu), coupled with an API 5500 QTrap mass spectrometer (Sciex, Foster City, CA), was used for sample analysis. The mobile phases were 0.1% FA (formic acid) in water (A) and 0.1% FA in MeCN (B). The gradient was as following: starting at 10% B and increased to 90% B in 0.6 min, maintained at 90% B for 0.2 min, then decreased to 10% B within 0.1 min. The total flow rate was 1.2 mL/min and column for separation was Kinetex XB-C18 column (50 mm × 2.1 mm, 2.6 μm) with a total run time of 1 min. Data were acquired using multiple reactions monitoring (MRM) in positive ion electrospray mode with an operating source temperature of 550 °C. The MRM transition was <i>m</i>/<i>z</i> 526.1 → 486.2 for <b>19</b> and 329.076 → 294.1 for labetalol. The lower and upper limits of quantitation of the assay for <b>19</b> were 0.002 and 39 μM, respectively.</div></div><div id="sec4-36" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> In Vitro Evaluation of <b>19</b> on T<sub>regs</sub></h4><div class="NLM_p">Human naïve CD4+T cells were isolated from PBMCs of healthy donors using naïve CD4+T Cell Isolation Kit II (Miltenyi Biotec) and differentiated to iT<sub>regs</sub> for 4 days using plate-bound anti-CD3 (5 μg/mL; eBioscience), soluble anti-CD28 (3 μg/mL; eBioscience), plus rTGFβ (5 ng/mL; R&D Systems), and rIL-2 (10 ng/mL; R&D Systems) in complete RPMI-1640 medium (10% FCS, 50 μM 2-mercaptoethanol, 10% penicillin/streptomycin, 10% NEAA, 10% sodium pyruvate). Compound <b>19</b> was used at 2 μM and titrated down at 2× dilution. This study followed the principles of research ethics as set forth in the Belmont Report and was approved by the Western Institutional Review Board (WIRB-Protocol number CEHS-CP 307.2).</div><div class="NLM_p">iT<sub>regs</sub> were stained using antibodies against surface markers CD4 FITC (clone OKT-4) and CD25 Pacific Blue (clone BC96) (all from eBioscience), fixed/permeabilized with the Foxp3/Transcription Factor Staining Buffer Set (eBioscience), and labeled for intracellular Foxp3 APC (clone 259D/C7; BD Biosciences). iT<sub>regs</sub> were stained for viability using fixable viability dye efluor 781. Samples were acquired on a BD LSR Fortessa using FACSDiva software (BD Biosciences). Data were analyzed using the FlowJo software (TreeStar, FLOWJO, LLC).</div><div class="NLM_p last">Total RNA was isolated from iT<sub>regs</sub> using RNeasy (Qiagen), including an on-column DNase I digestion. cDNA was prepared using High Capacity cDNA Reverse Transcriptase Kit (Life Technologies). Quantitative RT-PCR was performed to determine Foxp3 gene expression levels with the ABI 7900 HT Fast Real-Time PCR System (Applied Biosystems). Gene expression data was normalized to B2M as a housekeeping gene.</div></div><div id="sec4-37" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Kinetic Solubility Assay</h4><div class="NLM_p last">Kinetic solubility assay started with compound DMSO stock solutions. This assay used Millipore Multiscreen 96-well filter plates for the 24 h equilibration shaking. For routine equilibrium solubility determination of discovery chemistry compounds, samples were prepared by adding 4 μL of the 10 mM DMSO stock solution into 196 μL of PBS buffer pH 7.4 in the 96-well filter plates, yielding a compound concentration of 200 μM and 2% DMSO. The PBS buffer pH7.4 was prepared by the Genentech media lab. The filter plate was sealed with aluminum sealing film and shaken at room temperature for 24 h at 1000 rpm. When shaking was completed, the solutions were filtered into a clean 96-well plate utilizing a vacuum manifold. After filtration, some precipitate was often observed at the bottom of the filtration plate wells. The filtrate samples were diluted by a factor of 2 using PBS pH7.4 buffer and then transferred to a 384-well plate for analysis by LCMS-CLND (CLND: chemiluminescence nitrogen detector). Then 5 μL of each sample were injected twice into the LCMS-CLND instrument for repeat analysis. Samples were detected and analyzed using UV 254 nm and CLND. UV 254 nm was used primarily to confirm the sample purity but in rare cases was also used to quantify the concentration of compounds with no nitrogen, where additional work was done to create a compound specific calibration curve. The identification of CLND target peaks of each compound was confirmed by LCMS. Sample quantification was accomplished by CLND peak intensity, the CLND calibration curve, and the number of nitrogens contained in the compound. One calibration curve of caffeine was used for solubility quantitative determination. A fresh calibration curve was generated for every batch.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i98"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00796">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23105" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23105" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00796" class="ext-link">10.1021/acs.jmedchem.7b00796</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Full experimental details and characterization for all reported compounds, BromoScan data for <b>10</b> and <b>19</b>, Cerep off-target screening data for <b>19</b>, Invitrogen kinase data for <b>19</b>, ab initio torsion scan data for <b>8</b>, PK/PD data for <b>19</b>, crystallography methods for <b>3</b>-CBP, <b>8</b>-CBP, <b>17</b>-CBP, <b>10</b>-CBP, <b>19</b>-CBP, and <b>19</b>-BRD4(1) (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_001.pdf">jm7b00796_si_001.pdf (1.25 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_002.csv">jm7b00796_si_002.csv (1.98 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes for the structures of the CBP bromodomain in complex with <b>3</b>, <b>8</b>, <b>17</b>, <b>10</b>, and <b>19</b> are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0F">5W0F</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0I">5W0I</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0L">5W0L</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0Q">5W0Q</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0E">5W0E</a>, respectively. PDB code for the structure of the BRD4(1) in complex with <b>19</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VZS">5VZS</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b00796" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46317" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46317" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">F. Anthony Romero</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7917-1459" title="Orcid link">http://orcid.org/0000-0001-7917-1459</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b9d8d7cdd1d6d7c097cbd6d4dccbd6f9ccd7d0cdc0dbd0d6cddcdad1d7d6d5d6dec097dad6d4"><span class="__cf_email__" data-cfemail="75141b011d1a1b0c5b071a1810071a35001b1c010c171c1a0110161d1b1a191a120c5b161a18">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Le An</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Magnuson</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f09d91979e85839f9ede83849586959eb097959e95de939f9d"><span class="__cf_email__" data-cfemail="204d41474e55534f4e0e53544556454e6047454e450e434f4d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeremy Murray</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kwong Wah Lai</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vickie Tsui</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian K. Albrecht</span> - <span class="hlFld-Affiliation affiliation">Constellation
Pharmaceuticals, Inc., 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maureen H. Beresini</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gladys de Leon Boenig</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah M. Bronner</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily W. Chan</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin X. Chen</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhongguo Chen</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edna F. Choo</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4200-8302" title="Orcid link">http://orcid.org/0000-0003-4200-8302</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyle Clagg</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Clark</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Terry D. Crawford</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4663-4116" title="Orcid link">http://orcid.org/0000-0003-4663-4116</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Cyr</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5320-3483" title="Orcid link">http://orcid.org/0000-0001-5320-3483</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Denise de Almeida Nagata</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen E. Gascoigne</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jane L. Grogan</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Georgia Hatzivassiliou</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Huang</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas L. Hunsaker</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Kaufman</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan G. Koenig</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1878-614X" title="Orcid link">http://orcid.org/0000-0002-1878-614X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ruina Li</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingjie Li</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaorong Liang</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiangpeng Liao</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenfeng Liu</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Justin Ly</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan Maher</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Colin Masui</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Merchant</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingqing Ran</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander M. Taylor</span> - <span class="hlFld-Affiliation affiliation">Constellation
Pharmaceuticals, Inc., 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Wai</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fei Wang</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaocang Wei</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong Yu</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bing-Yan Zhu</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyu Zhu</span> - <span class="hlFld-Affiliation affiliation">Wuxi
Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s
Republic of China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02673" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02673" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Suzanne Brown, Ning Liu, Mika Kosaka, Emile Plise, and Jonathan Cheong in the DMPK department and Mengling Wong, Michael Hayes, and Amber Guillen for compound purification. Baiwei Lin, Deven Wang, and Yutao Jiang are acknowledged for analytical support. Grady Howes, Jan Seerveld, Hao Zheng, and Gigi Yuen for help with compound management and logistics are also recognized. This research used resources of the Advanced Light Source, which is a DOE Office of Science User Facility under contract no. DE-AC02-05CH11231. We would like to acknowledge the beamline staff at ALS 5.0.2 for their help and support</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i101" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i101"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i102" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i102"> Abbreviations Used</h2><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">BAZ2B</td><td class="NLM_def"><p class="first last">bromodomain adjacent to zinc finger domain 2B</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extra terminal</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">BPTF</td><td class="NLM_def"><p class="first last">bromodomain plant homeodomain finger transcription factor</p></td></tr><tr><td class="NLM_term">BRD4(X)</td><td class="NLM_def"><p class="first last">bromodomain X (X = 1, 2) of the bromodomain-containing protein 4</p></td></tr><tr><td class="NLM_term">BRD8</td><td class="NLM_def"><p class="first last">bromodomain-containing protein 8</p></td></tr><tr><td class="NLM_term">BRD9</td><td class="NLM_def"><p class="first last">bromodomain-containing protein 9</p></td></tr><tr><td class="NLM_term">BRET</td><td class="NLM_def"><p class="first last">bioluminescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">BRPF1</td><td class="NLM_def"><p class="first last">bromodomain and plant homeodomain finger containing <b>1</b></p></td></tr><tr><td class="NLM_term">CBP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate response element binding protein, binding protein</p></td></tr><tr><td class="NLM_term">CECR2</td><td class="NLM_def"><p class="first last">cat eye syndrome chromosome region, candidate <b>2</b></p></td></tr><tr><td class="NLM_term">Cl<sub>hep</sub></td><td class="NLM_def"><p class="first last">predicted hepatic clearance</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethyl amine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">Foxp3</td><td class="NLM_def"><p class="first last">forkhead box P3</p></td></tr><tr><td class="NLM_term">GCN5L</td><td class="NLM_def"><p class="first last">general control of amino-acid synthesis 5-like <b>2</b></p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">histone acetyl transferase</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">KAc</td><td class="NLM_def"><p class="first last">acetylated lysine</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>p,uu</sub></td><td class="NLM_def"><p class="first last">ratio of the unbound drug concentration in brain to unbound drug concentration in plasma</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">LM</td><td class="NLM_def"><p class="first last">liver microsomes</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">P300</td><td class="NLM_def"><p class="first last">adenoviral E1A binding protein</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub> A–B</td><td class="NLM_def"><p class="first last">apparent permeability apical-to-basolateral</p></td></tr><tr><td class="NLM_term">PBMCs</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cells</p></td></tr><tr><td class="NLM_term">PCAF</td><td class="NLM_def"><p class="first last">P300/CBP-associated factor</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">one a day</p></td></tr><tr><td class="NLM_term">q-RT-PCR</td><td class="NLM_def"><p class="first last">quantitative reverse transcriptase polymerase chain reaction</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">[2-(trimethylsilyl)ethoxy]methyl</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography;</p></td></tr><tr><td class="NLM_term">TAF1(X)</td><td class="NLM_def"><p class="first last">bromodomain X (X = 1, 2) of the TATA-box binding protein associated factor 1</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyran</p></td></tr><tr><td class="NLM_term">THQ</td><td class="NLM_def"><p class="first last">tetrahydroquinoline</p></td></tr><tr><td class="NLM_term"><i>t</i>PSA</td><td class="NLM_def"><p class="first last">total polar surface area</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">time-resolved fluorescence energy transfer</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42437" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42437" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 33 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Bannister, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouzarides, T.</span><span> </span><span class="NLM_article-title">The CBP Co-Activator Is a Histone Acetyltransferase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1038/384641a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2F384641a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=8967953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADyaK2sXlsVen" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=1996&pages=641-643&author=A.+J.+Bannisterauthor=T.+Kouzarides&title=The+CBP+Co-Activator+Is+a+Histone+Acetyltransferase&doi=10.1038%2F384641a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The CBP co-activator is a histone acetyltransferase</span></div><div class="casAuthors">Bannister, Andrew J.; Kouzarides, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">6610</span>),
    <span class="NLM_cas:pages">641-643</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The CBP protein acts as a transcriptional adaptor for many different transcription factors by directly contacting DNA-bound activators.  One mechanism by which CBP is thought to stimulate transcription is by recruiting the histone acetyltransferase (HAT) P/CAF to the promoter.  Here we show that CBP has intrinsic HAT activity.  The HAT domain of CBP is adjacent to the binding site for the transcriptional activator E1A.  Although E1A displaces P/CAF from CBP, is does not disrupt the CBP-assocd. HAT activity.  Thus E1A carries HAT activity when complexed with CBP.  Targeting CBP-assocd. HAT activity to specific promoters may therefore be a mechanism by which E1A acts as a transcriptional activator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiUdYJTsdfILVg90H21EOLACvtfcHk0lj8GKKiDvi4BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlsVen&md5=8c6fd1c0c0679a454a6c10c704200e2f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F384641a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F384641a0%26sid%3Dliteratum%253Aachs%26aulast%3DBannister%26aufirst%3DA.%2BJ.%26aulast%3DKouzarides%26aufirst%3DT.%26atitle%3DThe%2520CBP%2520Co-Activator%2520Is%2520a%2520Histone%2520Acetyltransferase%26jtitle%3DNature%26date%3D1996%26volume%3D384%26spage%3D641%26epage%3D643%26doi%3D10.1038%2F384641a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Delvecchio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaucher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilar-Gurrieri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panne, D.</span><span> </span><span class="NLM_article-title">Structure of the P300 Catalytic Core and Implications for Chromatin Targeting and HAT Regulation</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1040</span><span class="NLM_x">–</span> <span class="NLM_lpage">1046</span><span class="refDoi"> DOI: 10.1038/nsmb.2642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fnsmb.2642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=23934153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1040-1046&author=M.+Delvecchioauthor=J.+Gaucherauthor=C.+Aguilar-Gurrieriauthor=E.+Ortegaauthor=D.+Panne&title=Structure+of+the+P300+Catalytic+Core+and+Implications+for+Chromatin+Targeting+and+HAT+Regulation&doi=10.1038%2Fnsmb.2642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation</span></div><div class="casAuthors">Delvecchio, Manuela; Gaucher, Jonathan; Aguilar-Gurrieri, Carmen; Ortega, Esther; Panne, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1040-1046</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CBP and p300 are histone acetyltransferases (HATs) that assoc. with and acetylate transcriptional regulators and chromatin.  Mutations in their catalytic 'cores' are linked to genetic disorders, including cancer.  Here we present the 2.8-Å crystal structure of the catalytic core of human p300 contg. its bromodomain, CH2 region and HAT domain.  The structure reveals that the CH2 region contains a discontinuous PHD domain interrupted by a RING domain.  The bromodomain, PHD, RING and HAT domains adopt an assembled configuration with the RING domain positioned over the HAT substrate-binding pocket.  Disease mutations that disrupt RING attachment led to upregulation of HAT activity, thus revealing an inhibitory role for this domain.  The structure provides a starting point for understanding how chromatin-substrate targeting and HAT regulation are coupled and why mutations in the p300 core lead to dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlYehjRwdhJ7Vg90H21EOLACvtfcHk0ljUkqiTmRqMbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3J&md5=e9352198d513eac6fd93fc2896828d09</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2642%26sid%3Dliteratum%253Aachs%26aulast%3DDelvecchio%26aufirst%3DM.%26aulast%3DGaucher%26aufirst%3DJ.%26aulast%3DAguilar-Gurrieri%26aufirst%3DC.%26aulast%3DOrtega%26aufirst%3DE.%26aulast%3DPanne%26aufirst%3DD.%26atitle%3DStructure%2520of%2520the%2520P300%2520Catalytic%2520Core%2520and%2520Implications%2520for%2520Chromatin%2520Targeting%2520and%2520HAT%2520Regulation%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1040%26epage%3D1046%26doi%3D10.1038%2Fnsmb.2642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Mujtaba, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachchidanand</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeleznik-Le, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.-M.</span><span> </span><span class="NLM_article-title">Structural Mechanism of the Bromodomain of the Coactivator CBP in P53 Transcriptional Activation. Mol</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1016/S1097-2765(03)00528-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1016%2FS1097-2765%2803%2900528-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=251-263&author=S.+Mujtabaauthor=Y.+Heauthor=L.+Zengauthor=S.+Yanauthor=O.+Plotnikovaauthor=+Sachchidanandauthor=R.+Sanchezauthor=N.+J.+Zeleznik-Leauthor=Z.+Ronaiauthor=M.-M.+Zhou&title=Structural+Mechanism+of+the+Bromodomain+of+the+Coactivator+CBP+in+P53+Transcriptional+Activation.+Mol&doi=10.1016%2FS1097-2765%2803%2900528-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900528-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900528-8%26sid%3Dliteratum%253Aachs%26aulast%3DMujtaba%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DSachchidanand%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DZeleznik-Le%26aufirst%3DN.%2BJ.%26aulast%3DRonai%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DM.-M.%26atitle%3DStructural%2520Mechanism%2520of%2520the%2520Bromodomain%2520of%2520the%2520Coactivator%2520CBP%2520in%2520P53%2520Transcriptional%2520Activation.%2520Mol%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D251%26epage%3D263%26doi%3D10.1016%2FS1097-2765%2803%2900528-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Iyer, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozdag, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas, C.</span><span> </span><span class="NLM_article-title">p300/CBP and Cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4225</span><span class="NLM_x">–</span> <span class="NLM_lpage">4231</span><span class="refDoi"> DOI: 10.1038/sj.onc.1207118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fsj.onc.1207118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=15156177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvVChtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=4225-4231&author=N.+G.+Iyerauthor=H.+Ozdagauthor=C.+Caldas&title=p300%2FCBP+and+Cancer&doi=10.1038%2Fsj.onc.1207118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">p300/CBP and cancer</span></div><div class="casAuthors">Iyer, Narayanan Gopalakrishna; Oezdag, Hilal; Caldas, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4225-4231</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  P300 and cAMP response element-binding protein (CBP) are adenoviral E1A-binding proteins involved in multiple cellular processes, and function as transcriptional co-factors and histone acetyltransferases.  Germline mutation of CBP results in Rubinstein-Taybi syndrome, which is characterized by an increased predisposition to childhood malignancies.  Furthermore, somatic mutations of p300 and CBP occur in a no. of malignancies.  Chromosome translocations target CBP and, less commonly, p300 in acute myeloid leukemia and treatment-related hematol. disorders.  P300 mutations in solid tumors result in truncated p300 protein products or amino-acid substitutions in crit. protein domains, and these are often assocd. with inactivation of the second allele.  A mouse model confirms that p300 and CBP function as suppressors of hematol. tumor formation.  The involvement of these proteins in crit. tumorigenic pathways (including TGF-β, p53 and Rb) provides a mechanistic route as to how their inactivation could result in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKGBLVLWLqkrVg90H21EOLACvtfcHk0ljUkqiTmRqMbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvVChtrc%253D&md5=b68fe6bc258b06515c04a5207410f026</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207118%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DN.%2BG.%26aulast%3DOzdag%26aufirst%3DH.%26aulast%3DCaldas%26aufirst%3DC.%26atitle%3Dp300%252FCBP%2520and%2520Cancer%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D4225%26epage%3D4231%26doi%3D10.1038%2Fsj.onc.1207118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Dutta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, K. M.</span><span> </span><span class="NLM_article-title">CBP/P300 Acetyltransferase Activity in Hematologic Malignancies</span> <span class="citation_source-journal">Mol. Genet. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1016/j.ymgme.2016.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1016%2Fj.ymgme.2016.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=27380996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFemsb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2016&pages=37-43&author=R.+Duttaauthor=B.+Tiuauthor=K.+M.+Sakamoto&title=CBP%2FP300+Acetyltransferase+Activity+in+Hematologic+Malignancies&doi=10.1016%2Fj.ymgme.2016.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CBP/p300 acetyltransferase activity in hematologic malignancies</span></div><div class="casAuthors">Dutta, Ritika; Tiu, Bruce; Sakamoto, Kathleen M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Genetics and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">37-43</span>CODEN:
                <span class="NLM_cas:coden">MGMEFF</span>;
        ISSN:<span class="NLM_cas:issn">1096-7192</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">CREB binding protein (CBP) and p300 are crit. regulators of hematopoiesis through both their transcriptional coactivator and acetyltransferase activities.  Loss or mutation of CBP/p300 results in hematol. deficiencies in proliferation and differentiation as well as disruption of hematopoietic stem cell renewal and the microenvironment.  Aberrant lysine acetylation mediated by CBP/p300 has recently been implicated in the genesis of multiple hematol. cancers.  Understanding the effects of disrupting the acetyltransferase activity of CBP/p300 could pave the way for new therapeutic approaches to treat patients with these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMiCksEjVzo7Vg90H21EOLACvtfcHk0li5FG1NVT5nqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFemsb7J&md5=4c0437f742fb98fbefa871c73dade8f3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ymgme.2016.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymgme.2016.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%26aufirst%3DR.%26aulast%3DTiu%26aufirst%3DB.%26aulast%3DSakamoto%26aufirst%3DK.%2BM.%26atitle%3DCBP%252FP300%2520Acetyltransferase%2520Activity%2520in%2520Hematologic%2520Malignancies%26jtitle%3DMol.%2520Genet.%2520Metab.%26date%3D2016%26volume%3D119%26spage%3D37%26epage%3D43%26doi%3D10.1016%2Fj.ymgme.2016.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Dekker, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haisma, H. J.</span><span> </span><span class="NLM_article-title">Histone Acetyl Transferases as Emerging Drug Targets</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">948</span><span class="refDoi"> DOI: 10.1016/j.drudis.2009.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1016%2Fj.drudis.2009.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=19577000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFygs7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=942-948&author=F.+J.+Dekkerauthor=H.+J.+Haisma&title=Histone+Acetyl+Transferases+as+Emerging+Drug+Targets&doi=10.1016%2Fj.drudis.2009.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Histone acetyl transferases as emerging drug targets</span></div><div class="casAuthors">Dekker, Frank J.; Haisma, Hidde J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">19/20</span>),
    <span class="NLM_cas:pages">942-948</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Post-translational modifications, such as acetylation or phosphorylation, play a crucial role in the regulation of gene transcription in eukaryotes.  Different subtypes of histone acetyl transferases (HATs) catalyze the acetylation of histones on specific lysine residues.  A potential role of HATs in the pathol. of cancer, asthma, COPD and viral infection has been described.  This indicates that specific HAT inhibitors are potential tools for pharmacol. research and might find therapeutic applications.  This review focuses on the role of the HATs p300, CBP, PCAF and GCN5 in different diseases and the development of small-mol. inhibitors of these enzymes as potential drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Ao3F8nEy7bVg90H21EOLACvtfcHk0li5FG1NVT5nqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFygs7fL&md5=bff2f4e6d437e003e5b17cfb07215676</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DDekker%26aufirst%3DF.%2BJ.%26aulast%3DHaisma%26aufirst%3DH.%2BJ.%26atitle%3DHistone%2520Acetyl%2520Transferases%2520as%2520Emerging%2520Drug%2520Targets%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D942%26epage%3D948%26doi%3D10.1016%2Fj.drudis.2009.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Fujisawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span> </span><span class="NLM_article-title">Functions of Bromodomain-Containing Proteins and Their Roles in Homeostasis and Cancer</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1038/nrm.2016.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fnrm.2016.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=28053347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Kiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=246-262&author=T.+Fujisawaauthor=P.+Filippakopoulos&title=Functions+of+Bromodomain-Containing+Proteins+and+Their+Roles+in+Homeostasis+and+Cancer&doi=10.1038%2Fnrm.2016.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of bromodomain-containing proteins and their roles in homeostasis and cancer</span></div><div class="casAuthors">Fujisawa, Takao; Filippakopoulos, Panagis</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">246-262</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Bromodomains (BRDs) are evolutionarily conserved protein-protein interaction modules that are found in a wide range of proteins with diverse catalytic and scaffolding functions and are present in most tissues.  BRDs selectively recognize and bind to acetylated Lys residues - particularly in histones - and thereby have important roles in the regulation of gene expression.  BRD-contg. proteins are frequently dysregulated in cancer, they participate in gene fusions that generate diverse, frequently oncogenic proteins, and many cancer-causing mutations have been mapped to the BRDs themselves.  Importantly, BRDs can be targeted by small-mol. inhibitors, which has stimulated many translational research projects that seek to attenuate the aberrant functions of BRD-contg. proteins in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-drLvQK1rvLVg90H21EOLACvtfcHk0lh_AFGVPYvodg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Kiuw%253D%253D&md5=cbccdee8423bad7a426c9cea6566151f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2016.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2016.143%26sid%3Dliteratum%253Aachs%26aulast%3DFujisawa%26aufirst%3DT.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26atitle%3DFunctions%2520of%2520Bromodomain-Containing%2520Proteins%2520and%2520Their%2520Roles%2520in%2520Homeostasis%2520and%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2017%26volume%3D18%26spage%3D246%26epage%3D262%26doi%3D10.1038%2Fnrm.2016.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Predina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatti, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singhal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brindle, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albelda, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Inhibition of P300 Impairs Foxp3+ T Regulatory Cell Function and Promotes Antitumor Immunity</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1173</span><span class="NLM_x">–</span> <span class="NLM_lpage">1177</span><span class="refDoi"> DOI: 10.1038/nm.3286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fnm.3286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=23955711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yks77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1173-1177&author=Y.+Liuauthor=L.+Wangauthor=J.+Predinaauthor=R.+Hanauthor=U.+H.+Beierauthor=L.-C.+S.+Wangauthor=V.+Kapoorauthor=T.+R.+Bhattiauthor=T.+Akimovaauthor=S.+Singhalauthor=P.+K.+Brindleauthor=P.+A.+Coleauthor=S.+M.+Albeldaauthor=W.+W.+Hancock&title=Inhibition+of+P300+Impairs+Foxp3%2B+T+Regulatory+Cell+Function+and+Promotes+Antitumor+Immunity&doi=10.1038%2Fnm.3286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity</span></div><div class="casAuthors">Liu, Yujie; Wang, Liqing; Predina, Jarrod; Han, Rongxiang; Beier, Ulf H.; Wang, Liang-Chuan S.; Kapoor, Veena; Bhatti, Tricia R.; Akimova, Tatiana; Singhal, Sunil; Brindle, Paul K.; Cole, Philip A.; Albelda, Steven M.; Hancock, Wayne W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1173-1177</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Forkhead box P3 (Foxp3)+ T regulatory (Treg) cells maintain immune homeostasis and limit autoimmunity but can also curtail host immune responses to various types of tumors.  Foxp3+ Treg cells are therefore considered promising targets to enhance antitumor immunity, and approaches for their therapeutic modulation are being developed.  However, although studies showing that exptl. depleting Foxp3+ Treg cells can enhance antitumor responses provide proof of principle, these studies lack clear translational potential and have various shortcomings.  Histone/protein acetyltransferases (HATs) promote chromatin accessibility, gene transcription and the function of multiple transcription factors and nonhistone proteins.  We now report that conditional deletion or pharmacol. inhibition of one HAT, p300 (also known as Ep300 or KAT3B), in Foxp3+ Treg cells increased T cell receptor-induced apoptosis in Treg cells, impaired Treg cell suppressive function and peripheral Treg cell induction, and limited tumor growth in immunocompetent but not in immunodeficient mice.  Our data thereby demonstrate that p300 is important for Foxp3+ Treg cell function and homeostasis in vivo and in vitro, and identify mechanisms by which appropriate small-mol. inhibitors can diminish Treg cell function without overtly impairing T effector cell responses or inducing autoimmunity.  Collectively, these data suggest a new approach for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG1uh9kwBI_rVg90H21EOLACvtfcHk0lh_AFGVPYvodg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yks77K&md5=b381e7523f686ed8ea8d54aa38327c41</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnm.3286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3286%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DPredina%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DBeier%26aufirst%3DU.%2BH.%26aulast%3DWang%26aufirst%3DL.-C.%2BS.%26aulast%3DKapoor%26aufirst%3DV.%26aulast%3DBhatti%26aufirst%3DT.%2BR.%26aulast%3DAkimova%26aufirst%3DT.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DBrindle%26aufirst%3DP.%2BK.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DAlbelda%26aufirst%3DS.%2BM.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DInhibition%2520of%2520P300%2520Impairs%2520Foxp3%252B%2520T%2520Regulatory%2520Cell%2520Function%2520and%2520Promotes%2520Antitumor%2520Immunity%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1173%26epage%3D1177%26doi%3D10.1038%2Fnm.3286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Conery, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Centore, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neiss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spillane, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawadzke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bommi-Reddy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoigne, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, R. J.</span><span> </span><span class="NLM_article-title">Bromodomain Inhibition of the Transcriptional Coactivators CBP/EP300 as a Therapeutic Strategy to Target the IRF4 Network in Multiple Myeloma</span> <span class="citation_source-journal">eLife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">10483</span><span class="refDoi"> DOI: 10.7554/eLife.10483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.7554%2FeLife.10483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=10483&author=A.+R.+Coneryauthor=R.+C.+Centoreauthor=A.+Neissauthor=P.+J.+Kellerauthor=S.+Joshiauthor=K.+L.+Spillaneauthor=P.+Sandyauthor=C.+Hattonauthor=E.+Pardoauthor=L.+Zawadzkeauthor=A.+Bommi-Reddyauthor=K.+E.+Gascoigneauthor=B.+M.+Bryantauthor=J.+A.+Mertzauthor=R.+J.+Sims&title=Bromodomain+Inhibition+of+the+Transcriptional+Coactivators+CBP%2FEP300+as+a+Therapeutic+Strategy+to+Target+the+IRF4+Network+in+Multiple+Myeloma&doi=10.7554%2FeLife.10483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.7554%2FeLife.10483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10483%26sid%3Dliteratum%253Aachs%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DCentore%26aufirst%3DR.%2BC.%26aulast%3DNeiss%26aufirst%3DA.%26aulast%3DKeller%26aufirst%3DP.%2BJ.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DSpillane%26aufirst%3DK.%2BL.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DZawadzke%26aufirst%3DL.%26aulast%3DBommi-Reddy%26aufirst%3DA.%26aulast%3DGascoigne%26aufirst%3DK.%2BE.%26aulast%3DBryant%26aufirst%3DB.%2BM.%26aulast%3DMertz%26aufirst%3DJ.%2BA.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26atitle%3DBromodomain%2520Inhibition%2520of%2520the%2520Transcriptional%2520Coactivators%2520CBP%252FEP300%2520as%2520a%2520Therapeutic%2520Strategy%2520to%2520Target%2520the%2520IRF4%2520Network%2520in%2520Multiple%2520Myeloma%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26spage%3D10483%26doi%3D10.7554%2FeLife.10483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conery, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmeron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakle, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mele, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setser, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAlmeida-Nagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawadzke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audia, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grogan, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, R. J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lora, J. M.</span><span> </span><span class="NLM_article-title">Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">291</span><span class="NLM_x">, </span> <span class="NLM_fpage">13014</span><span class="NLM_x">–</span> <span class="NLM_lpage">13027</span><span class="refDoi"> DOI: 10.1074/jbc.M115.708560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1074%2Fjbc.M115.708560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=27056325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSksL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=13014-13027&author=S.+Ghoshauthor=A.+Taylorauthor=M.+Chinauthor=H.-R.+Huangauthor=A.+R.+Coneryauthor=J.+A.+Mertzauthor=A.+Salmeronauthor=P.+J.+Dakleauthor=D.+Meleauthor=A.+C%C3%B4t%C3%A9author=H.+Jayaramauthor=J.+W.+Setserauthor=F.+Poyauthor=G.+Hatzivassiliouauthor=D.+DeAlmeida-Nagataauthor=P.+Sandyauthor=C.+Hattonauthor=F.+A.+Romeroauthor=E.+Chiangauthor=T.+Reimerauthor=T.+Crawfordauthor=E.+Pardoauthor=V.+G.+Watsonauthor=V.+Tsuiauthor=A.+G.+Cochranauthor=L.+Zawadzkeauthor=J.-C.+Harmangeauthor=J.+E.+Audiaauthor=B.+M.+Bryantauthor=R.+T.+Cummingsauthor=S.+R.+Magnusonauthor=J.+L.+Groganauthor=S.+F.+Bellonauthor=B.+K.+Albrechtauthor=R.+J.+Simsauthor=J.+M.+Lora&title=Regulatory+T+Cell+Modulation+by+CBP%2FEP300+Bromodomain+Inhibition&doi=10.1074%2Fjbc.M115.708560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition</span></div><div class="casAuthors">Ghosh, Srimoyee; Taylor, Alexander; Chin, Melissa; Huang, Hon-Ren; Conery, Andrew R.; Mertz, Jennifer A.; Salmeron, Andres; Dakle, Pranal J.; Mele, Deanna; Cote, Alexandre; Jayaram, Hari; Setser, Jeremy W.; Poy, Florence; Hatzivassiliou, Georgia; DeAlmeida-Nagata, Denise; Sandy, Peter; Hatton, Charlie; Romero, F. Anthony; Chiang, Eugene; Reimer, Thornik; Crawford, Terry; Pardo, Eneida; Watson, Venita G.; Tsui, Vickie; Cochran, Andrea G.; Zawadzke, Laura; Harmange, Jean-Christophe; Audia, James E.; Bryant, Barbara M.; Cummings, Richard T.; Magnuson, Steven R.; Grogan, Jane L.; Bellon, Steve F.; Albrecht, Brian K.; Sims, Robert J. III; Lora, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">13014-13027</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Covalent modification of histones is a fundamental mechanism of regulated gene expression in eukaryotes, and interpretation of histone modifications is an essential feature of epigenetic control.  Bromodomains are specialized binding modules that interact with acetylated histones, linking chromatin recognition to gene transcription.  Because of their ability to function in a domain-specific fashion, selective disruption of bromodomain:acetylated histone interactions with chem. probes serves as a powerful means for understanding biol. processes regulated by these chromatin adaptors.  Here the authors describe the discovery and characterization of potent and selective small mol. inhibitors for the bromodomains of CREBBP/EP300 that engage their target in cellular assays.  The authors use these tools to demonstrate a crit. role for CREBBP/EP300 bromodomains in regulatory T cell biol.  Because regulatory T cell recruitment to tumors is a major mechanism of immune evasion by cancer cells, the authors' data highlight the importance of CREBBP/EP300 bromodomain inhibition as a novel, small mol.-based approach for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9maWuQVImyLVg90H21EOLACvtfcHk0ljv99s-DB9ueQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSksL3F&md5=bc8b4edba81bdbef30b1d8fcfaa19f1e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.708560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.708560%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DH.-R.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DMertz%26aufirst%3DJ.%2BA.%26aulast%3DSalmeron%26aufirst%3DA.%26aulast%3DDakle%26aufirst%3DP.%2BJ.%26aulast%3DMele%26aufirst%3DD.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DJayaram%26aufirst%3DH.%26aulast%3DSetser%26aufirst%3DJ.%2BW.%26aulast%3DPoy%26aufirst%3DF.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DDeAlmeida-Nagata%26aufirst%3DD.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DChiang%26aufirst%3DE.%26aulast%3DReimer%26aufirst%3DT.%26aulast%3DCrawford%26aufirst%3DT.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DWatson%26aufirst%3DV.%2BG.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DZawadzke%26aufirst%3DL.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBryant%26aufirst%3DB.%2BM.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DMagnuson%26aufirst%3DS.%2BR.%26aulast%3DGrogan%26aufirst%3DJ.%2BL.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26aulast%3DLora%26aufirst%3DJ.%2BM.%26atitle%3DRegulatory%2520T%2520Cell%2520Modulation%2520by%2520CBP%252FEP300%2520Bromodomain%2520Inhibition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D13014%26epage%3D13027%26doi%3D10.1074%2Fjbc.M115.708560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasveschuk, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantone, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Leon Boenig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conery, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawadzke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, R. J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audia, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">531</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00075</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00075" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Cms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=531-536&author=A.+M.+Taylorauthor=A.+C%C3%B4t%C3%A9author=M.+C.+Hewittauthor=R.+Pastorauthor=Y.+Leblancauthor=C.+G.+Nasveschukauthor=F.+A.+Romeroauthor=T.+D.+Crawfordauthor=N.+Cantoneauthor=H.+Jayaramauthor=J.+Setserauthor=J.+Murrayauthor=M.+H.+Beresiniauthor=G.+de+Leon+Boenigauthor=Z.+Chenauthor=A.+R.+Coneryauthor=R.+T.+Cummingsauthor=L.+A.+Dakinauthor=E.+M.+Flynnauthor=O.+W.+Huangauthor=S.+Kaufmanauthor=P.+J.+Kellerauthor=J.+R.+Kieferauthor=T.+Laiauthor=Y.+Liauthor=J.+Liaoauthor=W.+Liuauthor=H.+Luauthor=E.+Pardoauthor=V.+Tsuiauthor=J.+Wangauthor=Y.+Wangauthor=Z.+Xuauthor=F.+Yanauthor=D.+Yuauthor=L.+Zawadzkeauthor=X.+Zhuauthor=X.+Zhuauthor=R.+J.+Simsauthor=A.+G.+Cochranauthor=S.+Bellonauthor=J.+E.+Audiaauthor=S.+Magnusonauthor=B.+K.+Albrecht&title=Fragment-Based+Discovery+of+a+Selective+and+Cell-Active+Benzodiazepinone+CBP%2FEP300+Bromodomain+Inhibitor+%28CPI-637%29&doi=10.1021%2Facsmedchemlett.6b00075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)</span></div><div class="casAuthors">Taylor, Alexander M.; Cote, Alexandre; Hewitt, Michael C.; Pastor, Richard; Leblanc, Yves; Nasveschuk, Christopher G.; Romero, F. Anthony; Crawford, Terry D.; Cantone, Nico; Jayaram, Hariharan; Setser, Jeremy; Murray, Jeremy; Beresini, Maureen H.; de Leon Boenig, Gladys; Chen, Zhongguo; Conery, Andrew R.; Cummings, Richard T.; Dakin, Leslie A.; Flynn, E. Megan; Huang, Oscar W.; Kaufman, Susan; Keller, Patricia J.; Kiefer, James R.; Lai, Tommy; Li, Yingjie; Liao, Jiangpeng; Liu, Wenfeng; Lu, Henry; Pardo, Eneida; Tsui, Vickie; Wang, Jian; Wang, Yongyun; Xu, Zhaowu; Yan, Fen; Yu, Dong; Zawadzke, Laura; Zhu, Xiaoqin; Zhu, Xiaoyu; Sims, Robert J.; Cochran, Andrea G.; Bellon, Steve; Audia, James E.; Magnuson, Steven; Albrecht, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">531-536</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Benzo-fused heterocycles, particularly benzodiazepinones such as I, were prepd. as inhibitors of the bromodomain-contg. proteins CBP (CREB, cAMP response element binding protein) and EP300 (adenoviral E1A-binding protein of 300 kDa) for potential use as antitumor agents; the core benzodiazepinone moiety was identified using fragment-based screening.  The structures of four benzodiazepinones, including I, bound to the bromodomain fragment of human CREB were detd. by X-ray crystallog.  The free energy, enthalpy, and entropy of the binding of I to CREB and its selectivity for CREB and EP300 over other bromodomain-contg. proteins was detd.; I inhibited expression of the transcription factor MYC in human plasmacytoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNm7Blycl0-7Vg90H21EOLACvtfcHk0lj6Yu-niVaYlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Cms7c%253D&md5=8440a9bb3460ff66d43f15041dbbc19d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00075%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DPastor%26aufirst%3DR.%26aulast%3DLeblanc%26aufirst%3DY.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DJayaram%26aufirst%3DH.%26aulast%3DSetser%26aufirst%3DJ.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DBeresini%26aufirst%3DM.%2BH.%26aulast%3Dde%2BLeon%2BBoenig%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DFlynn%26aufirst%3DE.%2BM.%26aulast%3DHuang%26aufirst%3DO.%2BW.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DP.%2BJ.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLai%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DZawadzke%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Selective%2520and%2520Cell-Active%2520Benzodiazepinone%2520CBP%252FEP300%2520Bromodomain%2520Inhibitor%2520%2528CPI-637%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D531%26epage%3D536%26doi%3D10.1021%2Facsmedchemlett.6b00075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Crawford, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Leon Boenig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noland, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunsaker, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharbanda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoigne, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conery, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinheinz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spillane, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawadzke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">10549</span><span class="NLM_x">–</span> <span class="NLM_lpage">10563</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01022</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGhsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10549-10563&author=T.+D.+Crawfordauthor=F.+A.+Romeroauthor=K.+W.+Laiauthor=V.+Tsuiauthor=A.+M.+Taylorauthor=G.+de+Leon+Boenigauthor=C.+L.+Nolandauthor=J.+Murrayauthor=J.+Lyauthor=E.+F.+Chooauthor=T.+L.+Hunsakerauthor=E.+W.+Chanauthor=M.+Merchantauthor=S.+Kharbandaauthor=K.+E.+Gascoigneauthor=S.+Kaufmanauthor=M.+H.+Beresiniauthor=J.+Liaoauthor=W.+Liuauthor=K.+X.+Chenauthor=Z.+Chenauthor=A.+R.+Coneryauthor=A.+C%C3%B4t%C3%A9author=H.+Jayaramauthor=Y.+Jiangauthor=J.+R.+Kieferauthor=T.+Kleinheinzauthor=Y.+Liauthor=J.+Maherauthor=E.+Pardoauthor=F.+Poyauthor=K.+L.+Spillaneauthor=F.+Wangauthor=J.+Wangauthor=X.+Weiauthor=Z.+Xuauthor=Z.+Xuauthor=I.+Yenauthor=L.+Zawadzkeauthor=X.+Zhuauthor=S.+Bellonauthor=R.+Cummingsauthor=A.+G.+Cochranauthor=B.+K.+Albrechtauthor=S.+Magnuson&title=Discovery+of+a+Potent+and+Selective+in+Vivo+Probe+%28GNE-272%29+for+the+Bromodomains+of+CBP%2FEP300&doi=10.1021%2Facs.jmedchem.6b01022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300</span></div><div class="casAuthors">Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; de Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Cote, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; Pardo, Eneida; Poy, Florence; Spillane, Kerry L.; Wang, Fei; Wang, Jian; Wei, Xiaocang; Xu, Zhaowu; Xu, Zhongya; Yen, Ivana; Zawadzke, Laura; Zhu, Xiaoyu; Bellon, Steven; Cummings, Richard; Cochran, Andrea G.; Albrecht, Brian K.; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10549-10563</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The single bromodomain of the closely related transcriptional regulators CBP/EP300 is a target of much recent interest in cancer and immune system regulation.  A co-crystal structure of a ligand-efficient screening hit and the CBP bromodomain guided initial design targeting the LPF shelf, ZA loop, and acetylated lysine binding regions.  Structure-activity relationship studies allowed the authors to identify a more potent analog.  Optimization of permeability and microsomal stability and subsequent improvement of mouse hepatocyte stability afforded 59 (GNE-272, TR-FRET IC50 = 0.02 μM, BRET IC50 = 0.41 μM, BRD4(1) IC50 = 13 μM) that retained the best balance of cell potency, selectivity, and in vivo PK.  GNE-272 showed a marked antiproliferative effect in hematol. cancer cell lines and modulates MYC expression in vivo that corresponds with antitumor activity in an AML tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6T5ODn2Q-2LVg90H21EOLACvtfcHk0lhKtHbOp8ZmUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGhsb%252FO&md5=22ed46cb031022aa6aff23c20d07e7dd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01022%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DLai%26aufirst%3DK.%2BW.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3Dde%2BLeon%2BBoenig%26aufirst%3DG.%26aulast%3DNoland%26aufirst%3DC.%2BL.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DHunsaker%26aufirst%3DT.%2BL.%26aulast%3DChan%26aufirst%3DE.%2BW.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DKharbanda%26aufirst%3DS.%26aulast%3DGascoigne%26aufirst%3DK.%2BE.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DBeresini%26aufirst%3DM.%2BH.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DJayaram%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMaher%26aufirst%3DJ.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DPoy%26aufirst%3DF.%26aulast%3DSpillane%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DZawadzke%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DCummings%26aufirst%3DR.%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520in%2520Vivo%2520Probe%2520%2528GNE-272%2529%2520for%2520the%2520Bromodomains%2520of%2520CBP%252FEP300%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10549%26epage%3D10563%26doi%3D10.1021%2Facs.jmedchem.6b01022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Popp, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bracher, F.</span><span> </span><span class="NLM_article-title">Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">8889</span><span class="NLM_x">–</span> <span class="NLM_lpage">8912</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00774</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00774" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKis77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8889-8912&author=T.+A.+Poppauthor=C.+Tallantauthor=C.+Rogersauthor=O.+Fedorovauthor=P.+E.+Brennanauthor=S.+M%C3%BCllerauthor=S.+Knappauthor=F.+Bracher&title=Development+of+Selective+CBP%2FP300+Benzoxazepine+Bromodomain+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors</span></div><div class="casAuthors">Popp, Tobias A.; Tallant, Cynthia; Rogers, Catherine; Fedorov, Oleg; Brennan, Paul E.; Mueller, Susanne; Knapp, Stefan; Bracher, Franz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8889-8912</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CBP (CREB (cAMP responsive element binding protein) binding protein (CREBBP)) and P300 (adenovirus E1A-assocd. 300 kDa protein) are two closely related histone acetyltransferases (HATs) that play a key role in the regulation of gene transcription.  Both proteins contain a bromodomain flanking the HAT catalytic domain that is important for the targeting of CBP/P300 to chromatin and which offers an opportunity for the development of protein-protein interaction inhibitors.  Here the authors present the development of CBP/P300 bromodomain inhibitors with 2,3,4,5-tetrahydro-1,4-benzoxazepine backbone, an N-acetyl-lysine mimetic scaffold that led to the recent development of the chem. probe I-CBP112.  The authors present comprehensive SAR of this inhibitor class as well as demonstration of cellular on target activity of the most potent and selective inhibitor I, which showed 134 nM affinity for CBP with excellent selectivity over other bromodomains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwAZFuNP0NkLVg90H21EOLACvtfcHk0ljShg9xoCUoBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKis77E&md5=6bd914d24abf00a8f074bf1918fb4ee1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00774%26sid%3Dliteratum%253Aachs%26aulast%3DPopp%26aufirst%3DT.%2BA.%26aulast%3DTallant%26aufirst%3DC.%26aulast%3DRogers%26aufirst%3DC.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBracher%26aufirst%3DF.%26atitle%3DDevelopment%2520of%2520Selective%2520CBP%252FP300%2520Benzoxazepine%2520Bromodomain%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8889%26epage%3D8912%26doi%3D10.1021%2Facs.jmedchem.6b00774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Rooney, T. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortopassi, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heightman, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryde, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paton, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. J.</span><span> </span><span class="NLM_article-title">A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation-Π Interaction</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6126</span><span class="NLM_x">–</span> <span class="NLM_lpage">6130</span><span class="refDoi"> DOI: 10.1002/anie.201402750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1002%2Fanie.201402750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFWgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=6126-6130&author=T.+P.+C.+Rooneyauthor=P.+Filippakopoulosauthor=O.+Fedorovauthor=S.+Picaudauthor=W.+A.+Cortopassiauthor=D.+A.+Hayauthor=S.+Martinauthor=A.+Tumberauthor=C.+M.+Rogersauthor=M.+Philpottauthor=M.+Wangauthor=A.+L.+Thompsonauthor=T.+D.+Heightmanauthor=D.+C.+Prydeauthor=A.+Cookauthor=R.+S.+Patonauthor=S.+M%C3%BCllerauthor=S.+Knappauthor=P.+E.+Brennanauthor=S.+J.+Conway&title=A+Series+of+Potent+CREBBP+Bromodomain+Ligands+Reveals+an+Induced-Fit+Pocket+Stabilized+by+a+Cation-%CE%A0+Interaction&doi=10.1002%2Fanie.201402750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation-π Interaction</span></div><div class="casAuthors">Rooney, Timothy P. C.; Filippakopoulos, Panagis; Fedorov, Oleg; Picaud, Sarah; Cortopassi, Wilian A.; Hay, Duncan A.; Martin, Sarah; Tumber, Anthony; Rogers, Catherine M.; Philpott, Martin; Wang, Minghua; Thompson, Amber L.; Heightman, Tom D.; Pryde, David C.; Cook, Andrew; Paton, Robert S.; Mueller, Susanne; Knapp, Stefan; Brennan, Paul E.; Conway, Stuart J.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6126-6130</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Benzoxazinone and dihydroquinoxalinone fragments were employed as novel acetyl lysine mimics in the development of CREBBP bromodomain ligands.  While the benzoxazinone series showed low affinity for the CREBBP bromodomain, expansion of the dihydroquinoxalinone series resulted in the first potent inhibitors, e.g., I, of a bromodomain outside the BET family.  Structural and computational studies revealed that an internal hydrogen bond stabilized the protein-bound conformation of the dihydroquinoxalinone series.  The side chain of this series binds in an induced-fit pocket forming a cation-π interaction with R1173 of CREBBP.  Compd. I, the most potent compd., inhibited binding of CREBBP to chromatin in U2OS cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHFgTVUKe7lrVg90H21EOLACvtfcHk0ljShg9xoCUoBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFWgsb0%253D&md5=42b12e1fe855d2af02c49f8e1031d39e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fanie.201402750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201402750%26sid%3Dliteratum%253Aachs%26aulast%3DRooney%26aufirst%3DT.%2BP.%2BC.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DCortopassi%26aufirst%3DW.%2BA.%26aulast%3DHay%26aufirst%3DD.%2BA.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DRogers%26aufirst%3DC.%2BM.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DThompson%26aufirst%3DA.%2BL.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DPryde%26aufirst%3DD.%2BC.%26aulast%3DCook%26aufirst%3DA.%26aulast%3DPaton%26aufirst%3DR.%2BS.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DConway%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Series%2520of%2520Potent%2520CREBBP%2520Bromodomain%2520Ligands%2520Reveals%2520an%2520Induced-Fit%2520Pocket%2520Stabilized%2520by%2520a%2520Cation-%25CE%25A0%2520Interaction%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D6126%26epage%3D6130%26doi%3D10.1002%2Fanie.201402750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Hay, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singleton, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteiro, O. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, T. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schofield, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of Small-Molecule Ligands for the CBP/P300 Bromodomains</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">9308</span><span class="NLM_x">–</span> <span class="NLM_lpage">9319</span><span class="refDoi"> DOI: 10.1021/ja412434f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja412434f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=9308-9319&author=D.+A.+Hayauthor=O.+Fedorovauthor=S.+Martinauthor=D.+C.+Singletonauthor=C.+Tallantauthor=C.+Wellsauthor=S.+Picaudauthor=M.+Philpottauthor=O.+P.+Monteiroauthor=C.+M.+Rogersauthor=S.+J.+Conwayauthor=T.+P.+C.+Rooneyauthor=A.+Tumberauthor=C.+Yappauthor=P.+Filippakopoulosauthor=M.+E.+Bunnageauthor=S.+M%C3%BCllerauthor=S.+Knappauthor=C.+J.+Schofieldauthor=P.+E.+Brennan&title=Discovery+and+Optimization+of+Small-Molecule+Ligands+for+the+CBP%2FP300+Bromodomains&doi=10.1021%2Fja412434f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains</span></div><div class="casAuthors">Hay, Duncan A.; Fedorov, Oleg; Martin, Sarah; Singleton, Dean C.; Tallant, Cynthia; Wells, Christopher; Picaud, Sarah; Philpott, Martin; Monteiro, Octovia P.; Rogers, Catherine M.; Conway, Stuart J.; Rooney, Timothy P. C.; Tumber, Anthony; Yapp, Clarence; Filippakopoulos, Panagis; Bunnage, Mark E.; Muller, Susanne; Knapp, Stefan; Schofield, Christopher J.; Brennan, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9308-9319</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small-mol. inhibitors that target bromodomains outside of the bromodomain and extra-terminal (BET) sub-family are lacking.  Here, the authors describe highly potent and selective ligands for the bromodomain module of the human lysine acetyl transferase CBP/p300, developed from a series of 5-isoxazolyl-benzimidazoles.  The starting point was a fragment hit, which was optimized into a more potent and selective lead using parallel synthesis employing Suzuki couplings, benzimidazole-forming reactions, and reductive aminations.  The selectivity of the lead compd. against other bromodomain family members was investigated using a thermal stability assay, which revealed some inhibition of the structurally related BET family members.  To address the BET selectivity issue, x-ray crystal structures of the lead compd. bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compds.  The crystal structures obtained revealed two distinct binding modes.  By varying the aryl substitution pattern and developing conformationally constrained analogs, selectivity for CBP over BRD4(1) was increased.  The optimized compd. is highly potent (Kd = 21 nM) and selective, displaying 40-fold selectivity over BRD4(1).  Cellular activity was demonstrated using fluorescence recovery after photo-bleaching (FRAP) and a p53 reporter assay.  The optimized compds. are cell-active and have nanomolar affinity for CBP/p300; therefore, they should be useful in studies investigating the biol. roles of CBP and p300 and to validate the CBP and p300 bromodomains as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFzgs1DD4QZLVg90H21EOLACvtfcHk0liAcZO7ETGlRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsLvP&md5=e5da3e96a4d234453a481c7ee5e788f2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fja412434f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja412434f%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DD.%2BA.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DSingleton%26aufirst%3DD.%2BC.%26aulast%3DTallant%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DMonteiro%26aufirst%3DO.%2BP.%26aulast%3DRogers%26aufirst%3DC.%2BM.%26aulast%3DConway%26aufirst%3DS.%2BJ.%26aulast%3DRooney%26aufirst%3DT.%2BP.%2BC.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DYapp%26aufirst%3DC.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DSchofield%26aufirst%3DC.%2BJ.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Small-Molecule%2520Ligands%2520for%2520the%2520CBP%252FP300%2520Bromodomains%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D9308%26epage%3D9319%26doi%3D10.1021%2Fja412434f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Unzue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiedmer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiliotopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevado, C.</span><span> </span><span class="NLM_article-title">Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00172</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00172" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1350-1356&author=A.+Unzueauthor=M.+Xuauthor=J.+Dongauthor=L.+Wiedmerauthor=D.+Spiliotopoulosauthor=A.+Caflischauthor=C.+Nevado&title=Fragment-Based+Design+of+Selective+Nanomolar+Ligands+of+the+CREBBP+Bromodomain&doi=10.1021%2Facs.jmedchem.5b00172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain</span></div><div class="casAuthors">Unzue, Andrea; Xu, Min; Dong, Jing; Wiedmer, Lars; Spiliotopoulos, Dimitrios; Caflisch, Amedeo; Nevado, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1350-1356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel ligands of the CREBBP bromodomain were identified by fragment-based docking.  The in silico discovered hits have been optimized by chem. synthesis into selective nanomolar compds., thereby preserving the ligand efficiency.  The selectivity for the CREBBP bromodomain over other human bromodomain subfamilies has achieved by a benzoate moiety which was predicted by docking to be involved in favorable electrostatic interactions with the Arg1173 side chain, a prediction that could be verified a posteriori by the high-resoln. crystal structure of the CREBBP bromodomain in complex with ligand 6 and also by MD simulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy4MHhgfhyu7Vg90H21EOLACvtfcHk0liAcZO7ETGlRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaktLg%253D&md5=aff73b86b04fc4d7243adcba364ca6a6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00172%26sid%3Dliteratum%253Aachs%26aulast%3DUnzue%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DWiedmer%26aufirst%3DL.%26aulast%3DSpiliotopoulos%26aufirst%3DD.%26aulast%3DCaflisch%26aufirst%3DA.%26aulast%3DNevado%26aufirst%3DC.%26atitle%3DFragment-Based%2520Design%2520of%2520Selective%2520Nanomolar%2520Ligands%2520of%2520the%2520CREBBP%2520Bromodomain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1350%26epage%3D1356%26doi%3D10.1021%2Facs.jmedchem.5b00172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thanasopoulou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonards, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olzscha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteiro, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bannister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecellio, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bountra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velichko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Thangue, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouzarides, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwaller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Generation of a Selective Small Molecule Inhibitor of the CBP/P300 Bromodomain for Leukemia Therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">5106</span><span class="NLM_x">–</span> <span class="NLM_lpage">5119</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-0236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1158%2F0008-5472.CAN-15-0236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=26552700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFensrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=5106-5119&author=S.+Picaudauthor=O.+Fedorovauthor=A.+Thanasopoulouauthor=K.+Leonardsauthor=K.+Jonesauthor=J.+Meierauthor=H.+Olzschaauthor=O.+Monteiroauthor=S.+Martinauthor=M.+Philpottauthor=A.+Tumberauthor=P.+Filippakopoulosauthor=C.+Yappauthor=C.+Wellsauthor=K.+H.+Cheauthor=A.+Bannisterauthor=S.+Robsonauthor=U.+Kumarauthor=N.+Parrauthor=K.+Leeauthor=D.+Lugoauthor=P.+Jeffreyauthor=S.+Taylorauthor=M.+L.+Vecellioauthor=C.+Bountraauthor=P.+E.+Brennanauthor=A.+O%E2%80%99Mahonyauthor=S.+Velichkoauthor=S.+M%C3%BCllerauthor=D.+Hayauthor=D.+L.+Danielsauthor=M.+Urhauthor=N.+B.+La+Thangueauthor=T.+Kouzaridesauthor=R.+Prinjhaauthor=J.+Schwallerauthor=S.+Knapp&title=Generation+of+a+Selective+Small+Molecule+Inhibitor+of+the+CBP%2FP300+Bromodomain+for+Leukemia+Therapy&doi=10.1158%2F0008-5472.CAN-15-0236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy</span></div><div class="casAuthors">Picaud, Sarah; Fedorov, Oleg; Thanasopoulou, Angeliki; Leonards, Katharina; Jones, Katherine; Meier, Julia; Olzscha, Heidi; Monteiro, Octovia; Martin, Sarah; Philpott, Martin; Tumber, Anthony; Filippakopoulos, Panagis; Yapp, Clarence; Wells, Christopher; Che, Ka Hing; Bannister, Andrew; Robson, Samuel; Kumar, Umesh; Parr, Nigel; Lee, Kevin; Lugo, Dave; Jeffrey, Philip; Taylor, Simon; Vecellio, Matteo L.; Bountra, Chas; Brennan, Paul E.; O'Mahony, Alison; Velichko, Sharlene; Mueller, Susanne; Hay, Duncan; Daniels, Danette L.; Urh, Marjeta; La Thangue, Nicholas B.; Kouzarides, Tony; Prinjha, Rab; Schwaller, Juerg; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5106-5119</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The histone acetyltransferases CBP/p300 are involved in recurrent leukemia-assocd. chromosomal translocations and are key regulators of cell growth.  Therefore, efforts to generate inhibitors of CBP/p300 are of clin. value.  We developed a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, I-CBP112, that targets the CBP/p300 bromodomains.  Exposure of human and mouse leukemic cell lines to I-CBP112 resulted in substantially impaired colony formation and induced cellular differentiation without significant cytotoxicity.  I-CBP112 significantly reduced the leukemia-initiating potential of MLL-AF9+ acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo.  Interestingly, I-CBP112 increased the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin.  Collectively, we report the development and preclin. evaluation of a novel, potent inhibitor targeting CBP/p300 bromodomains that impairs aberrant self-renewal of leukemic cells.  The synergistic effects of I-CBP112 and current std. therapy (doxorubicin) as well as emerging treatment strategies (BET inhibition) provide new opportunities for combinatorial treatment of leukemia and potentially other cancers.  Cancer Res; 75(23); 5106-19. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWk5dMbmC6K7Vg90H21EOLACvtfcHk0liywC9mI_H3Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFensrzN&md5=da936fa34139ba27abc748db5f78c95e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-0236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-0236%26sid%3Dliteratum%253Aachs%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DThanasopoulou%26aufirst%3DA.%26aulast%3DLeonards%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DMeier%26aufirst%3DJ.%26aulast%3DOlzscha%26aufirst%3DH.%26aulast%3DMonteiro%26aufirst%3DO.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DYapp%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DChe%26aufirst%3DK.%2BH.%26aulast%3DBannister%26aufirst%3DA.%26aulast%3DRobson%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DU.%26aulast%3DParr%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DLugo%26aufirst%3DD.%26aulast%3DJeffrey%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DVecellio%26aufirst%3DM.%2BL.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DVelichko%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DHay%26aufirst%3DD.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DUrh%26aufirst%3DM.%26aulast%3DLa%2BThangue%26aufirst%3DN.%2BB.%26aulast%3DKouzarides%26aufirst%3DT.%26aulast%3DPrinjha%26aufirst%3DR.%26aulast%3DSchwaller%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DGeneration%2520of%2520a%2520Selective%2520Small%2520Molecule%2520Inhibitor%2520of%2520the%2520CBP%252FP300%2520Bromodomain%2520for%2520Leukemia%2520Therapy%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D5106%26epage%3D5119%26doi%3D10.1158%2F0008-5472.CAN-15-0236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Hammitzsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Mossawi, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Wit, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecellio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wordsworth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowness, P.</span><span> </span><span class="NLM_article-title">CBP30, a Selective CBP/P300 Bromodomain Inhibitor, Suppresses Human Th17 Responses</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">10768</span><span class="NLM_x">–</span> <span class="NLM_lpage">10773</span><span class="refDoi"> DOI: 10.1073/pnas.1501956112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1073%2Fpnas.1501956112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=26261308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSit7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=10768-10773&author=A.+Hammitzschauthor=C.+Tallantauthor=O.+Fedorovauthor=A.+O%E2%80%99Mahonyauthor=P.+E.+Brennanauthor=D.+A.+Hayauthor=F.+O.+Martinezauthor=M.+H.+Al-Mossawiauthor=J.+de+Witauthor=M.+Vecellioauthor=C.+Wellsauthor=P.+Wordsworthauthor=S.+M%C3%BCllerauthor=S.+Knappauthor=P.+Bowness&title=CBP30%2C+a+Selective+CBP%2FP300+Bromodomain+Inhibitor%2C+Suppresses+Human+Th17+Responses&doi=10.1073%2Fpnas.1501956112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses</span></div><div class="casAuthors">Hammitzsch, Ariane; Tallant, Cynthia; Fedorov, Oleg; O'Mahony, Alison; Brennan, Paul E.; Hay, Duncan A.; Martinez, Fernando O.; Al-Mossawi, M. Hussein; de Wit, Jelle; Vecellio, Matteo; Wells, Christopher; Wordsworth, Paul; Muller, Susanne; Knapp, Stefan; Bowness, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">10768-10773</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Th17 responses are crit. to a variety of human autoimmune diseases, and therapeutic targeting with monoclonal antibodies against IL-17 and IL-23 has shown considerable promise.  Here, the authors report data to support selective bromodomain blockade of the transcriptional coactivators CBP (CREB binding protein) and p300 as an alternative approach to inhibit human Th17 responses.  The authors show that CBP30 has marked mol. specificity for the bromodomains of CBP and p300, compared with 43 other bromodomains.  In unbiased cellular testing on a diverse panel of cultured primary human cells, CBP30 reduced immune cell prodn. of IL-17A and other proinflammatory cytokines.  CBP30 also inhibited IL-17A secretion by Th17 cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis.  Transcriptional profiling of human T cells after CBP30 treatment showed a much more restricted effect on gene expression than that obsd. with the pan-BET (bromo and extraterminal domain protein family) bromodomain inhibitor JQ1.  This selective targeting of the CBP/p300 bromodomain by CBP30 will potentially lead to fewer side effects than with the broadly acting epigenetic inhibitors currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4fYjOUV2xW7Vg90H21EOLACvtfcHk0liywC9mI_H3Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSit7jI&md5=fb9de88ecdd6441628ae1455ac11b65c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1501956112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1501956112%26sid%3Dliteratum%253Aachs%26aulast%3DHammitzsch%26aufirst%3DA.%26aulast%3DTallant%26aufirst%3DC.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DHay%26aufirst%3DD.%2BA.%26aulast%3DMartinez%26aufirst%3DF.%2BO.%26aulast%3DAl-Mossawi%26aufirst%3DM.%2BH.%26aulast%3Dde%2BWit%26aufirst%3DJ.%26aulast%3DVecellio%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DWordsworth%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBowness%26aufirst%3DP.%26atitle%3DCBP30%252C%2520a%2520Selective%2520CBP%252FP300%2520Bromodomain%2520Inhibitor%252C%2520Suppresses%2520Human%2520Th17%2520Responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D10768%26epage%3D10773%26doi%3D10.1073%2Fpnas.1501956112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Denny, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coe, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langille, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahasrabudhe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonin, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pletcher, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chekler, E. L. P.</span><span> </span><span class="NLM_article-title">Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">5349</span><span class="NLM_x">–</span> <span class="NLM_lpage">5363</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01839</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01839" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Glu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5349-5363&author=R.+A.+Dennyauthor=A.+C.+Flickauthor=J.+W.+Coeauthor=J.+Langilleauthor=A.+Basakauthor=S.+Liuauthor=I.+A.+Stockauthor=P.+Sahasrabudheauthor=P.+D.+Boninauthor=D.+A.+Hayauthor=P.+E.+Brennanauthor=M.+T.+Pletcherauthor=L.+H.+Jonesauthor=E.+L.+P.+Chekler&title=Structure-Based+Design+of+Highly+Selective+Inhibitors+of+the+CREB+Binding+Protein+Bromodomain&doi=10.1021%2Facs.jmedchem.6b01839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain</span></div><div class="casAuthors">Denny, R. Aldrin; Flick, Andrew C.; Coe, Jotham; Langille, Jonathan; Basak, Arindrajit; Liu, Shenping; Stock, Ingrid; Sahasrabudhe, Parag; Bonin, Paul; Hay, Duncan A.; Brennan, Paul E.; Pletcher, Mathew; Jones, Lyn H.; Chekler, Eugene L. Piatnitski</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5349-5363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. probes are required for preclin. target validation to interrogate novel biol. targets and pathways.  Selective inhibitors of the CREB binding protein (CREBBP)/EP300 bromodomains are required to facilitate the elucidation of biol. assocd. with these important epigenetic targets.  Medicinal chem. optimization that paid particular attention to physiochem. properties delivered chem. probes with desirable potency, selectivity, and permeability attributes.  An important feature of the optimization process was the successful application of rational structure-based drug design to address bromodomain selectivity issues (particularly against the structurally related BRD4 protein).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLWkqF-qAmdbVg90H21EOLACvtfcHk0lgCvPRA3ODvUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Glu70%253D&md5=23676a973abba59088dedd5502877105</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01839%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DR.%2BA.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DCoe%26aufirst%3DJ.%2BW.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DStock%26aufirst%3DI.%2BA.%26aulast%3DSahasrabudhe%26aufirst%3DP.%26aulast%3DBonin%26aufirst%3DP.%2BD.%26aulast%3DHay%26aufirst%3DD.%2BA.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DPletcher%26aufirst%3DM.%2BT.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DChekler%26aufirst%3DE.%2BL.%2BP.%26atitle%3DStructure-Based%2520Design%2520of%2520Highly%2520Selective%2520Inhibitors%2520of%2520the%2520CREB%2520Binding%2520Protein%2520Bromodomain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5349%26epage%3D5363%26doi%3D10.1021%2Facs.jmedchem.6b01839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Romero, F. A.; Magnuson, S.; Pastor, R.; Tsui, V.; Murray, J.; Crawford, T.; Albrecht, B. K.; Côté, A.; Taylor, A. M.; Lai, K. W.; Chen, K. X.; Bronner, S.; Adler, M.; Egen, J.; Liao, J.; Wang, F.; Cyr, P.; Zhu, B.-Y.; Kauder, S.</span><span> </span><span class="NLM_article-title">4,5,6,7-Tetrahydro-1<i>H</i>-pyrazolo[4,3-C]pyridin-3-amine Compounds as CBP and/or EP300 Inhibitors</span>. WO2016086200.<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=F.+A.+Romero&author=S.+Magnuson&author=R.+Pastor&author=V.+Tsui&author=J.+Murray&author=T.+Crawford&author=B.+K.+Albrecht&author=A.+C%C3%B4t%C3%A9&author=A.+M.+Taylor&author=K.+W.+Lai&author=K.+X.+Chen&author=S.+Bronner&author=M.+Adler&author=J.+Egen&author=J.+Liao&author=F.+Wang&author=P.+Cyr&author=B.-Y.+Zhu&author=S.+Kauder&title=4%2C5%2C6%2C7-Tetrahydro-1H-pyrazolo%5B4%2C3-C%5Dpyridin-3-amine+Compounds+as+CBP+and%2For+EP300+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DF.%2BA.%26atitle%3D4%252C5%252C6%252C7-Tetrahydro-1H-pyrazolo%255B4%252C3-C%255Dpyridin-3-amine%2520Compounds%2520as%2520CBP%2520and%252For%2520EP300%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1271</span><span class="NLM_x">–</span> <span class="NLM_lpage">1298</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1271-1298&author=F.+A.+Romeroauthor=A.+M.+Taylorauthor=T.+D.+Crawfordauthor=V.+Tsuiauthor=A.+C%C3%B4t%C3%A9author=S.+Magnuson&title=Disrupting+Acetyl-Lysine+Recognition%3A+Progress+in+the+Development+of+Bromodomain+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors</span></div><div class="casAuthors">Romero, F. Anthony; Taylor, Alexander M.; Crawford, Terry D.; Tsui, Vickie; Cote, Alexandre; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1271-1298</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomains, small protein modules that recognize acetylated lysine on histones, play a significant role in the epigenome, where they function as "readers" that ultimately det. the functional outcome of the post-translational modification.  Because the initial discovery of selective BET inhibitors have helped define the role of that protein family in oncol. and inflammation, BET bromodomains have continued to garner the most attention of any other bromodomain.  More recently, non-BET bromodomain inhibitors that are potent and selective have been disclosed for ATAD2, CBP, BRD7/9, BRPF, BRPF/TRIM24, CECR2, SMARCA4, and BAZ2A/B.  Such novel inhibitors can be used to probe the physiol. function of these non-BET bromodomains and further understanding of their role in certain disease states.  Here, we provide an update to the progress in identifying selective bromodomain inhibitors and their use as biol. tools, as well as our perspective on the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgbRrKGlHaVLVg90H21EOLACvtfcHk0ljMLMG6_GmpNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO&md5=260352f61301aa88aad48c0b63e6152f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01514%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DDisrupting%2520Acetyl-Lysine%2520Recognition%253A%2520Progress%2520in%2520the%2520Development%2520of%2520Bromodomain%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1271%26epage%3D1298%26doi%3D10.1021%2Facs.jmedchem.5b01514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">The (<i>S</i>) absolute stereochemistry of <b>8</b> was determined from the cocrystal structure of <b>8</b> in the CBP bromodomain. In every instance the (<i>S</i>)-enantiomer was always more potent than the (<i>R</i>)-enantiomer (data not shown). compounds <b>3</b>, <b>5</b>, <b>6</b>, <b>7</b>, and <b>9</b> were synthesized from (<i>R</i>)-tetrahydrofuran-3-ol and thus the absolute stereochemistry is unambiguously that of the (<i>S</i>)-configuration.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><div class="note"><p class="first last">Mo Ka Molecular Discovery, Perugia.</p></div><a href="http://www.moldiscovery.com/software/moka/" class="extLink">http://www.moldiscovery.com/software/moka/</a> (Accessed July 27,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Mo+Ka+Molecular+Discovery%2C+Perugia.http%3A%2F%2Fwww.moldiscovery.com%2Fsoftware%2Fmoka%2F+%28Accessed+July+27%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljMLMG6_GmpNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, A.</span><span> </span><span class="NLM_article-title">Ligand Efficiency: A Useful Metric for Lead Selection</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+Efficiency%3A+A+Useful+Metric+for+Lead+Selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2ebfh8G-Kl0VNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520Efficiency%253A%2520A%2520Useful%2520Metric%2520for%2520Lead%2520Selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Chan, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Thangue, N. B.</span><span> </span><span class="NLM_article-title">P300/CBP Proteins: HATs for Transcriptional Bridges and Scaffolds</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2363</span><span class="NLM_x">–</span> <span class="NLM_lpage">2373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=11559745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsFamt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2001&pages=2363-2373&author=H.+M.+Chanauthor=N.+B.+La+Thangue&title=P300%2FCBP+Proteins%3A+HATs+for+Transcriptional+Bridges+and+Scaffolds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">p300/CBP proteins: HATs for transcriptional bridges and scaffolds</span></div><div class="casAuthors">Chan, Ho Man; La Thangue, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2363-2373</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review with 139 refs.  P300/CBP transcriptional co-activator proteins play a central role in co-ordinating and integrating multiple signal-dependent events with the transcription app., allowing the appropriate level of gene activity to occur in response to diverse physiol. cues that influence, for example, proliferation, differentiation and apoptosis.  P300/CBP activity can be under aberrant control in human disease, particularly in cancer, which may inactivate a p300/CBP tumor-suppressor-like activity.  The transcription regulating-properties of p300 and CBP appear to be exerted through multiple mechanisms.  They act as protein bridges, thereby connecting different sequence-specific transcription factors to the transcription app.  Providing a protein scaffold upon which to build a multicomponent transcriptional regulatory complex is likely to be an important feature of p300/CBP control.  Another key property is the presence of histone acetyltransferase (HAT) activity, which endows p300/CBP with the capacity to influence chromatin activity by modulating nucleosomal histones.  Other proteins, including the p53 tumor suppressor, are targets for acetylation by p300/CBP.  With the current intense level of research activity, p300/CBP will continue to be in the limelight and, we can be confident, yield new and important information on fundamental processes involved in transcriptional control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNuaZehN-7bVg90H21EOLACvtfcHk0limH6uTq6wMFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsFamt7c%253D&md5=f4c7d310294dc7253ad9818bd52cb792</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DLa%2BThangue%26aufirst%3DN.%2BB.%26atitle%3DP300%252FCBP%2520Proteins%253A%2520HATs%2520for%2520Transcriptional%2520Bridges%2520and%2520Scaffolds%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2001%26volume%3D114%26spage%3D2363%26epage%3D2373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Sakaguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, M.</span><span> </span><span class="NLM_article-title">Regulatory T Cells and Immune Tolerance</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">787</span><span class="refDoi"> DOI: 10.1016/j.cell.2008.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1016%2Fj.cell.2008.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=18510923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFaltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=775-787&author=S.+Sakaguchiauthor=T.+Yamaguchiauthor=T.+Nomuraauthor=M.+Ono&title=Regulatory+T+Cells+and+Immune+Tolerance&doi=10.1016%2Fj.cell.2008.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory T cells and immune tolerance</span></div><div class="casAuthors">Sakaguchi, Shimon; Yamaguchi, Tomoyuki; Nomura, Takashi; Ono, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">775-787</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Regulatory T cells (Tregs) play an indispensable role in maintaining immunol. unresponsiveness to self-antigens and in suppressing excessive immune responses deleterious to the host.  Tregs are produced in the thymus as a functionally mature subpopulation of T cells and can also be induced from naive T cells in the periphery.  Recent research reveals the cellular and mol. basis of Treg development and function and implicates dysregulation of Tregs in immunol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoATufEZGfRqrVg90H21EOLACvtfcHk0limH6uTq6wMFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFaltrg%253D&md5=a0e32e258b46e4975f40d937a7c8f6d8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DSakaguchi%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DOno%26aufirst%3DM.%26atitle%3DRegulatory%2520T%2520Cells%2520and%2520Immune%2520Tolerance%26jtitle%3DCell%26date%3D2008%26volume%3D133%26spage%3D775%26epage%3D787%26doi%3D10.1016%2Fj.cell.2008.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Tanaka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, S.</span><span> </span><span class="NLM_article-title">Regulatory T Cells in Cancer Immunotherapy</span> <span class="citation_source-journal">Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1038/cr.2016.151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fcr.2016.151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=27995907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCmtr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=109-118&author=A.+Tanakaauthor=S.+Sakaguchi&title=Regulatory+T+Cells+in+Cancer+Immunotherapy&doi=10.1038%2Fcr.2016.151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory T cells in cancer immunotherapy</span></div><div class="casAuthors">Tanaka, Atsushi; Sakaguchi, Shimon</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-118</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">FOXP3-expressing regulatory T (Treg) cells, which suppress aberrant immune response against self-antigens, also suppress anti-tumor immune response.  Infiltration of a large no. of Treg cells into tumor tissues is often assocd. with poor prognosis.  There is accumulating evidence that the removal of Treg cells is able to evoke and enhance anti-tumor immune response.  However, systemic depletion of Treg cells may concurrently elicit deleterious autoimmunity.  One strategy for evoking effective tumor immunity without autoimmunity is to specifically target terminally differentiated effector Treg cells rather than all FOXP3+ T cells, because effector Treg cells are the predominant cell type in tumor tissues.  Various cell surface mols., including chemokine receptors such as CCR4, that are specifically expressed by effector Treg cells can be the candidates for depleting effector Treg cells by specific cell-depleting monoclonal antibodies.  In addn., other immunol. characteristics of effector Treg cells, such as their high expression of CTLA-4, active proliferation, and apoptosis-prone tendency, can be exploited to control specifically their functions.  For example, anti-CTLA-4 antibody may kill effector Treg cells or attenuate their suppressive activity.  It is hoped that combination of Treg-cell targeting (e.g., by reducing Treg cells or attenuating their suppressive activity in tumor tissues) with the activation of tumor-specific effector T cells (e.g., by cancer vaccine or immune checkpoint blockade) will make the current cancer immunotherapy more effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqpJ04a1bId7Vg90H21EOLACvtfcHk0limH6uTq6wMFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCmtr7M&md5=124edc1c7d0aa3739c53ba74790437cb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fcr.2016.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.2016.151%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DSakaguchi%26aufirst%3DS.%26atitle%3DRegulatory%2520T%2520Cells%2520in%2520Cancer%2520Immunotherapy%26jtitle%3DCell%2520Res.%26date%3D2017%26volume%3D27%26spage%3D109%26epage%3D118%26doi%3D10.1038%2Fcr.2016.151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Shimizu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, S.</span><span> </span><span class="NLM_article-title">Induction of Tumor Immunity by Removing CD25 + CD4+ T Cells: a Common Basis Between Tumor Immunity and Autoimmunity</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">5211</span><span class="NLM_x">–</span> <span class="NLM_lpage">5218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=1999&pages=5211-5218&author=J.+Shimizuauthor=S.+Yamazakiauthor=S.+Sakaguchi&title=Induction+of+Tumor+Immunity+by+Removing+CD25+%2B+CD4%2B+T+Cells%3A+a+Common+Basis+Between+Tumor+Immunity+and+Autoimmunity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DJ.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DSakaguchi%26aufirst%3DS.%26atitle%3DInduction%2520of%2520Tumor%2520Immunity%2520by%2520Removing%2520CD25%2520%252B%2520CD4%252B%2520T%2520Cells%253A%2520a%2520Common%2520Basis%2520Between%2520Tumor%2520Immunity%2520and%2520Autoimmunity%26jtitle%3DJ.%2520Immunol.%26date%3D1999%26volume%3D163%26spage%3D5211%26epage%3D5218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Hori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, S.</span><span> </span><span class="NLM_article-title">Control of Regulatory T Cell Development by the Transcription Factor Foxp3</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1126/science.1079490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1126%2Fscience.1079490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=12522256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtFarsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=1057-1061&author=S.+Horiauthor=T.+Nomuraauthor=S.+Sakaguchi&title=Control+of+Regulatory+T+Cell+Development+by+the+Transcription+Factor+Foxp3&doi=10.1126%2Fscience.1079490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Control of Regulatory T Cell Development by the Transcription Factor Foxp3</span></div><div class="casAuthors">Hori, Shohei; Nomura, Takashi; Sakaguchi, Shimon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5609</span>),
    <span class="NLM_cas:pages">1057-1061</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Regulatory T cells engage in the maintenance of immunol. self-tolerance by actively suppressing self-reactive lymphocytes.  Little is known, however, about the mol. mechanism of their development.  Here we show that Foxp3, which encodes a transcription factor that is genetically defective in an autoimmune and inflammatory syndrome in humans and mice, is specifically expressed in naturally arising CD4+ regulatory T cells.  Furthermore, retroviral gene transfer of Foxp3 converts naive T cells toward a regulatory T cell phenotype similar to that of naturally occurring CD4+ regulatory T cells.  Thus, Foxp3 is a key regulatory gene for the development of regulatory T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY_22m45Ig-bVg90H21EOLACvtfcHk0lhDx6Od1gCt2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtFarsbw%253D&md5=eb4ecdd3a735c2ba41703ef65fb5587d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1126%2Fscience.1079490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1079490%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DS.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DSakaguchi%26aufirst%3DS.%26atitle%3DControl%2520of%2520Regulatory%2520T%2520Cell%2520Development%2520by%2520the%2520Transcription%2520Factor%2520Foxp3%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D1057%26epage%3D1061%26doi%3D10.1126%2Fscience.1079490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatti, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brindle, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Two Histone/Protein Acetyltransferases, CBP and P300, Are Indispensable for Foxp3+ T-Regulatory Cell Development and Function</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">3993</span><span class="NLM_x">–</span> <span class="NLM_lpage">4007</span><span class="refDoi"> DOI: 10.1128/MCB.00919-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1128%2FMCB.00919-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=25154413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCqtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=3993-4007&author=Y.+Liuauthor=L.+Wangauthor=R.+Hanauthor=U.+H.+Beierauthor=T.+Akimovaauthor=T.+Bhattiauthor=H.+Xiaoauthor=P.+A.+Coleauthor=P.+K.+Brindleauthor=W.+W.+Hancock&title=Two+Histone%2FProtein+Acetyltransferases%2C+CBP+and+P300%2C+Are+Indispensable+for+Foxp3%2B+T-Regulatory+Cell+Development+and+Function&doi=10.1128%2FMCB.00919-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Two histone/protein acetyltransferases, CBP and p300, are indispensable for fFoxp3+ T-regulatory cell development and function</span></div><div class="casAuthors">Liu, Yujie; Wang, Liqing; Han, Rongxiang; Beier, Ulf H.; Akimova, Tatiana; Bhatti, Tricia; Xiao, Haiyan; Cole, Philip A.; Brindle, Paul K.; Hancock, Wayne W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3993-4007, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">T-regulatory (Treg) cells are important to immune homeostasis, and Treg cell deficiency or dysfunction leads to autoimmune disease.  A histone/protein acetyltransferase (HAT), p300, was recently found to be important for Treg function and stability, but further insights into the mechanisms by which p300 or other HATs affect Treg biol. are needed.  Here we show that CBP, a p300 paralog, is also important in controlling Treg function and stability.  Thus, while mice with Treg-specific deletion of CBP or p300 developed minimal autoimmune disease, the combined deletion of CBP and p300 led to fatal autoimmunity by 3 to 4 wk of age.  The effects of CBP and p300 deletion on Treg development are dose dependent and involve multiple mechanisms.  CBP and p300 cooperate with several key Treg transcription factors that act on the Foxp3 promoter to promote Foxp3 prodn.  CBP and p300 also act on the Foxp3 conserved noncoding sequence 2 (CNS2) region to maintain Treg stability in inflammatory environments by regulating pCREB function and GATA3 expression, resp.  Lastly, CBP and p300 regulate the epigenetic status and function of Foxp3.  Our findings provide insights into how HATs orchestrate multiple aspects of Treg development and function and identify overlapping but also discrete activities for p300 and CBP in control of Treg cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI1fb6sF005bVg90H21EOLACvtfcHk0lhDx6Od1gCt2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCqtbzI&md5=104de0308e0127578dca578d3ea68ed3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1128%2FMCB.00919-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00919-14%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DBeier%26aufirst%3DU.%2BH.%26aulast%3DAkimova%26aufirst%3DT.%26aulast%3DBhatti%26aufirst%3DT.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DBrindle%26aufirst%3DP.%2BK.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DTwo%2520Histone%252FProtein%2520Acetyltransferases%252C%2520CBP%2520and%2520P300%252C%2520Are%2520Indispensable%2520for%2520Foxp3%252B%2520T-Regulatory%2520Cell%2520Development%2520and%2520Function%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26spage%3D3993%26epage%3D4007%26doi%3D10.1128%2FMCB.00919-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Crawford, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audia, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duplessis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasveschuk, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawadzke, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, A. G.</span><span> </span><span class="NLM_article-title">Diving Into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">5391</span><span class="NLM_x">–</span> <span class="NLM_lpage">5402</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00264</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00264" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5391-5402&author=T.+D.+Crawfordauthor=V.+Tsuiauthor=E.+M.+Flynnauthor=S.+Wangauthor=A.+M.+Taylorauthor=A.+C%C3%B4t%C3%A9author=J.+E.+Audiaauthor=M.+H.+Beresiniauthor=D.+J.+Burdickauthor=R.+T.+Cummingsauthor=L.+A.+Dakinauthor=M.+Duplessisauthor=A.+C.+Goodauthor=M.+C.+Hewittauthor=H.-R.+Huangauthor=H.+Jayaramauthor=J.+R.+Kieferauthor=Y.+Jiangauthor=J.+M.+Murrayauthor=C.+G.+Nasveschukauthor=E.+Pardoauthor=F.+Poyauthor=F.+A.+Romeroauthor=Y.+Tangauthor=J.+Wangauthor=Z.+Xuauthor=L.+E.+Zawadzkeauthor=X.+Zhuauthor=B.+K.+Albrechtauthor=S.+R.+Magnusonauthor=S.+F.+Bellonauthor=A.+G.+Cochran&title=Diving+Into+the+Water%3A+Inducible+Binding+Conformations+for+BRD4%2C+TAF1%282%29%2C+BRD9%2C+and+CECR2+Bromodomains&doi=10.1021%2Facs.jmedchem.6b00264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains</span></div><div class="casAuthors">Crawford, Terry D.; Tsui, Vickie; Flynn, E. Megan; Wang, Shumei; Taylor, Alexander M.; Cote, Alexandre; Audia, James E.; Beresini, Maureen H.; Burdick, Daniel J.; Cummings, Richard; Dakin, Les A.; Duplessis, Martin; Good, Andrew C.; Hewitt, Michael C.; Huang, Hon-Ren; Jayaram, Hariharan; Kiefer, James R.; Jiang, Ying; Murray, Jeremy; Nasveschuk, Christopher G.; Pardo, Eneida; Poy, Florence; Romero, F. Anthony; Tang, Yong; Wang, Jian; Xu, Zhaowu; Zawadzke, Laura E.; Zhu, Xiaoyu; Albrecht, Brian K.; Magnuson, Steven R.; Bellon, Steve; Cochran, Andrea G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5391-5402</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The biol. role played by non-BET bromodomains remains poorly understood, and it is therefore imperative to identify potent and highly selective inhibitors to effectively explore the biol. of individual bromodomain proteins.  A ligand-efficient nonselective bromodomain inhibitor was identified from a 6-Me pyrrolopyridone fragment.  Small hydrophobic substituents replacing the N-Me group were designed directing toward the conserved bromodomain water pocket, and two distinct binding conformations were then obsd.  The substituents either directly displaced and rearranged the conserved solvent network, as in BRD4(1) and TAF1(2), or induced a narrow hydrophobic channel adjacent to the lipophilic shelf, as in BRD9 and CECR2.  The preference of distinct substituents for individual bromodomains provided selectivity handles useful for future lead optimization efforts for selective BRD9, CECR2, and TAF1(2) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTLnuVCIKdHbVg90H21EOLACvtfcHk0lgKj0CY0sw-Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSnsbs%253D&md5=bf92e94c5fd3ee36bd8441294ca85185</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00264%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DFlynn%26aufirst%3DE.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBeresini%26aufirst%3DM.%2BH.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DHuang%26aufirst%3DH.-R.%26aulast%3DJayaram%26aufirst%3DH.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DPoy%26aufirst%3DF.%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZawadzke%26aufirst%3DL.%2BE.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DMagnuson%26aufirst%3DS.%2BR.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DCochran%26aufirst%3DA.%2BG.%26atitle%3DDiving%2520Into%2520the%2520Water%253A%2520Inducible%2520Binding%2520Conformations%2520for%2520BRD4%252C%2520TAF1%25282%2529%252C%2520BRD9%252C%2520and%2520CECR2%2520Bromodomains%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5391%26epage%3D5402%26doi%3D10.1021%2Facs.jmedchem.6b00264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehling, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaswani, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasveschuk, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantone, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neiss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Meara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, R. J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audia, J. E.</span><span> </span><span class="NLM_article-title">Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1330</span><span class="NLM_x">–</span> <span class="NLM_lpage">1339</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01882</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01882" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1330-1339&author=B.+K.+Albrechtauthor=V.+S.+Gehlingauthor=M.+C.+Hewittauthor=R.+G.+Vaswaniauthor=A.+C%C3%B4t%C3%A9author=Y.+Leblancauthor=C.+G.+Nasveschukauthor=S.+Bellonauthor=L.+Bergeronauthor=R.+Campbellauthor=N.+Cantoneauthor=M.+R.+Cooperauthor=R.+T.+Cummingsauthor=H.+Jayaramauthor=S.+Joshiauthor=J.+A.+Mertzauthor=A.+Neissauthor=E.+Normantauthor=M.+O%E2%80%99Mearaauthor=E.+Pardoauthor=F.+Poyauthor=P.+Sandyauthor=J.+Supkoauthor=R.+J.+Simsauthor=J.-C.+Harmangeauthor=A.+M.+Taylorauthor=J.+E.+Audia&title=Identification+of+a+Benzoisoxazoloazepine+Inhibitor+%28CPI-0610%29+of+the+Bromodomain+and+Extra-Terminal+%28BET%29+Family+as+a+Candidate+for+Human+Clinical+Trials&doi=10.1021%2Facs.jmedchem.5b01882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials</span></div><div class="casAuthors">Albrecht, Brian K.; Gehling, Victor S.; Hewitt, Michael C.; Vaswani, Rishi G.; Cote, Alexandre; Leblanc, Yves; Nasveschuk, Christopher G.; Bellon, Steve; Bergeron, Louise; Campbell, Robert; Cantone, Nico; Cooper, Michael R.; Cummings, Richard T.; Jayaram, Hariharan; Joshi, Shivangi; Mertz, Jennifer A.; Neiss, Adrianne; Normant, Emmanuel; O'Meara, Michael; Pardo, Eneida; Poy, Florence; Sandy, Peter; Supko, Jeffrey; Sims, Robert J.; Harmange, Jean-Christophe; Taylor, Alexander M.; Audia, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1330-1339</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In recent years, inhibition of the interaction between the bromodomain and extra-terminal domain (BET) family of chromatin adaptors and acetyl-lysine residues on chromatin has emerged as a promising approach to regulate the expression of important disease-relevant genes, including MYC, BCL-2, and NF-κB.  Here we describe the identification and characterization of a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor that attenuates BET-dependent gene expression in vivo, demonstrates antitumor efficacy in an MV-4-11 mouse xenograft model, and is currently undergoing human clin. trials for hematol. malignancies (CPI-0610).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp40qjnYl4EZLVg90H21EOLACvtfcHk0ljNRtY720qRkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKjs7g%253D&md5=5e1c5aab26aa58844a9f6670a7bbd78b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01882%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DLeblanc%26aufirst%3DY.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DBergeron%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DCooper%26aufirst%3DM.%2BR.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DJayaram%26aufirst%3DH.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DMertz%26aufirst%3DJ.%2BA.%26aulast%3DNeiss%26aufirst%3DA.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DPoy%26aufirst%3DF.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DSupko%26aufirst%3DJ.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26atitle%3DIdentification%2520of%2520a%2520Benzoisoxazoloazepine%2520Inhibitor%2520%2528CPI-0610%2529%2520of%2520the%2520Bromodomain%2520and%2520Extra-Terminal%2520%2528BET%2529%2520Family%2520as%2520a%2520Candidate%2520for%2520Human%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1330%26epage%3D1339%26doi%3D10.1021%2Facs.jmedchem.5b01882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':[],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 37 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Michael Brand, James Clayton, Mustafa Moroglu, Matthias Schiedel, Sarah Picaud, Joseph P. Bluck, Anna Skwarska, Hannah Bolland, Anthony K. N. Chan, Corentine M. C. Laurin, Amy R. Scorah, Larissa See, Timothy P. C. Rooney, Katrina H. Andrews, Oleg Fedorov, Gabriella Perell, Prakriti Kalra, Kayla B. Vinh, Wilian A. Cortopassi, Pascal Heitel, Kirsten E. Christensen, Richard I. Cooper, Robert S. Paton, William C. K. Pomerantz, Philip C. Biggin, Ester M. Hammond, Panagis Filippakopoulos, <span class="NLM_string-name hlFld-ContribAuthor">Stuart J. Conway</span>. </span><span class="cited-content_cbyCitation_article-title">Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 10102-10123. <a href="https://doi.org/10.1021/acs.jmedchem.1c00348" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00348%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DControlling%252BIntramolecular%252BInteractions%252Bin%252Bthe%252BDesign%252Bof%252BSelective%25252C%252BHigh-Affinity%252BLigands%252Bfor%252Bthe%252BCREBBP%252BBromodomain%26aulast%3DBrand%26aufirst%3DMichael%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D25022021%26date%3D13072021%26volume%3D64%26issue%3D14%26spage%3D10102%26epage%3D10123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Irena Hlushchuk, Heikki Ruskoaho, Andrii Domanskyi, Mikko Airavaara, <span class="NLM_string-name hlFld-ContribAuthor">Mika J. Välimäki</span>. </span><span class="cited-content_cbyCitation_article-title">Domain-Independent Inhibition of CBP/p300 Attenuates α-Synuclein Aggregation. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (13)
                                     , 2273-2279. <a href="https://doi.org/10.1021/acschemneuro.1c00215" title="DOI URL">https://doi.org/10.1021/acschemneuro.1c00215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.1c00215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.1c00215%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DDomain-Independent%252BInhibition%252Bof%252BCBP%25252Fp300%252BAttenuates%252B%2525CE%2525B1-Synuclein%252BAggregation%26aulast%3DHlushchuk%26aufirst%3DIrena%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08042021%26date%3D07062021%26date%3D10062021%26volume%3D12%26issue%3D13%26spage%3D2273%26epage%3D2279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alex Muthengi, Virangika K. Wimalasena, Hailemichael O. Yosief, Melissa J. Bikowitz, Logan H. Sigua, Tingjian Wang, Deyao Li, Zied Gaieb, Gagan Dhawan, Shuai Liu, Jon Erickson, Rommie E. Amaro, Ernst Schönbrunn, Jun Qi, <span class="NLM_string-name hlFld-ContribAuthor">Wei Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 5787-5801. <a href="https://doi.org/10.1021/acs.jmedchem.0c02232" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02232%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BDimethylisoxazole-Attached%252BImidazo%25255B1%25252C2-a%25255Dpyridines%252Bas%252BPotent%252Band%252BSelective%252BCBP%25252FP300%252BInhibitors%26aulast%3DMuthengi%26aufirst%3DAlex%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23122020%26date%3D19042021%26volume%3D64%26issue%3D9%26spage%3D5787%26epage%3D5801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paul N. Mortenson, Daniel A. Erlanson, Iwan J. P. de Esch, Wolfgang Jahnke, <span class="NLM_string-name hlFld-ContribAuthor">Christopher N. Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-to-Lead Medicinal Chemistry Publications in 2017. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 3857-3872. <a href="https://doi.org/10.1021/acs.jmedchem.8b01472" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01472%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment-to-Lead%252BMedicinal%252BChemistry%252BPublications%252Bin%252B2017%26aulast%3DMortenson%26aufirst%3DPaul%2BN.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D21092018%26date%3D21112018%26volume%3D62%26issue%3D8%26spage%3D3857%26epage%3D3872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jian Zhu, Jing Dong, Laurent Batiste, Andrea Unzue, Aymeric Dolbois, Vlad Pascanu, Paweł Śledź, Cristina Nevado, <span class="NLM_string-name hlFld-ContribAuthor">Amedeo Caflisch</span>. </span><span class="cited-content_cbyCitation_article-title">Binding Motifs in the CBP Bromodomain: An Analysis of 20 Crystal Structures of Complexes with Small Molecules. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (9)
                                     , 929-934. <a href="https://doi.org/10.1021/acsmedchemlett.8b00286" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00286</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00286%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBinding%252BMotifs%252Bin%252Bthe%252BCBP%252BBromodomain%25253A%252BAn%252BAnalysis%252Bof%252B20%252BCrystal%252BStructures%252Bof%252BComplexes%252Bwith%252BSmall%252BMolecules%26aulast%3DZhu%26aufirst%3DJian%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D22062018%26date%3D08082018%26date%3D13082018%26date%3D08082018%26volume%3D9%26issue%3D9%26spage%3D929%26epage%3D934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurent  Batiste</span>, <span class="hlFld-ContribAuthor ">Andrea  Unzue</span>, <span class="hlFld-ContribAuthor ">Aymeric  Dolbois</span>, <span class="hlFld-ContribAuthor ">Fabrice  Hassler</span>, <span class="hlFld-ContribAuthor ">Xuan  Wang</span>, <span class="hlFld-ContribAuthor ">Nicholas  Deerain</span>, <span class="hlFld-ContribAuthor ">Jian  Zhu</span>, <span class="hlFld-ContribAuthor ">Dimitrios  Spiliotopoulos</span>, <span class="hlFld-ContribAuthor ">Cristina  Nevado</span>, and <span class="hlFld-ContribAuthor ">Amedeo  Caflisch</span>  . </span><span class="cited-content_cbyCitation_article-title">Chemical Space Expansion of Bromodomain Ligands Guided by in Silico Virtual Couplings (AutoCouple). </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2018,</strong> <em>4 </em>
                                    (2)
                                     , 180-188. <a href="https://doi.org/10.1021/acscentsci.7b00401" title="DOI URL">https://doi.org/10.1021/acscentsci.7b00401</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.7b00401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.7b00401%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DChemical%252BSpace%252BExpansion%252Bof%252BBromodomain%252BLigands%252BGuided%252Bby%252Bin%252BSilico%252BVirtual%252BCouplings%252B%252528AutoCouple%252529%26aulast%3DBatiste%26aufirst%3DLaurent%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D29082017%26date%3D07022018%26date%3D28022018%26volume%3D4%26issue%3D2%26spage%3D180%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah M.  Bronner</span>, <span class="hlFld-ContribAuthor ">Jeremy  Murray</span>, <span class="hlFld-ContribAuthor ">F. Anthony  Romero</span>, <span class="hlFld-ContribAuthor ">Kwong Wah  Lai</span>, <span class="hlFld-ContribAuthor ">Vickie  Tsui</span>, <span class="hlFld-ContribAuthor ">Patrick  Cyr</span>, <span class="hlFld-ContribAuthor ">Maureen H.  Beresini</span>, <span class="hlFld-ContribAuthor ">Gladys  de leon Boenig</span>, <span class="hlFld-ContribAuthor ">Zhongguo  Chen</span>, <span class="hlFld-ContribAuthor ">Edna F.  Choo</span>, <span class="hlFld-ContribAuthor ">Kevin R.  Clark</span>, <span class="hlFld-ContribAuthor ">Terry D.  Crawford</span>, <span class="hlFld-ContribAuthor ">Hariharan  Jayaram</span>, <span class="hlFld-ContribAuthor ">Susan  Kaufman</span>, <span class="hlFld-ContribAuthor ">Ruina  Li</span>, <span class="hlFld-ContribAuthor ">Yingjie  Li</span>, <span class="hlFld-ContribAuthor ">Jiangpeng  Liao</span>, <span class="hlFld-ContribAuthor ">Xiaorong  Liang</span>, <span class="hlFld-ContribAuthor ">Wenfeng  Liu</span>, <span class="hlFld-ContribAuthor ">Justin  Ly</span>, <span class="hlFld-ContribAuthor ">Jonathan  Maher</span>, <span class="hlFld-ContribAuthor ">John  Wai</span>, <span class="hlFld-ContribAuthor ">Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Aijun  Zheng</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Zhu</span>, and <span class="hlFld-ContribAuthor ">Steven  Magnuson</span>  . </span><span class="cited-content_cbyCitation_article-title">A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (24)
                                     , 10151-10171. <a href="https://doi.org/10.1021/acs.jmedchem.7b01372" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01372%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BUnique%252BApproach%252Bto%252BDesign%252BPotent%252Band%252BSelective%252BCyclic%252BAdenosine%252BMonophosphate%252BResponse%252BElement%252BBinding%252BProtein%25252C%252BBinding%252BProtein%252B%252528CBP%252529%252BInhibitors%26aulast%3DBronner%26aufirst%3DSarah%2BM.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D23092017%26date%3D11122017%26date%3D28122017%26date%3D20112017%26volume%3D60%26issue%3D24%26spage%3D10151%26epage%3D10171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron  Waddell</span>, <span class="hlFld-ContribAuthor ">Iqbal  Mahmud</span>, <span class="hlFld-ContribAuthor ">Haocheng  Ding</span>, <span class="hlFld-ContribAuthor ">Zhiguang  Huo</span>, <span class="hlFld-ContribAuthor ">Daiqing  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (11)
                                     , 2799. <a href="https://doi.org/10.3390/cancers13112799" title="DOI URL">https://doi.org/10.3390/cancers13112799</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13112799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13112799%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DPharmacological%252BInhibition%252Bof%252BCBP%25252Fp300%252BBlocks%252BEstrogen%252BReceptor%252BAlpha%252B%252528ER%2525CE%2525B1%252529%252BFunction%252Bthrough%252BSuppressing%252BEnhancer%252BH3K27%252BAcetylation%252Bin%252BLuminal%252BBreast%252BCancer%26aulast%3DWaddell%26aufirst%3DAaron%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D11%26spage%3D2799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron R.  Waddell</span>, <span class="hlFld-ContribAuthor ">Haojie  Huang</span>, <span class="hlFld-ContribAuthor ">Daiqing  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (12)
                                     , 2872. <a href="https://doi.org/10.3390/cancers13122872" title="DOI URL">https://doi.org/10.3390/cancers13122872</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13122872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13122872%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DCBP%25252Fp300%25253A%252BCritical%252BCo-Activators%252Bfor%252BNuclear%252BSteroid%252BHormone%252BReceptors%252Band%252BEmerging%252BTherapeutic%252BTargets%252Bin%252BProstate%252Band%252BBreast%252BCancers%26aulast%3DWaddell%26aufirst%3DAaron%2BR.%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D12%26spage%3D2872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin G.  Jaeger</span>, <span class="hlFld-ContribAuthor ">Georg E.  Winter</span>. </span><span class="cited-content_cbyCitation_article-title">Fast-acting chemical tools to delineate causality in transcriptional control. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cell</span><span> <strong>2021,</strong> <em>81 </em>
                                    (8)
                                     , 1617-1630. <a href="https://doi.org/10.1016/j.molcel.2021.02.015" title="DOI URL">https://doi.org/10.1016/j.molcel.2021.02.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molcel.2021.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molcel.2021.02.015%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cell%26atitle%3DFast-acting%252Bchemical%252Btools%252Bto%252Bdelineate%252Bcausality%252Bin%252Btranscriptional%252Bcontrol%26aulast%3DJaeger%26aufirst%3DMartin%2BG.%26date%3D2021%26volume%3D81%26issue%3D8%26spage%3D1617%26epage%3D1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raghu  Vannam</span>, <span class="hlFld-ContribAuthor ">Jan  Sayilgan</span>, <span class="hlFld-ContribAuthor ">Samuel  Ojeda</span>, <span class="hlFld-ContribAuthor ">Barbara  Karakyriakou</span>, <span class="hlFld-ContribAuthor ">Eileen  Hu</span>, <span class="hlFld-ContribAuthor ">Johannes  Kreuzer</span>, <span class="hlFld-ContribAuthor ">Robert  Morris</span>, <span class="hlFld-ContribAuthor ">Xcanda Ixchel  Herrera Lopez</span>, <span class="hlFld-ContribAuthor ">Sumit  Rai</span>, <span class="hlFld-ContribAuthor ">Wilhelm  Haas</span>, <span class="hlFld-ContribAuthor ">Michael  Lawrence</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Ott</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>28 </em>
                                    (4)
                                     , 503-514.e12. <a href="https://doi.org/10.1016/j.chembiol.2020.12.004" title="DOI URL">https://doi.org/10.1016/j.chembiol.2020.12.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2020.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2020.12.004%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DTargeted%252Bdegradation%252Bof%252Bthe%252Benhancer%252Blysine%252Bacetyltransferases%252BCBP%252Band%252Bp300%26aulast%3DVannam%26aufirst%3DRaghu%26date%3D2021%26volume%3D28%26issue%3D4%26spage%3D503%26epage%3D514.e12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.L.  Wu</span>, <span class="hlFld-ContribAuthor ">J.  Zhao</span>, <span class="hlFld-ContribAuthor ">H.B.  Sun</span>, <span class="hlFld-ContribAuthor ">H.Y.  Li</span>, <span class="hlFld-ContribAuthor ">Y.Y.  Yin</span>, <span class="hlFld-ContribAuthor ">L.L.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into interaction mechanism of inhibitors E3T, E3H and E3B with CREB binding protein by using molecular dynamics simulations and MM-GBSA calculations. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2021,</strong> <em>32 </em>
                                    (3)
                                     , 221-246. <a href="https://doi.org/10.1080/1062936X.2021.1887351" title="DOI URL">https://doi.org/10.1080/1062936X.2021.1887351</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2021.1887351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2021.1887351%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DInsights%252Binto%252Binteraction%252Bmechanism%252Bof%252Binhibitors%252BE3T%25252C%252BE3H%252Band%252BE3B%252Bwith%252BCREB%252Bbinding%252Bprotein%252Bby%252Busing%252Bmolecular%252Bdynamics%252Bsimulations%252Band%252BMM-GBSA%252Bcalculations%26aulast%3DWu%26aufirst%3DS.L.%26date%3D2021%26date%3D2021%26volume%3D32%26issue%3D3%26spage%3D221%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kyle P.  Eagen</span>, <span class="hlFld-ContribAuthor ">Christopher A.  French</span>. </span><span class="cited-content_cbyCitation_article-title">Supercharging BRD4 with NUT in carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2021,</strong> <em>40 </em>
                                    (8)
                                     , 1396-1408. <a href="https://doi.org/10.1038/s41388-020-01625-0" title="DOI URL">https://doi.org/10.1038/s41388-020-01625-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-020-01625-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-020-01625-0%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DSupercharging%252BBRD4%252Bwith%252BNUT%252Bin%252Bcarcinoma%26aulast%3DEagen%26aufirst%3DKyle%2BP.%26date%3D2021%26date%3D2021%26volume%3D40%26issue%3D8%26spage%3D1396%26epage%3D1408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhang-Xu  He</span>, <span class="hlFld-ContribAuthor ">Bing-Fei  Wei</span>, <span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yun-Peng  Gong</span>, <span class="hlFld-ContribAuthor ">Li-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Current development of CBP/p300 inhibitors in the last decade. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112861. <a href="https://doi.org/10.1016/j.ejmech.2020.112861" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112861</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112861%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Bdevelopment%252Bof%252BCBP%25252Fp300%252Binhibitors%252Bin%252Bthe%252Blast%252Bdecade%26aulast%3DHe%26aufirst%3DZhang-Xu%26date%3D2021%26volume%3D209%26spage%3D112861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eleni  Pitsillou</span>, <span class="hlFld-ContribAuthor ">Julia  Liang</span>, <span class="hlFld-ContribAuthor ">Andrew  Hung</span>, <span class="hlFld-ContribAuthor ">Tom C.  Karagiannis</span>. </span><span class="cited-content_cbyCitation_article-title">The circadian machinery links metabolic disorders and depression: A review of pathways, proteins and potential pharmacological interventions. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2021,</strong> <em>265 </em>, 118809. <a href="https://doi.org/10.1016/j.lfs.2020.118809" title="DOI URL">https://doi.org/10.1016/j.lfs.2020.118809</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2020.118809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2020.118809%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DThe%252Bcircadian%252Bmachinery%252Blinks%252Bmetabolic%252Bdisorders%252Band%252Bdepression%25253A%252BA%252Breview%252Bof%252Bpathways%25252C%252Bproteins%252Band%252Bpotential%252Bpharmacological%252Binterventions%26aulast%3DPitsillou%26aufirst%3DEleni%26date%3D2021%26volume%3D265%26spage%3D118809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sweta  Sikder</span>, <span class="hlFld-ContribAuthor ">Stephanie  Kaypee</span>, <span class="hlFld-ContribAuthor ">Tapas K  Kundu</span>. </span><span class="cited-content_cbyCitation_article-title">Regulation of epigenetic state by non-histone chromatin proteins and transcription factors: Implications in disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biosciences</span><span> <strong>2020,</strong> <em>45 </em>
                                    (1)
                                     <a href="https://doi.org/10.1007/s12038-019-9974-3" title="DOI URL">https://doi.org/10.1007/s12038-019-9974-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12038-019-9974-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12038-019-9974-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biosciences%26atitle%3DRegulation%252Bof%252Bepigenetic%252Bstate%252Bby%252Bnon-histone%252Bchromatin%252Bproteins%252Band%252Btranscription%252Bfactors%25253A%252BImplications%252Bin%252Bdisease%26aulast%3DSikder%26aufirst%3DSweta%26date%3D2020%26date%3D2020%26volume%3D45%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Wnt/β-catenin signaling pathway in cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-020-00990-3" title="DOI URL">https://doi.org/10.1186/s13045-020-00990-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-020-00990-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-020-00990-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DTargeting%252Bthe%252BWnt%25252F%2525CE%2525B2-catenin%252Bsignaling%252Bpathway%252Bin%252Bcancer%26aulast%3DZhang%26aufirst%3DYa%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Xiong</span>, <span class="hlFld-ContribAuthor ">Mingming  Zhang</span>, <span class="hlFld-ContribAuthor ">Yingxia  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (33)
                                     , 5583-5598. <a href="https://doi.org/10.2174/0929867326666190731141055" title="DOI URL">https://doi.org/10.2174/0929867326666190731141055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867326666190731141055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867326666190731141055%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BCBP%25252Fp300%252BBromodomain%252BInhibitors%26aulast%3DXiong%26aufirst%3DYing%26date%3D2020%26volume%3D27%26issue%3D33%26spage%3D5583%26epage%3D5598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Lin</span>, <span class="hlFld-ContribAuthor ">Juan I.  Luengo</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting binding-site arginines in drug design: Recent examples. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (19)
                                     , 127442. <a href="https://doi.org/10.1016/j.bmcl.2020.127442" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127442</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127442%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DExploiting%252Bbinding-site%252Barginines%252Bin%252Bdrug%252Bdesign%25253A%252BRecent%252Bexamples%26aulast%3DLin%26aufirst%3DHong%26date%3D2020%26volume%3D30%26issue%3D19%26spage%3D127442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoyang  Bi</span>, <span class="hlFld-ContribAuthor ">Fengcai  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhongya  Sun</span>, <span class="hlFld-ContribAuthor ">Pan  Xu</span>, <span class="hlFld-ContribAuthor ">Hao  Jiang</span>, <span class="hlFld-ContribAuthor ">Wenchao  Lu</span>, <span class="hlFld-ContribAuthor ">Tian  Lu</span>, <span class="hlFld-ContribAuthor ">Hong  Ding</span>, <span class="hlFld-ContribAuthor ">Naixia  Zhang</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Kaixian  Chen</span>, <span class="hlFld-ContribAuthor ">Bing  Zhou</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 103991. <a href="https://doi.org/10.1016/j.bioorg.2020.103991" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103991</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103991%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Btetrahydroquinolin%252Bderivatives%252Bas%252Bpotent%252Binhibitors%252Bof%252BCBP%252Bbromodomain%26aulast%3DChen%26aufirst%3DYu%26date%3D2020%26volume%3D101%26spage%3D103991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandra  Cipriano</span>, <span class="hlFld-ContribAuthor ">Gianluca  Sbardella</span>, <span class="hlFld-ContribAuthor ">Alessio  Ciulli</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting epigenetic reader domains by chemical biology. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 82-94. <a href="https://doi.org/10.1016/j.cbpa.2020.05.006" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.006%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTargeting%252Bepigenetic%252Breader%252Bdomains%252Bby%252Bchemical%252Bbiology%26aulast%3DCipriano%26aufirst%3DAlessandra%26date%3D2020%26volume%3D57%26spage%3D82%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhipeng A.  Wang</span>, <span class="hlFld-ContribAuthor ">Philip A.  Cole</span>. </span><span class="cited-content_cbyCitation_article-title">The Chemical Biology of Reversible Lysine Post-translational Modifications. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2020,</strong> <em>27 </em>
                                    (8)
                                     , 953-969. <a href="https://doi.org/10.1016/j.chembiol.2020.07.002" title="DOI URL">https://doi.org/10.1016/j.chembiol.2020.07.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2020.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2020.07.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DThe%252BChemical%252BBiology%252Bof%252BReversible%252BLysine%252BPost-translational%252BModifications%26aulast%3DWang%26aufirst%3DZhipeng%2BA.%26date%3D2020%26volume%3D27%26issue%3D8%26spage%3D953%26epage%3D969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chevaun D.  Morrison-Smith</span>, <span class="hlFld-ContribAuthor ">Tatiana M.  Knox</span>, <span class="hlFld-ContribAuthor ">Ivona  Filic</span>, <span class="hlFld-ContribAuthor ">Kara M.  Soroko</span>, <span class="hlFld-ContribAuthor ">Benjamin K.  Eschle</span>, <span class="hlFld-ContribAuthor ">Margaret K.  Wilkens</span>, <span class="hlFld-ContribAuthor ">Prafulla C.  Gokhale</span>, <span class="hlFld-ContribAuthor ">Francis  Giles</span>, <span class="hlFld-ContribAuthor ">Andrew  Griffin</span>, <span class="hlFld-ContribAuthor ">Bill  Brown</span>, <span class="hlFld-ContribAuthor ">Geoffrey I.  Shapiro</span>, <span class="hlFld-ContribAuthor ">Beth E.  Zucconi</span>, <span class="hlFld-ContribAuthor ">Philip A.  Cole</span>, <span class="hlFld-ContribAuthor ">Madeleine E.  Lemieux</span>, <span class="hlFld-ContribAuthor ">Christopher A.  French</span>. </span><span class="cited-content_cbyCitation_article-title">Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (7)
                                     , 1406-1414. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0087" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0087%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DCombined%252BTargeting%252Bof%252Bthe%252BBRD4%2525E2%252580%252593NUT%2525E2%252580%252593p300%252BAxis%252Bin%252BNUT%252BMidline%252BCarcinoma%252Bby%252BDual%252BSelective%252BBromodomain%252BInhibitor%25252C%252BNEO2734%26aulast%3DMorrison-Smith%26aufirst%3DChevaun%2BD.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D7%26spage%3D1406%26epage%3D1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Katavolos</span>, <span class="hlFld-ContribAuthor ">Gary  Cain</span>, <span class="hlFld-ContribAuthor ">Cindy  Farman</span>, <span class="hlFld-ContribAuthor ">F. Anthony  Romero</span>, <span class="hlFld-ContribAuthor ">Steven  Magnuson</span>, <span class="hlFld-ContribAuthor ">Justin Q.  Ly</span>, <span class="hlFld-ContribAuthor ">Edna F.  Choo</span>, <span class="hlFld-ContribAuthor ">Anand Kumar  Katakam</span>, <span class="hlFld-ContribAuthor ">Roxanne  Andaya</span>, <span class="hlFld-ContribAuthor ">Jonathan  Maher</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs. </span><span class="cited-content_cbyCitation_journal-name">Toxicologic Pathology</span><span> <strong>2020,</strong> <em>48 </em>
                                    (3)
                                     , 465-480. <a href="https://doi.org/10.1177/0192623319898469" title="DOI URL">https://doi.org/10.1177/0192623319898469</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/0192623319898469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F0192623319898469%26sid%3Dliteratum%253Aachs%26jtitle%3DToxicologic%2520Pathology%26atitle%3DPreclinical%252BSafety%252BAssessment%252Bof%252Ba%252BHighly%252BSelective%252Band%252BPotent%252BDual%252BSmall-Molecule%252BInhibitor%252Bof%252BCBP%25252FP300%252Bin%252BRats%252Band%252BDogs%26aulast%3DKatavolos%26aufirst%3DPaula%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D3%26spage%3D465%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Birgitta  Lindqvist</span>, <span class="hlFld-ContribAuthor ">Sara  Svensson Akusjärvi</span>, <span class="hlFld-ContribAuthor ">Anders  Sönnerborg</span>, <span class="hlFld-ContribAuthor ">Marios  Dimitriou</span>, <span class="hlFld-ContribAuthor ">J. Peter  Svensson</span>, . </span><span class="cited-content_cbyCitation_article-title">Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. </span><span class="cited-content_cbyCitation_journal-name">PLOS Pathogens</span><span> <strong>2020,</strong> <em>16 </em>
                                    (1)
                                     , e1008264. <a href="https://doi.org/10.1371/journal.ppat.1008264" title="DOI URL">https://doi.org/10.1371/journal.ppat.1008264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.ppat.1008264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.ppat.1008264%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520Pathogens%26atitle%3DChromatin%252Bmaturation%252Bof%252Bthe%252BHIV-1%252Bprovirus%252Bin%252Bprimary%252Bresting%252BCD4%25252B%2525C2%2525A0T%252Bcells%26aulast%3DLindqvist%26aufirst%3DBirgitta%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D1%26spage%3De1008264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dahong  Yao</span>, <span class="hlFld-ContribAuthor ">Jin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinhui  Wang</span>, <span class="hlFld-ContribAuthor ">Dabo  Pan</span>, <span class="hlFld-ContribAuthor ">Zhendan  He</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 713-725. <a href="https://doi.org/10.1080/14756366.2020.1740924" title="DOI URL">https://doi.org/10.1080/14756366.2020.1740924</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1740924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1740924%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252BATAD2%252Bbromodomain%252Binhibitors%252Bthat%252Btrigger%252Bapoptosis%252Band%252Bautophagy%252Bin%252Bbreast%252Bcells%252Bby%252Bstructure-based%252Bvirtual%252Bscreening%26aulast%3DYao%26aufirst%3DDahong%26date%3D2020%26date%3D2020%26volume%3D35%26issue%3D1%26spage%3D713%26epage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qin  Wu</span>, <span class="hlFld-ContribAuthor ">David  Heidenreich</span>, <span class="hlFld-ContribAuthor ">Stanley  Zhou</span>, <span class="hlFld-ContribAuthor ">Suzanne  Ackloo</span>, <span class="hlFld-ContribAuthor ">Andreas  Krämer</span>, <span class="hlFld-ContribAuthor ">Kiran  Nakka</span>, <span class="hlFld-ContribAuthor ">Evelyne  Lima-Fernandes</span>, <span class="hlFld-ContribAuthor ">Genevieve  Deblois</span>, <span class="hlFld-ContribAuthor ">Shili  Duan</span>, <span class="hlFld-ContribAuthor ">Ravi N.  Vellanki</span>, <span class="hlFld-ContribAuthor ">Fengling  Li</span>, <span class="hlFld-ContribAuthor ">Masoud  Vedadi</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Dilworth</span>, <span class="hlFld-ContribAuthor ">Mathieu  Lupien</span>, <span class="hlFld-ContribAuthor ">Paul E.  Brennan</span>, <span class="hlFld-ContribAuthor ">Cheryl H.  Arrowsmith</span>, <span class="hlFld-ContribAuthor ">Susanne  Müller</span>, <span class="hlFld-ContribAuthor ">Oleg  Fedorov</span>, <span class="hlFld-ContribAuthor ">Panagis  Filippakopoulos</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>. </span><span class="cited-content_cbyCitation_article-title">A chemical toolbox for the study of bromodomains and epigenetic signaling. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-019-09672-2" title="DOI URL">https://doi.org/10.1038/s41467-019-09672-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-019-09672-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-019-09672-2%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DA%252Bchemical%252Btoolbox%252Bfor%252Bthe%252Bstudy%252Bof%252Bbromodomains%252Band%252Bepigenetic%252Bsignaling%26aulast%3DWu%26aufirst%3DQin%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea G.  Cochran</span>, <span class="hlFld-ContribAuthor ">Andrew R.  Conery</span>, <span class="hlFld-ContribAuthor ">Robert J.  Sims</span>. </span><span class="cited-content_cbyCitation_article-title">Bromodomains: a new target class for drug development. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2019,</strong> <em>18 </em>
                                    (8)
                                     , 609-628. <a href="https://doi.org/10.1038/s41573-019-0030-7" title="DOI URL">https://doi.org/10.1038/s41573-019-0030-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-019-0030-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-019-0030-7%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DBromodomains%25253A%252Ba%252Bnew%252Btarget%252Bclass%252Bfor%2525C2%2525A0drug%252Bdevelopment%26aulast%3DCochran%26aufirst%3DAndrea%2BG.%26date%3D2019%26date%3D2019%26volume%3D18%26issue%3D8%26spage%3D609%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph  Castillo</span>, <span class="hlFld-ContribAuthor ">Esther  Wu</span>, <span class="hlFld-ContribAuthor ">Christopher  Lowe</span>, <span class="hlFld-ContribAuthor ">Shrividhya  Srinivasan</span>, <span class="hlFld-ContribAuthor ">Ron  McCord</span>, <span class="hlFld-ContribAuthor ">Marie-Claire  Wagle</span>, <span class="hlFld-ContribAuthor ">Sangeeta  Jayakar</span>, <span class="hlFld-ContribAuthor ">Melissa Gonzalez  Edick</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Eastham-Anderson</span>, <span class="hlFld-ContribAuthor ">Bonnie  Liu</span>, <span class="hlFld-ContribAuthor ">Katherine E.  Hutchinson</span>, <span class="hlFld-ContribAuthor ">Wendell  Jones</span>, <span class="hlFld-ContribAuthor ">Matthew P.  Stokes</span>, <span class="hlFld-ContribAuthor ">Somayeh S.  Tarighat</span>, <span class="hlFld-ContribAuthor ">Thomas  Holcomb</span>, <span class="hlFld-ContribAuthor ">Andrew  Glibicky</span>, <span class="hlFld-ContribAuthor ">F. Anthony  Romero</span>, <span class="hlFld-ContribAuthor ">Steven  Magnuson</span>, <span class="hlFld-ContribAuthor ">Shih-Min A.  Huang</span>, <span class="hlFld-ContribAuthor ">Vicki  Plaks</span>, <span class="hlFld-ContribAuthor ">Jennifer M.  Giltnane</span>, <span class="hlFld-ContribAuthor ">Mark R.  Lackner</span>, <span class="hlFld-ContribAuthor ">Zineb  Mounir</span>. </span><span class="cited-content_cbyCitation_article-title">CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2019,</strong> <em>79 </em>
                                    (15)
                                     , 3916-3927. <a href="https://doi.org/10.1158/0008-5472.CAN-18-3622" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-18-3622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-18-3622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-18-3622%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DCBP%25252Fp300%252BDrives%252Bthe%252BDifferentiation%252Bof%252BRegulatory%252BT%252BCells%252Bthrough%252BTranscriptional%252Band%252BNon-Transcriptional%252BMechanisms%26aulast%3DCastillo%26aufirst%3DJoseph%26date%3D2019%26date%3D2019%26volume%3D79%26issue%3D15%26spage%3D3916%26epage%3D3927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy R.  Bishop</span>, <span class="hlFld-ContribAuthor ">Yuxiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Michael A.  Erb</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Modulation of Transcriptional Coregulators in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2019,</strong> <em>40 </em>
                                    (6)
                                     , 388-402. <a href="https://doi.org/10.1016/j.tips.2019.04.004" title="DOI URL">https://doi.org/10.1016/j.tips.2019.04.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2019.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2019.04.004%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DPharmacological%252BModulation%252Bof%252BTranscriptional%252BCoregulators%252Bin%252BCancer%26aulast%3DBishop%26aufirst%3DTimothy%2BR.%26date%3D2019%26volume%3D40%26issue%3D6%26spage%3D388%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Denise E.  de Almeida Nagata</span>, <span class="hlFld-ContribAuthor ">Eugene Y.  Chiang</span>, <span class="hlFld-ContribAuthor ">Suchit  Jhunjhunwala</span>, <span class="hlFld-ContribAuthor ">Patrick  Caplazi</span>, <span class="hlFld-ContribAuthor ">Vidhyalakshmi  Arumugam</span>, <span class="hlFld-ContribAuthor ">Zora  Modrusan</span>, <span class="hlFld-ContribAuthor ">Emily  Chan</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">Lingyan  Jin</span>, <span class="hlFld-ContribAuthor ">David  Arnott</span>, <span class="hlFld-ContribAuthor ">F. Anthony  Romero</span>, <span class="hlFld-ContribAuthor ">Steven  Magnuson</span>, <span class="hlFld-ContribAuthor ">Karen E.  Gascoigne</span>, <span class="hlFld-ContribAuthor ">Jane L.  Grogan</span>. </span><span class="cited-content_cbyCitation_article-title">Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. </span><span class="cited-content_cbyCitation_journal-name">Cell Reports</span><span> <strong>2019,</strong> <em>27 </em>
                                    (1)
                                     , 269-281.e4. <a href="https://doi.org/10.1016/j.celrep.2019.03.008" title="DOI URL">https://doi.org/10.1016/j.celrep.2019.03.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.celrep.2019.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.celrep.2019.03.008%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Reports%26atitle%3DRegulation%252Bof%252BTumor-Associated%252BMyeloid%252BCell%252BActivity%252Bby%252BCBP%25252FEP300%252BBromodomain%252BModulation%252Bof%252BH3K27%252BAcetylation%26aulast%3Dde%2BAlmeida%2BNagata%26aufirst%3DDenise%2BE.%26date%3D2019%26volume%3D27%26issue%3D1%26spage%3D269%26epage%3D281.e4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael A.  Clegg</span>, <span class="hlFld-ContribAuthor ">Nicholas C. O.  Tomkinson</span>, <span class="hlFld-ContribAuthor ">Rab K.  Prinjha</span>, <span class="hlFld-ContribAuthor ">Philip G.  Humphreys</span>. </span><span class="cited-content_cbyCitation_article-title">Advancements in the Development of non‐BET Bromodomain Chemical Probes. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (4)
                                     , 362-385. <a href="https://doi.org/10.1002/cmdc.201800738" title="DOI URL">https://doi.org/10.1002/cmdc.201800738</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800738%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DAdvancements%252Bin%252Bthe%252BDevelopment%252Bof%252Bnon%2525E2%252580%252590BET%252BBromodomain%252BChemical%252BProbes%26aulast%3DClegg%26aufirst%3DMichael%2BA.%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D4%26spage%3D362%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William G.  Kerr</span>, <span class="hlFld-ContribAuthor ">John D.  Chisholm</span>. </span><span class="cited-content_cbyCitation_article-title">The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Immunology</span><span> <strong>2019,</strong> <em>202 </em>
                                    (1)
                                     , 11-19. <a href="https://doi.org/10.4049/jimmunol.1800991" title="DOI URL">https://doi.org/10.4049/jimmunol.1800991</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4049/jimmunol.1800991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4049%2Fjimmunol.1800991%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Immunology%26atitle%3DThe%252BNext%252BGeneration%252Bof%252BImmunotherapy%252Bfor%252BCancer%25253A%252BSmall%252BMolecules%252BCould%252BMake%252BBig%252BWaves%26aulast%3DKerr%26aufirst%3DWilliam%2BG.%26date%3D2019%26date%3D2018%26volume%3D202%26issue%3D1%26spage%3D11%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meghan E  Breen</span>, <span class="hlFld-ContribAuthor ">Anna K  Mapp</span>. </span><span class="cited-content_cbyCitation_article-title">Modulating the masters: chemical tools to dissect CBP and p300 function. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2018,</strong> <em>45 </em>, 195-203. <a href="https://doi.org/10.1016/j.cbpa.2018.06.005" title="DOI URL">https://doi.org/10.1016/j.cbpa.2018.06.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2018.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2018.06.005%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DModulating%252Bthe%252Bmasters%25253A%252Bchemical%252Btools%252Bto%252Bdissect%252BCBP%252Band%252Bp300%252Bfunction%26aulast%3DBreen%26aufirst%3DMeghan%2BE%26date%3D2018%26volume%3D45%26spage%3D195%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Schiedel</span>, <span class="hlFld-ContribAuthor ">Stuart J  Conway</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules as tools to study the chemical epigenetics of lysine acetylation. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2018,</strong> <em>45 </em>, 166-178. <a href="https://doi.org/10.1016/j.cbpa.2018.06.015" title="DOI URL">https://doi.org/10.1016/j.cbpa.2018.06.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2018.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2018.06.015%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DSmall%252Bmolecules%252Bas%252Btools%252Bto%252Bstudy%252Bthe%252Bchemical%252Bepigenetics%252Bof%252Blysine%252Bacetylation%26aulast%3DSchiedel%26aufirst%3DMatthias%26date%3D2018%26volume%3D45%26spage%3D166%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan  Raisner</span>, <span class="hlFld-ContribAuthor ">Samir  Kharbanda</span>, <span class="hlFld-ContribAuthor ">Lingyan  Jin</span>, <span class="hlFld-ContribAuthor ">Edwin  Jeng</span>, <span class="hlFld-ContribAuthor ">Emily  Chan</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">Peter M.  Haverty</span>, <span class="hlFld-ContribAuthor ">Russell  Bainer</span>, <span class="hlFld-ContribAuthor ">Tommy  Cheung</span>, <span class="hlFld-ContribAuthor ">David  Arnott</span>, <span class="hlFld-ContribAuthor ">E. Megan  Flynn</span>, <span class="hlFld-ContribAuthor ">F. Anthony  Romero</span>, <span class="hlFld-ContribAuthor ">Steven  Magnuson</span>, <span class="hlFld-ContribAuthor ">Karen E.  Gascoigne</span>. </span><span class="cited-content_cbyCitation_article-title">Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. </span><span class="cited-content_cbyCitation_journal-name">Cell Reports</span><span> <strong>2018,</strong> <em>24 </em>
                                    (7)
                                     , 1722-1729. <a href="https://doi.org/10.1016/j.celrep.2018.07.041" title="DOI URL">https://doi.org/10.1016/j.celrep.2018.07.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.celrep.2018.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.celrep.2018.07.041%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Reports%26atitle%3DEnhancer%252BActivity%252BRequires%252BCBP%25252FP300%252BBromodomain-Dependent%252BHistone%252BH3K27%252BAcetylation%26aulast%3DRaisner%26aufirst%3DRyan%26date%3D2018%26volume%3D24%26issue%3D7%26spage%3D1722%26epage%3D1729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qianqian  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoli  An</span>, <span class="hlFld-ContribAuthor ">Jiahui  Xu</span>, <span class="hlFld-ContribAuthor ">Yuwei  Wang</span>, <span class="hlFld-ContribAuthor ">Liang  Liu</span>, <span class="hlFld-ContribAuthor ">Elaine Lai-Han  Leung</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Classical molecular dynamics and metadynamics simulations decipher the mechanism of CBP30 selectively inhibiting CBP/p300 bromodomains. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (35)
                                     , 6521-6530. <a href="https://doi.org/10.1039/C8OB01526K" title="DOI URL">https://doi.org/10.1039/C8OB01526K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB01526K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB01526K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DClassical%252Bmolecular%252Bdynamics%252Band%252Bmetadynamics%252Bsimulations%252Bdecipher%252Bthe%252Bmechanism%252Bof%252BCBP30%252Bselectively%252Binhibiting%252BCBP%25252Fp300%252Bbromodomains%26aulast%3DWang%26aufirst%3DQianqian%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D35%26spage%3D6521%26epage%3D6530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. In vivo chemical tool <b>1</b> and potency data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. . (A) A co-crystal structure of <b>1</b> (green) in the CBP bromodomain (yellow, 1.23 Å resolution, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KTX">5KTX</a>) highlighting hydrogen bond interactions between the ligand and receptor. Water molecules are shown as small red spheres. (B) A co-crystal structure of <b>1</b> (green) and BRD4(1) (cyan, 1.14 Å resolution, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KU3">5KU3</a>), highlighting hydrogen bond interactions between the ligand and receptor. Water molecules are shown as small red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. A co-crystal structure of <b>3</b> in the CBP (cyan) bromodomain (yellow, 1.6 Å resolution, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0F">5W0F</a>) displaying important contacts between the ligand and receptor. Water molecules are shown as small red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Co-crystal structure of <b>8</b> (orange) in the CBP bromodomain (yellow, 1.43 Å resolution, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0I">5W0I</a>) displaying important contacts between the ligand and receptor. Water molecules are shown as small red spheres. (B) The solvent accessible surface of the CBP bromodomain colored to highlight hydrophobicity and charge where hydrocarbon groups are white, atoms with a partial negative charge are red, and atoms with partial positive charge are blue. Bound ligand <b>8</b> is shown in stick representation (orange). Water molecules are shown as small red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Co-crystal structure of <b>10</b> (purple) in the CBP bromodomain (yellow, 1.55 Å resolution, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0L">5W0L</a>) displaying important contacts between the ligand and receptor. Water molecules are shown as small red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Summary of potency, selectivity, and DMPK properties of <b>10</b>. <sup><i>a</i></sup>All IC<sub>50</sub> values are reported as the geometric mean from at least two determinations. <sup><i>b</i></sup>MDCK cell line: apical-to-basolateral; units = × 10<sup>–6</sup> cm s<sup>–1</sup>. <sup><i>c</i></sup>Mouse (M), rat (R), dog (D), cynomolgus monkey (C), and human (H) plasma protein binding. <sup><i>d</i></sup>Liver microsome-predicted hepatic clearance (mL/min/kg). <sup><i>e</i></sup>Hepatocyte-predicted hepatic clearance (mL/min/kg). <sup><i>f</i></sup>Compound was dosed iv (1 mg/kg) as PEG400/H<sub>2</sub>O (35/65) solution and po (5 mg/kg) as an aqueous suspension with 0.5% methylcellulose and 0.2% Tween 80. <sup><i>g</i></sup>Compound was dosed iv (1 mg/kg) as EtOH/PEG400/H<sub>2</sub>O (20/15/65) solution and po (5 mg/kg) as an aqueous suspension with 0.5% methylcellulose and 0.2% Tween 80.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) CBP-selective fragment screening hit <b>17</b>. (B) Co-crystal structure of <b>17</b> (aqua) and the CBP bromodomain (yellow, 1.7 Å resolution; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0Q">5W0Q</a>). Residues engaging in important contacts between the ligand and receptor are shown in stick representation. Water molecules are shown as small red spheres. (C) Compound <b>17</b> (aqua) overlaid with <b>10</b> (purple) in the CBP binding site (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Co-crystal structure of <b>19</b> (pink) and the CBP bromodomain (yellow, 1.41 Å resolution; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0E">5W0E</a>). Residues engaging in important contacts between the ligand and receptor are shown in stick representation. Water molecules are shown as small red spheres. (B) Co-crystal structure of <b>19</b> (pink) and the BRD4(1) bromodomain (cyan, 1.71 Å resolution; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VZS">5VZS</a>). Residues engaging in important contacts between the ligand and receptor are shown in stick representation. Water molecules are shown as small red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Summary of potency, selectivity, and DMPK properties of <b>19</b>. <sup><i>a</i></sup>All IC<sub>50</sub> values are reported as the geometric mean from at least two determinations. <sup><i>b</i></sup>MDCK cell line: apical-to-basolateral; units = × 10<sup>–6</sup> cm s<sup>–1</sup>. <sup><i>c</i></sup>Mouse (M), rat (R), dog (D), cynomolgus monkey (C), and human (H) plasma protein binding. <sup><i>d</i></sup>Liver microsome-predicted hepatic clearance (mL/min/kg). <sup><i>e</i></sup>Hepatic clearance (mL/min/kg). <sup><i>f</i></sup>Compound was dosed iv (1 mg/kg) as PEG400/H<sub>2</sub>O (35/65) solution and po (5 mg/kg) as an aqueous suspension with 0.5% methylcellulose and 0.2% Tween 80. <sup><i>g</i></sup>Compound was dosed iv (1 mg/kg) as EtOH/PEG400/H<sub>2</sub>O (20/15/65) solution and po (5 mg/kg) as an aqueous suspension with 0.5% methylcellulose and 0.2% Tween 80.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. In vivo evaluation of <b>19</b>. (A) Effect on <b>19</b> treatment on <i>MYC</i> transcript levels in MOLM-16 xenograft tumors with single doses of <b>19</b> (<i>n</i> = 3/group; mean ± SEM plotted). Plasma and tumor levels were adjusted for PPB and tissue binding, respectively, and mean plasma and tumor unbound drug levels (±SD) are displayed. (B) Antitumor efficacy of <b>19</b> at 3, 10, and 30 mg/kg in the MOLM-16 AML xenograft tumor model and effect on body weight (<i>n</i> = 10/group; tumor volume, mean ± SEM plotted; body weight, group fitted % body weight loss plotted).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compound <b>19</b> decreased the generation of iT<sub>regs</sub> in vitro without affecting cell viability. Human iT<sub>reg</sub> cells were differentiated in vitro from naïve CD4+T cells derived from peripheral blood mononuclear cells (PBMCs) of a healthy donor in the presence of <b>19</b> or DMSO as control. On day 4, cells were harvested. (A) <i>FOXP3</i> expression was assessed by q-RT-PCR and normalized with <i>B2M</i>. (B) Cell viability was assessed by flow cytometry using a fixable viability dye. (C) T<sub>reg</sub> cells were also fixed, permeabilized, and intracellular FOXP3 protein assessed in CD4<sup>+</sup>CD25<sup>+</sup> by flow cytometry. Graph shows % FOXP3+iTregs cells out of total CD4+T cells. Data are representative of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediates <b>27</b>–<b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) NaOH, acrylonitrile, MeOH, 70 °C, (ii) di-<i>tert</i>-butyl dicarbonate, 0 °C, 99%; (b) NaH, toluene, 100 °C, 100%; (c) hydrazine monohydrate, EtOH, 60 °C, 70%; (d) isopentyl nitrite, MeCN, CuBr<sub>2</sub>, 60 °C, 34%; (e) R-OMs, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 28–71%; (f) (i) TFA, DCM, rt, (ii) Ac<sub>2</sub>O, TEA, DMF, rt, 77–87%; (g) oxone, THF, H<sub>2</sub>O, rt, 98%.</p></p></figure><figure data-id="sch2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>2</b> and <b>3</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 120 °C, 47–86%; (b) <b>32</b>, RuPhos Pd G1, RuPhos, <i>t</i>-BuONa, dioxane, 120 °C, supercritical fluid chromatography (SFC) chiral resolution, 16%; (c) <b>33</b>, RuPhos Pd G1, RuPhos, <i>t</i>-BuONa, dioxane,120 °C, 34%</p></p></figure><figure data-id="sch3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>4</b> and <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>33</b>, RuPhos Pd G1, RuPhos, <i>t</i>-BuONa, dioxane, 120 °C, 26–39%; (b) NBS, DCM, 0 °C to rt 90–97%; (c) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 110 °C, 23–24%.</p></p></figure><figure data-id="sch4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>5</b>, <b>6</b>, <b>8</b>, and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NBS, DCM, 0 °C to rt, 36–60%; (b) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub> or Na<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 110 °C, 86–95%; (c) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, XPhos Pd G2, XPhos, Na<sub>2</sub>CO<sub>3</sub>, THF, H<sub>2</sub>O, 80 °C, 70%; (d) <b>33</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, <i>t</i>-BuONa, dioxane, toluene, 90 °C, 50%; (e) <b>32</b>, RuPhos Pd G1, RuPhos, <i>t</i>-BuONa, dioxane, 130 °C, SFC chiral resolution, 16%; (f) <b>33</b>, Pd-PEPPSI-IPent, <i>t</i>-BuONa, dioxane, 150 °C, 21%; (g) <b>6</b>, Ad<sub>2</sub>PBu, MeBF<sub>3</sub>K, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, toluene, H<sub>2</sub>O, 100 °C, 15%.</p></p></figure><figure data-id="sch5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>53</b>, XPhos Pd G3, K<sub>3</sub>PO<sub>4</sub>, <i>t</i>-amyl alcohol, 95 °C, 74%.</p></p></figure><figure data-id="sch6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>11</b>–<b>13</b> and <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, SEM-Cl, THF, 0 °C to rt, 83%; (b) <b>53</b>, RuPhos Pd G2, RuPhos, <i>t</i>-BuONa, dioxane, 120 °C, 20%; (c) TBAF, THF, 60 °C, 66%; (d) TFA, DCM, rt, 100%; (e) Ac<sub>2</sub>O, TEA, DMF, rt, 14%; (f), R<sub>2</sub>-Br or R<sub>2</sub>-OMs, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 5–17%; (g) <b>60</b>, TFA, DCM, 0 °C to rt, 49%; (h) aq CH<sub>2</sub>O, CH<sub>3</sub>CO<sub>2</sub>H, NaBH(OAc)<sub>3</sub>, DCE, rt, 23%.</p></p></figure><figure data-id="sch7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>14</b> and <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>53</b>, Pd-PEPPSi-IPent, <i>t</i>-BuONa, dioxane, 120 °C, 42–46%; (b) TFA, DCM, rt, 100%; (c) Ac<sub>2</sub>O, TEA, DCM, 0 °C to rt, 40–52%.</p></p></figure><figure data-id="sch8" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/medium/jm-2017-00796y_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>18</b>–<b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b00796/20171117/images/large/jm-2017-00796y_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00796&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>53</b>, RuPhos Pd G1, RuPhos, <i>t</i>-BuONa, dioxane, 120 °C, 73%; (b) TFA, DCM, rt; (c) TMSNCO, DCM, rt, 20%; (d) <i>N</i>-methyl-1<i>H</i>-imidazole-1-carboxamide, DCM, rt, 22%; (e) (i) 4-nitrophenyl chloroformate, pyridine, DMF, rt, (ii) EtNH<sub>2</sub>, THF, rt, 14%; (f) dimethylcarbamyl chloride, TEA, DMF, rt, 22%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88452" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88452" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 33 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Bannister, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouzarides, T.</span><span> </span><span class="NLM_article-title">The CBP Co-Activator Is a Histone Acetyltransferase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1038/384641a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2F384641a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=8967953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADyaK2sXlsVen" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=1996&pages=641-643&author=A.+J.+Bannisterauthor=T.+Kouzarides&title=The+CBP+Co-Activator+Is+a+Histone+Acetyltransferase&doi=10.1038%2F384641a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The CBP co-activator is a histone acetyltransferase</span></div><div class="casAuthors">Bannister, Andrew J.; Kouzarides, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">6610</span>),
    <span class="NLM_cas:pages">641-643</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The CBP protein acts as a transcriptional adaptor for many different transcription factors by directly contacting DNA-bound activators.  One mechanism by which CBP is thought to stimulate transcription is by recruiting the histone acetyltransferase (HAT) P/CAF to the promoter.  Here we show that CBP has intrinsic HAT activity.  The HAT domain of CBP is adjacent to the binding site for the transcriptional activator E1A.  Although E1A displaces P/CAF from CBP, is does not disrupt the CBP-assocd. HAT activity.  Thus E1A carries HAT activity when complexed with CBP.  Targeting CBP-assocd. HAT activity to specific promoters may therefore be a mechanism by which E1A acts as a transcriptional activator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiUdYJTsdfILVg90H21EOLACvtfcHk0lhzErb69Mj4KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlsVen&md5=8c6fd1c0c0679a454a6c10c704200e2f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F384641a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F384641a0%26sid%3Dliteratum%253Aachs%26aulast%3DBannister%26aufirst%3DA.%2BJ.%26aulast%3DKouzarides%26aufirst%3DT.%26atitle%3DThe%2520CBP%2520Co-Activator%2520Is%2520a%2520Histone%2520Acetyltransferase%26jtitle%3DNature%26date%3D1996%26volume%3D384%26spage%3D641%26epage%3D643%26doi%3D10.1038%2F384641a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Delvecchio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaucher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilar-Gurrieri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panne, D.</span><span> </span><span class="NLM_article-title">Structure of the P300 Catalytic Core and Implications for Chromatin Targeting and HAT Regulation</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1040</span><span class="NLM_x">–</span> <span class="NLM_lpage">1046</span><span class="refDoi"> DOI: 10.1038/nsmb.2642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fnsmb.2642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=23934153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1040-1046&author=M.+Delvecchioauthor=J.+Gaucherauthor=C.+Aguilar-Gurrieriauthor=E.+Ortegaauthor=D.+Panne&title=Structure+of+the+P300+Catalytic+Core+and+Implications+for+Chromatin+Targeting+and+HAT+Regulation&doi=10.1038%2Fnsmb.2642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation</span></div><div class="casAuthors">Delvecchio, Manuela; Gaucher, Jonathan; Aguilar-Gurrieri, Carmen; Ortega, Esther; Panne, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1040-1046</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CBP and p300 are histone acetyltransferases (HATs) that assoc. with and acetylate transcriptional regulators and chromatin.  Mutations in their catalytic 'cores' are linked to genetic disorders, including cancer.  Here we present the 2.8-Å crystal structure of the catalytic core of human p300 contg. its bromodomain, CH2 region and HAT domain.  The structure reveals that the CH2 region contains a discontinuous PHD domain interrupted by a RING domain.  The bromodomain, PHD, RING and HAT domains adopt an assembled configuration with the RING domain positioned over the HAT substrate-binding pocket.  Disease mutations that disrupt RING attachment led to upregulation of HAT activity, thus revealing an inhibitory role for this domain.  The structure provides a starting point for understanding how chromatin-substrate targeting and HAT regulation are coupled and why mutations in the p300 core lead to dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlYehjRwdhJ7Vg90H21EOLACvtfcHk0ljbMLWAAgT5Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3J&md5=e9352198d513eac6fd93fc2896828d09</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2642%26sid%3Dliteratum%253Aachs%26aulast%3DDelvecchio%26aufirst%3DM.%26aulast%3DGaucher%26aufirst%3DJ.%26aulast%3DAguilar-Gurrieri%26aufirst%3DC.%26aulast%3DOrtega%26aufirst%3DE.%26aulast%3DPanne%26aufirst%3DD.%26atitle%3DStructure%2520of%2520the%2520P300%2520Catalytic%2520Core%2520and%2520Implications%2520for%2520Chromatin%2520Targeting%2520and%2520HAT%2520Regulation%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1040%26epage%3D1046%26doi%3D10.1038%2Fnsmb.2642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Mujtaba, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachchidanand</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeleznik-Le, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.-M.</span><span> </span><span class="NLM_article-title">Structural Mechanism of the Bromodomain of the Coactivator CBP in P53 Transcriptional Activation. Mol</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1016/S1097-2765(03)00528-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1016%2FS1097-2765%2803%2900528-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=251-263&author=S.+Mujtabaauthor=Y.+Heauthor=L.+Zengauthor=S.+Yanauthor=O.+Plotnikovaauthor=+Sachchidanandauthor=R.+Sanchezauthor=N.+J.+Zeleznik-Leauthor=Z.+Ronaiauthor=M.-M.+Zhou&title=Structural+Mechanism+of+the+Bromodomain+of+the+Coactivator+CBP+in+P53+Transcriptional+Activation.+Mol&doi=10.1016%2FS1097-2765%2803%2900528-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900528-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900528-8%26sid%3Dliteratum%253Aachs%26aulast%3DMujtaba%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DSachchidanand%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DZeleznik-Le%26aufirst%3DN.%2BJ.%26aulast%3DRonai%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DM.-M.%26atitle%3DStructural%2520Mechanism%2520of%2520the%2520Bromodomain%2520of%2520the%2520Coactivator%2520CBP%2520in%2520P53%2520Transcriptional%2520Activation.%2520Mol%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D251%26epage%3D263%26doi%3D10.1016%2FS1097-2765%2803%2900528-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Iyer, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozdag, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas, C.</span><span> </span><span class="NLM_article-title">p300/CBP and Cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4225</span><span class="NLM_x">–</span> <span class="NLM_lpage">4231</span><span class="refDoi"> DOI: 10.1038/sj.onc.1207118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fsj.onc.1207118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=15156177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvVChtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=4225-4231&author=N.+G.+Iyerauthor=H.+Ozdagauthor=C.+Caldas&title=p300%2FCBP+and+Cancer&doi=10.1038%2Fsj.onc.1207118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">p300/CBP and cancer</span></div><div class="casAuthors">Iyer, Narayanan Gopalakrishna; Oezdag, Hilal; Caldas, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4225-4231</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  P300 and cAMP response element-binding protein (CBP) are adenoviral E1A-binding proteins involved in multiple cellular processes, and function as transcriptional co-factors and histone acetyltransferases.  Germline mutation of CBP results in Rubinstein-Taybi syndrome, which is characterized by an increased predisposition to childhood malignancies.  Furthermore, somatic mutations of p300 and CBP occur in a no. of malignancies.  Chromosome translocations target CBP and, less commonly, p300 in acute myeloid leukemia and treatment-related hematol. disorders.  P300 mutations in solid tumors result in truncated p300 protein products or amino-acid substitutions in crit. protein domains, and these are often assocd. with inactivation of the second allele.  A mouse model confirms that p300 and CBP function as suppressors of hematol. tumor formation.  The involvement of these proteins in crit. tumorigenic pathways (including TGF-β, p53 and Rb) provides a mechanistic route as to how their inactivation could result in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKGBLVLWLqkrVg90H21EOLACvtfcHk0ljbMLWAAgT5Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvVChtrc%253D&md5=b68fe6bc258b06515c04a5207410f026</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207118%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DN.%2BG.%26aulast%3DOzdag%26aufirst%3DH.%26aulast%3DCaldas%26aufirst%3DC.%26atitle%3Dp300%252FCBP%2520and%2520Cancer%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D4225%26epage%3D4231%26doi%3D10.1038%2Fsj.onc.1207118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Dutta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, K. M.</span><span> </span><span class="NLM_article-title">CBP/P300 Acetyltransferase Activity in Hematologic Malignancies</span> <span class="citation_source-journal">Mol. Genet. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1016/j.ymgme.2016.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1016%2Fj.ymgme.2016.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=27380996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFemsb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2016&pages=37-43&author=R.+Duttaauthor=B.+Tiuauthor=K.+M.+Sakamoto&title=CBP%2FP300+Acetyltransferase+Activity+in+Hematologic+Malignancies&doi=10.1016%2Fj.ymgme.2016.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CBP/p300 acetyltransferase activity in hematologic malignancies</span></div><div class="casAuthors">Dutta, Ritika; Tiu, Bruce; Sakamoto, Kathleen M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Genetics and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">37-43</span>CODEN:
                <span class="NLM_cas:coden">MGMEFF</span>;
        ISSN:<span class="NLM_cas:issn">1096-7192</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">CREB binding protein (CBP) and p300 are crit. regulators of hematopoiesis through both their transcriptional coactivator and acetyltransferase activities.  Loss or mutation of CBP/p300 results in hematol. deficiencies in proliferation and differentiation as well as disruption of hematopoietic stem cell renewal and the microenvironment.  Aberrant lysine acetylation mediated by CBP/p300 has recently been implicated in the genesis of multiple hematol. cancers.  Understanding the effects of disrupting the acetyltransferase activity of CBP/p300 could pave the way for new therapeutic approaches to treat patients with these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMiCksEjVzo7Vg90H21EOLACvtfcHk0liZVGYXOorLAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFemsb7J&md5=4c0437f742fb98fbefa871c73dade8f3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ymgme.2016.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymgme.2016.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%26aufirst%3DR.%26aulast%3DTiu%26aufirst%3DB.%26aulast%3DSakamoto%26aufirst%3DK.%2BM.%26atitle%3DCBP%252FP300%2520Acetyltransferase%2520Activity%2520in%2520Hematologic%2520Malignancies%26jtitle%3DMol.%2520Genet.%2520Metab.%26date%3D2016%26volume%3D119%26spage%3D37%26epage%3D43%26doi%3D10.1016%2Fj.ymgme.2016.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Dekker, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haisma, H. J.</span><span> </span><span class="NLM_article-title">Histone Acetyl Transferases as Emerging Drug Targets</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">948</span><span class="refDoi"> DOI: 10.1016/j.drudis.2009.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1016%2Fj.drudis.2009.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=19577000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFygs7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=942-948&author=F.+J.+Dekkerauthor=H.+J.+Haisma&title=Histone+Acetyl+Transferases+as+Emerging+Drug+Targets&doi=10.1016%2Fj.drudis.2009.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Histone acetyl transferases as emerging drug targets</span></div><div class="casAuthors">Dekker, Frank J.; Haisma, Hidde J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">19/20</span>),
    <span class="NLM_cas:pages">942-948</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Post-translational modifications, such as acetylation or phosphorylation, play a crucial role in the regulation of gene transcription in eukaryotes.  Different subtypes of histone acetyl transferases (HATs) catalyze the acetylation of histones on specific lysine residues.  A potential role of HATs in the pathol. of cancer, asthma, COPD and viral infection has been described.  This indicates that specific HAT inhibitors are potential tools for pharmacol. research and might find therapeutic applications.  This review focuses on the role of the HATs p300, CBP, PCAF and GCN5 in different diseases and the development of small-mol. inhibitors of these enzymes as potential drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Ao3F8nEy7bVg90H21EOLACvtfcHk0liZVGYXOorLAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFygs7fL&md5=bff2f4e6d437e003e5b17cfb07215676</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DDekker%26aufirst%3DF.%2BJ.%26aulast%3DHaisma%26aufirst%3DH.%2BJ.%26atitle%3DHistone%2520Acetyl%2520Transferases%2520as%2520Emerging%2520Drug%2520Targets%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D942%26epage%3D948%26doi%3D10.1016%2Fj.drudis.2009.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Fujisawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span> </span><span class="NLM_article-title">Functions of Bromodomain-Containing Proteins and Their Roles in Homeostasis and Cancer</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1038/nrm.2016.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fnrm.2016.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=28053347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Kiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=246-262&author=T.+Fujisawaauthor=P.+Filippakopoulos&title=Functions+of+Bromodomain-Containing+Proteins+and+Their+Roles+in+Homeostasis+and+Cancer&doi=10.1038%2Fnrm.2016.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of bromodomain-containing proteins and their roles in homeostasis and cancer</span></div><div class="casAuthors">Fujisawa, Takao; Filippakopoulos, Panagis</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">246-262</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Bromodomains (BRDs) are evolutionarily conserved protein-protein interaction modules that are found in a wide range of proteins with diverse catalytic and scaffolding functions and are present in most tissues.  BRDs selectively recognize and bind to acetylated Lys residues - particularly in histones - and thereby have important roles in the regulation of gene expression.  BRD-contg. proteins are frequently dysregulated in cancer, they participate in gene fusions that generate diverse, frequently oncogenic proteins, and many cancer-causing mutations have been mapped to the BRDs themselves.  Importantly, BRDs can be targeted by small-mol. inhibitors, which has stimulated many translational research projects that seek to attenuate the aberrant functions of BRD-contg. proteins in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-drLvQK1rvLVg90H21EOLACvtfcHk0liZVGYXOorLAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Kiuw%253D%253D&md5=cbccdee8423bad7a426c9cea6566151f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2016.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2016.143%26sid%3Dliteratum%253Aachs%26aulast%3DFujisawa%26aufirst%3DT.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26atitle%3DFunctions%2520of%2520Bromodomain-Containing%2520Proteins%2520and%2520Their%2520Roles%2520in%2520Homeostasis%2520and%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2017%26volume%3D18%26spage%3D246%26epage%3D262%26doi%3D10.1038%2Fnrm.2016.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Predina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatti, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singhal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brindle, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albelda, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Inhibition of P300 Impairs Foxp3+ T Regulatory Cell Function and Promotes Antitumor Immunity</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1173</span><span class="NLM_x">–</span> <span class="NLM_lpage">1177</span><span class="refDoi"> DOI: 10.1038/nm.3286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fnm.3286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=23955711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yks77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1173-1177&author=Y.+Liuauthor=L.+Wangauthor=J.+Predinaauthor=R.+Hanauthor=U.+H.+Beierauthor=L.-C.+S.+Wangauthor=V.+Kapoorauthor=T.+R.+Bhattiauthor=T.+Akimovaauthor=S.+Singhalauthor=P.+K.+Brindleauthor=P.+A.+Coleauthor=S.+M.+Albeldaauthor=W.+W.+Hancock&title=Inhibition+of+P300+Impairs+Foxp3%2B+T+Regulatory+Cell+Function+and+Promotes+Antitumor+Immunity&doi=10.1038%2Fnm.3286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity</span></div><div class="casAuthors">Liu, Yujie; Wang, Liqing; Predina, Jarrod; Han, Rongxiang; Beier, Ulf H.; Wang, Liang-Chuan S.; Kapoor, Veena; Bhatti, Tricia R.; Akimova, Tatiana; Singhal, Sunil; Brindle, Paul K.; Cole, Philip A.; Albelda, Steven M.; Hancock, Wayne W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1173-1177</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Forkhead box P3 (Foxp3)+ T regulatory (Treg) cells maintain immune homeostasis and limit autoimmunity but can also curtail host immune responses to various types of tumors.  Foxp3+ Treg cells are therefore considered promising targets to enhance antitumor immunity, and approaches for their therapeutic modulation are being developed.  However, although studies showing that exptl. depleting Foxp3+ Treg cells can enhance antitumor responses provide proof of principle, these studies lack clear translational potential and have various shortcomings.  Histone/protein acetyltransferases (HATs) promote chromatin accessibility, gene transcription and the function of multiple transcription factors and nonhistone proteins.  We now report that conditional deletion or pharmacol. inhibition of one HAT, p300 (also known as Ep300 or KAT3B), in Foxp3+ Treg cells increased T cell receptor-induced apoptosis in Treg cells, impaired Treg cell suppressive function and peripheral Treg cell induction, and limited tumor growth in immunocompetent but not in immunodeficient mice.  Our data thereby demonstrate that p300 is important for Foxp3+ Treg cell function and homeostasis in vivo and in vitro, and identify mechanisms by which appropriate small-mol. inhibitors can diminish Treg cell function without overtly impairing T effector cell responses or inducing autoimmunity.  Collectively, these data suggest a new approach for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG1uh9kwBI_rVg90H21EOLACvtfcHk0lgNqMAIsyOCkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yks77K&md5=b381e7523f686ed8ea8d54aa38327c41</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnm.3286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3286%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DPredina%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DBeier%26aufirst%3DU.%2BH.%26aulast%3DWang%26aufirst%3DL.-C.%2BS.%26aulast%3DKapoor%26aufirst%3DV.%26aulast%3DBhatti%26aufirst%3DT.%2BR.%26aulast%3DAkimova%26aufirst%3DT.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DBrindle%26aufirst%3DP.%2BK.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DAlbelda%26aufirst%3DS.%2BM.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DInhibition%2520of%2520P300%2520Impairs%2520Foxp3%252B%2520T%2520Regulatory%2520Cell%2520Function%2520and%2520Promotes%2520Antitumor%2520Immunity%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1173%26epage%3D1177%26doi%3D10.1038%2Fnm.3286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Conery, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Centore, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neiss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spillane, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawadzke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bommi-Reddy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoigne, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, R. J.</span><span> </span><span class="NLM_article-title">Bromodomain Inhibition of the Transcriptional Coactivators CBP/EP300 as a Therapeutic Strategy to Target the IRF4 Network in Multiple Myeloma</span> <span class="citation_source-journal">eLife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">10483</span><span class="refDoi"> DOI: 10.7554/eLife.10483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.7554%2FeLife.10483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=10483&author=A.+R.+Coneryauthor=R.+C.+Centoreauthor=A.+Neissauthor=P.+J.+Kellerauthor=S.+Joshiauthor=K.+L.+Spillaneauthor=P.+Sandyauthor=C.+Hattonauthor=E.+Pardoauthor=L.+Zawadzkeauthor=A.+Bommi-Reddyauthor=K.+E.+Gascoigneauthor=B.+M.+Bryantauthor=J.+A.+Mertzauthor=R.+J.+Sims&title=Bromodomain+Inhibition+of+the+Transcriptional+Coactivators+CBP%2FEP300+as+a+Therapeutic+Strategy+to+Target+the+IRF4+Network+in+Multiple+Myeloma&doi=10.7554%2FeLife.10483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.7554%2FeLife.10483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10483%26sid%3Dliteratum%253Aachs%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DCentore%26aufirst%3DR.%2BC.%26aulast%3DNeiss%26aufirst%3DA.%26aulast%3DKeller%26aufirst%3DP.%2BJ.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DSpillane%26aufirst%3DK.%2BL.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DZawadzke%26aufirst%3DL.%26aulast%3DBommi-Reddy%26aufirst%3DA.%26aulast%3DGascoigne%26aufirst%3DK.%2BE.%26aulast%3DBryant%26aufirst%3DB.%2BM.%26aulast%3DMertz%26aufirst%3DJ.%2BA.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26atitle%3DBromodomain%2520Inhibition%2520of%2520the%2520Transcriptional%2520Coactivators%2520CBP%252FEP300%2520as%2520a%2520Therapeutic%2520Strategy%2520to%2520Target%2520the%2520IRF4%2520Network%2520in%2520Multiple%2520Myeloma%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26spage%3D10483%26doi%3D10.7554%2FeLife.10483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conery, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmeron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakle, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mele, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setser, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAlmeida-Nagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawadzke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audia, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grogan, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, R. J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lora, J. M.</span><span> </span><span class="NLM_article-title">Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">291</span><span class="NLM_x">, </span> <span class="NLM_fpage">13014</span><span class="NLM_x">–</span> <span class="NLM_lpage">13027</span><span class="refDoi"> DOI: 10.1074/jbc.M115.708560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1074%2Fjbc.M115.708560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=27056325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSksL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=13014-13027&author=S.+Ghoshauthor=A.+Taylorauthor=M.+Chinauthor=H.-R.+Huangauthor=A.+R.+Coneryauthor=J.+A.+Mertzauthor=A.+Salmeronauthor=P.+J.+Dakleauthor=D.+Meleauthor=A.+C%C3%B4t%C3%A9author=H.+Jayaramauthor=J.+W.+Setserauthor=F.+Poyauthor=G.+Hatzivassiliouauthor=D.+DeAlmeida-Nagataauthor=P.+Sandyauthor=C.+Hattonauthor=F.+A.+Romeroauthor=E.+Chiangauthor=T.+Reimerauthor=T.+Crawfordauthor=E.+Pardoauthor=V.+G.+Watsonauthor=V.+Tsuiauthor=A.+G.+Cochranauthor=L.+Zawadzkeauthor=J.-C.+Harmangeauthor=J.+E.+Audiaauthor=B.+M.+Bryantauthor=R.+T.+Cummingsauthor=S.+R.+Magnusonauthor=J.+L.+Groganauthor=S.+F.+Bellonauthor=B.+K.+Albrechtauthor=R.+J.+Simsauthor=J.+M.+Lora&title=Regulatory+T+Cell+Modulation+by+CBP%2FEP300+Bromodomain+Inhibition&doi=10.1074%2Fjbc.M115.708560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition</span></div><div class="casAuthors">Ghosh, Srimoyee; Taylor, Alexander; Chin, Melissa; Huang, Hon-Ren; Conery, Andrew R.; Mertz, Jennifer A.; Salmeron, Andres; Dakle, Pranal J.; Mele, Deanna; Cote, Alexandre; Jayaram, Hari; Setser, Jeremy W.; Poy, Florence; Hatzivassiliou, Georgia; DeAlmeida-Nagata, Denise; Sandy, Peter; Hatton, Charlie; Romero, F. Anthony; Chiang, Eugene; Reimer, Thornik; Crawford, Terry; Pardo, Eneida; Watson, Venita G.; Tsui, Vickie; Cochran, Andrea G.; Zawadzke, Laura; Harmange, Jean-Christophe; Audia, James E.; Bryant, Barbara M.; Cummings, Richard T.; Magnuson, Steven R.; Grogan, Jane L.; Bellon, Steve F.; Albrecht, Brian K.; Sims, Robert J. III; Lora, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">13014-13027</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Covalent modification of histones is a fundamental mechanism of regulated gene expression in eukaryotes, and interpretation of histone modifications is an essential feature of epigenetic control.  Bromodomains are specialized binding modules that interact with acetylated histones, linking chromatin recognition to gene transcription.  Because of their ability to function in a domain-specific fashion, selective disruption of bromodomain:acetylated histone interactions with chem. probes serves as a powerful means for understanding biol. processes regulated by these chromatin adaptors.  Here the authors describe the discovery and characterization of potent and selective small mol. inhibitors for the bromodomains of CREBBP/EP300 that engage their target in cellular assays.  The authors use these tools to demonstrate a crit. role for CREBBP/EP300 bromodomains in regulatory T cell biol.  Because regulatory T cell recruitment to tumors is a major mechanism of immune evasion by cancer cells, the authors' data highlight the importance of CREBBP/EP300 bromodomain inhibition as a novel, small mol.-based approach for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9maWuQVImyLVg90H21EOLACvtfcHk0lhDo811NL4-dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSksL3F&md5=bc8b4edba81bdbef30b1d8fcfaa19f1e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.708560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.708560%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DH.-R.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DMertz%26aufirst%3DJ.%2BA.%26aulast%3DSalmeron%26aufirst%3DA.%26aulast%3DDakle%26aufirst%3DP.%2BJ.%26aulast%3DMele%26aufirst%3DD.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DJayaram%26aufirst%3DH.%26aulast%3DSetser%26aufirst%3DJ.%2BW.%26aulast%3DPoy%26aufirst%3DF.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DDeAlmeida-Nagata%26aufirst%3DD.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DChiang%26aufirst%3DE.%26aulast%3DReimer%26aufirst%3DT.%26aulast%3DCrawford%26aufirst%3DT.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DWatson%26aufirst%3DV.%2BG.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DZawadzke%26aufirst%3DL.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBryant%26aufirst%3DB.%2BM.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DMagnuson%26aufirst%3DS.%2BR.%26aulast%3DGrogan%26aufirst%3DJ.%2BL.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26aulast%3DLora%26aufirst%3DJ.%2BM.%26atitle%3DRegulatory%2520T%2520Cell%2520Modulation%2520by%2520CBP%252FEP300%2520Bromodomain%2520Inhibition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D13014%26epage%3D13027%26doi%3D10.1074%2Fjbc.M115.708560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasveschuk, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantone, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Leon Boenig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conery, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawadzke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, R. J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audia, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">531</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00075</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00075" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Cms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=531-536&author=A.+M.+Taylorauthor=A.+C%C3%B4t%C3%A9author=M.+C.+Hewittauthor=R.+Pastorauthor=Y.+Leblancauthor=C.+G.+Nasveschukauthor=F.+A.+Romeroauthor=T.+D.+Crawfordauthor=N.+Cantoneauthor=H.+Jayaramauthor=J.+Setserauthor=J.+Murrayauthor=M.+H.+Beresiniauthor=G.+de+Leon+Boenigauthor=Z.+Chenauthor=A.+R.+Coneryauthor=R.+T.+Cummingsauthor=L.+A.+Dakinauthor=E.+M.+Flynnauthor=O.+W.+Huangauthor=S.+Kaufmanauthor=P.+J.+Kellerauthor=J.+R.+Kieferauthor=T.+Laiauthor=Y.+Liauthor=J.+Liaoauthor=W.+Liuauthor=H.+Luauthor=E.+Pardoauthor=V.+Tsuiauthor=J.+Wangauthor=Y.+Wangauthor=Z.+Xuauthor=F.+Yanauthor=D.+Yuauthor=L.+Zawadzkeauthor=X.+Zhuauthor=X.+Zhuauthor=R.+J.+Simsauthor=A.+G.+Cochranauthor=S.+Bellonauthor=J.+E.+Audiaauthor=S.+Magnusonauthor=B.+K.+Albrecht&title=Fragment-Based+Discovery+of+a+Selective+and+Cell-Active+Benzodiazepinone+CBP%2FEP300+Bromodomain+Inhibitor+%28CPI-637%29&doi=10.1021%2Facsmedchemlett.6b00075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)</span></div><div class="casAuthors">Taylor, Alexander M.; Cote, Alexandre; Hewitt, Michael C.; Pastor, Richard; Leblanc, Yves; Nasveschuk, Christopher G.; Romero, F. Anthony; Crawford, Terry D.; Cantone, Nico; Jayaram, Hariharan; Setser, Jeremy; Murray, Jeremy; Beresini, Maureen H.; de Leon Boenig, Gladys; Chen, Zhongguo; Conery, Andrew R.; Cummings, Richard T.; Dakin, Leslie A.; Flynn, E. Megan; Huang, Oscar W.; Kaufman, Susan; Keller, Patricia J.; Kiefer, James R.; Lai, Tommy; Li, Yingjie; Liao, Jiangpeng; Liu, Wenfeng; Lu, Henry; Pardo, Eneida; Tsui, Vickie; Wang, Jian; Wang, Yongyun; Xu, Zhaowu; Yan, Fen; Yu, Dong; Zawadzke, Laura; Zhu, Xiaoqin; Zhu, Xiaoyu; Sims, Robert J.; Cochran, Andrea G.; Bellon, Steve; Audia, James E.; Magnuson, Steven; Albrecht, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">531-536</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Benzo-fused heterocycles, particularly benzodiazepinones such as I, were prepd. as inhibitors of the bromodomain-contg. proteins CBP (CREB, cAMP response element binding protein) and EP300 (adenoviral E1A-binding protein of 300 kDa) for potential use as antitumor agents; the core benzodiazepinone moiety was identified using fragment-based screening.  The structures of four benzodiazepinones, including I, bound to the bromodomain fragment of human CREB were detd. by X-ray crystallog.  The free energy, enthalpy, and entropy of the binding of I to CREB and its selectivity for CREB and EP300 over other bromodomain-contg. proteins was detd.; I inhibited expression of the transcription factor MYC in human plasmacytoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNm7Blycl0-7Vg90H21EOLACvtfcHk0lisquLrNQxkGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Cms7c%253D&md5=8440a9bb3460ff66d43f15041dbbc19d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00075%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DPastor%26aufirst%3DR.%26aulast%3DLeblanc%26aufirst%3DY.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DJayaram%26aufirst%3DH.%26aulast%3DSetser%26aufirst%3DJ.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DBeresini%26aufirst%3DM.%2BH.%26aulast%3Dde%2BLeon%2BBoenig%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DFlynn%26aufirst%3DE.%2BM.%26aulast%3DHuang%26aufirst%3DO.%2BW.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DP.%2BJ.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLai%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DZawadzke%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Selective%2520and%2520Cell-Active%2520Benzodiazepinone%2520CBP%252FEP300%2520Bromodomain%2520Inhibitor%2520%2528CPI-637%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D531%26epage%3D536%26doi%3D10.1021%2Facsmedchemlett.6b00075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Crawford, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Leon Boenig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noland, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunsaker, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharbanda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoigne, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conery, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinheinz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spillane, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawadzke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">10549</span><span class="NLM_x">–</span> <span class="NLM_lpage">10563</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01022</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGhsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10549-10563&author=T.+D.+Crawfordauthor=F.+A.+Romeroauthor=K.+W.+Laiauthor=V.+Tsuiauthor=A.+M.+Taylorauthor=G.+de+Leon+Boenigauthor=C.+L.+Nolandauthor=J.+Murrayauthor=J.+Lyauthor=E.+F.+Chooauthor=T.+L.+Hunsakerauthor=E.+W.+Chanauthor=M.+Merchantauthor=S.+Kharbandaauthor=K.+E.+Gascoigneauthor=S.+Kaufmanauthor=M.+H.+Beresiniauthor=J.+Liaoauthor=W.+Liuauthor=K.+X.+Chenauthor=Z.+Chenauthor=A.+R.+Coneryauthor=A.+C%C3%B4t%C3%A9author=H.+Jayaramauthor=Y.+Jiangauthor=J.+R.+Kieferauthor=T.+Kleinheinzauthor=Y.+Liauthor=J.+Maherauthor=E.+Pardoauthor=F.+Poyauthor=K.+L.+Spillaneauthor=F.+Wangauthor=J.+Wangauthor=X.+Weiauthor=Z.+Xuauthor=Z.+Xuauthor=I.+Yenauthor=L.+Zawadzkeauthor=X.+Zhuauthor=S.+Bellonauthor=R.+Cummingsauthor=A.+G.+Cochranauthor=B.+K.+Albrechtauthor=S.+Magnuson&title=Discovery+of+a+Potent+and+Selective+in+Vivo+Probe+%28GNE-272%29+for+the+Bromodomains+of+CBP%2FEP300&doi=10.1021%2Facs.jmedchem.6b01022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300</span></div><div class="casAuthors">Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; de Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Cote, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; Pardo, Eneida; Poy, Florence; Spillane, Kerry L.; Wang, Fei; Wang, Jian; Wei, Xiaocang; Xu, Zhaowu; Xu, Zhongya; Yen, Ivana; Zawadzke, Laura; Zhu, Xiaoyu; Bellon, Steven; Cummings, Richard; Cochran, Andrea G.; Albrecht, Brian K.; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10549-10563</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The single bromodomain of the closely related transcriptional regulators CBP/EP300 is a target of much recent interest in cancer and immune system regulation.  A co-crystal structure of a ligand-efficient screening hit and the CBP bromodomain guided initial design targeting the LPF shelf, ZA loop, and acetylated lysine binding regions.  Structure-activity relationship studies allowed the authors to identify a more potent analog.  Optimization of permeability and microsomal stability and subsequent improvement of mouse hepatocyte stability afforded 59 (GNE-272, TR-FRET IC50 = 0.02 μM, BRET IC50 = 0.41 μM, BRD4(1) IC50 = 13 μM) that retained the best balance of cell potency, selectivity, and in vivo PK.  GNE-272 showed a marked antiproliferative effect in hematol. cancer cell lines and modulates MYC expression in vivo that corresponds with antitumor activity in an AML tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6T5ODn2Q-2LVg90H21EOLACvtfcHk0li5WBIwLXLuGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGhsb%252FO&md5=22ed46cb031022aa6aff23c20d07e7dd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01022%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DLai%26aufirst%3DK.%2BW.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3Dde%2BLeon%2BBoenig%26aufirst%3DG.%26aulast%3DNoland%26aufirst%3DC.%2BL.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DHunsaker%26aufirst%3DT.%2BL.%26aulast%3DChan%26aufirst%3DE.%2BW.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DKharbanda%26aufirst%3DS.%26aulast%3DGascoigne%26aufirst%3DK.%2BE.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DBeresini%26aufirst%3DM.%2BH.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DJayaram%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMaher%26aufirst%3DJ.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DPoy%26aufirst%3DF.%26aulast%3DSpillane%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DZawadzke%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DCummings%26aufirst%3DR.%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520in%2520Vivo%2520Probe%2520%2528GNE-272%2529%2520for%2520the%2520Bromodomains%2520of%2520CBP%252FEP300%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10549%26epage%3D10563%26doi%3D10.1021%2Facs.jmedchem.6b01022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Popp, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bracher, F.</span><span> </span><span class="NLM_article-title">Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">8889</span><span class="NLM_x">–</span> <span class="NLM_lpage">8912</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00774</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00774" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKis77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8889-8912&author=T.+A.+Poppauthor=C.+Tallantauthor=C.+Rogersauthor=O.+Fedorovauthor=P.+E.+Brennanauthor=S.+M%C3%BCllerauthor=S.+Knappauthor=F.+Bracher&title=Development+of+Selective+CBP%2FP300+Benzoxazepine+Bromodomain+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors</span></div><div class="casAuthors">Popp, Tobias A.; Tallant, Cynthia; Rogers, Catherine; Fedorov, Oleg; Brennan, Paul E.; Mueller, Susanne; Knapp, Stefan; Bracher, Franz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8889-8912</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CBP (CREB (cAMP responsive element binding protein) binding protein (CREBBP)) and P300 (adenovirus E1A-assocd. 300 kDa protein) are two closely related histone acetyltransferases (HATs) that play a key role in the regulation of gene transcription.  Both proteins contain a bromodomain flanking the HAT catalytic domain that is important for the targeting of CBP/P300 to chromatin and which offers an opportunity for the development of protein-protein interaction inhibitors.  Here the authors present the development of CBP/P300 bromodomain inhibitors with 2,3,4,5-tetrahydro-1,4-benzoxazepine backbone, an N-acetyl-lysine mimetic scaffold that led to the recent development of the chem. probe I-CBP112.  The authors present comprehensive SAR of this inhibitor class as well as demonstration of cellular on target activity of the most potent and selective inhibitor I, which showed 134 nM affinity for CBP with excellent selectivity over other bromodomains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwAZFuNP0NkLVg90H21EOLACvtfcHk0li5WBIwLXLuGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKis77E&md5=6bd914d24abf00a8f074bf1918fb4ee1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00774%26sid%3Dliteratum%253Aachs%26aulast%3DPopp%26aufirst%3DT.%2BA.%26aulast%3DTallant%26aufirst%3DC.%26aulast%3DRogers%26aufirst%3DC.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBracher%26aufirst%3DF.%26atitle%3DDevelopment%2520of%2520Selective%2520CBP%252FP300%2520Benzoxazepine%2520Bromodomain%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8889%26epage%3D8912%26doi%3D10.1021%2Facs.jmedchem.6b00774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Rooney, T. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortopassi, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heightman, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryde, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paton, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. J.</span><span> </span><span class="NLM_article-title">A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation-Π Interaction</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6126</span><span class="NLM_x">–</span> <span class="NLM_lpage">6130</span><span class="refDoi"> DOI: 10.1002/anie.201402750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1002%2Fanie.201402750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFWgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=6126-6130&author=T.+P.+C.+Rooneyauthor=P.+Filippakopoulosauthor=O.+Fedorovauthor=S.+Picaudauthor=W.+A.+Cortopassiauthor=D.+A.+Hayauthor=S.+Martinauthor=A.+Tumberauthor=C.+M.+Rogersauthor=M.+Philpottauthor=M.+Wangauthor=A.+L.+Thompsonauthor=T.+D.+Heightmanauthor=D.+C.+Prydeauthor=A.+Cookauthor=R.+S.+Patonauthor=S.+M%C3%BCllerauthor=S.+Knappauthor=P.+E.+Brennanauthor=S.+J.+Conway&title=A+Series+of+Potent+CREBBP+Bromodomain+Ligands+Reveals+an+Induced-Fit+Pocket+Stabilized+by+a+Cation-%CE%A0+Interaction&doi=10.1002%2Fanie.201402750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation-π Interaction</span></div><div class="casAuthors">Rooney, Timothy P. C.; Filippakopoulos, Panagis; Fedorov, Oleg; Picaud, Sarah; Cortopassi, Wilian A.; Hay, Duncan A.; Martin, Sarah; Tumber, Anthony; Rogers, Catherine M.; Philpott, Martin; Wang, Minghua; Thompson, Amber L.; Heightman, Tom D.; Pryde, David C.; Cook, Andrew; Paton, Robert S.; Mueller, Susanne; Knapp, Stefan; Brennan, Paul E.; Conway, Stuart J.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6126-6130</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Benzoxazinone and dihydroquinoxalinone fragments were employed as novel acetyl lysine mimics in the development of CREBBP bromodomain ligands.  While the benzoxazinone series showed low affinity for the CREBBP bromodomain, expansion of the dihydroquinoxalinone series resulted in the first potent inhibitors, e.g., I, of a bromodomain outside the BET family.  Structural and computational studies revealed that an internal hydrogen bond stabilized the protein-bound conformation of the dihydroquinoxalinone series.  The side chain of this series binds in an induced-fit pocket forming a cation-π interaction with R1173 of CREBBP.  Compd. I, the most potent compd., inhibited binding of CREBBP to chromatin in U2OS cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHFgTVUKe7lrVg90H21EOLACvtfcHk0ljjxOe9ReKVaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFWgsb0%253D&md5=42b12e1fe855d2af02c49f8e1031d39e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fanie.201402750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201402750%26sid%3Dliteratum%253Aachs%26aulast%3DRooney%26aufirst%3DT.%2BP.%2BC.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DCortopassi%26aufirst%3DW.%2BA.%26aulast%3DHay%26aufirst%3DD.%2BA.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DRogers%26aufirst%3DC.%2BM.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DThompson%26aufirst%3DA.%2BL.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DPryde%26aufirst%3DD.%2BC.%26aulast%3DCook%26aufirst%3DA.%26aulast%3DPaton%26aufirst%3DR.%2BS.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DConway%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Series%2520of%2520Potent%2520CREBBP%2520Bromodomain%2520Ligands%2520Reveals%2520an%2520Induced-Fit%2520Pocket%2520Stabilized%2520by%2520a%2520Cation-%25CE%25A0%2520Interaction%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D6126%26epage%3D6130%26doi%3D10.1002%2Fanie.201402750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Hay, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singleton, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteiro, O. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, T. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schofield, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of Small-Molecule Ligands for the CBP/P300 Bromodomains</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">9308</span><span class="NLM_x">–</span> <span class="NLM_lpage">9319</span><span class="refDoi"> DOI: 10.1021/ja412434f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja412434f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=9308-9319&author=D.+A.+Hayauthor=O.+Fedorovauthor=S.+Martinauthor=D.+C.+Singletonauthor=C.+Tallantauthor=C.+Wellsauthor=S.+Picaudauthor=M.+Philpottauthor=O.+P.+Monteiroauthor=C.+M.+Rogersauthor=S.+J.+Conwayauthor=T.+P.+C.+Rooneyauthor=A.+Tumberauthor=C.+Yappauthor=P.+Filippakopoulosauthor=M.+E.+Bunnageauthor=S.+M%C3%BCllerauthor=S.+Knappauthor=C.+J.+Schofieldauthor=P.+E.+Brennan&title=Discovery+and+Optimization+of+Small-Molecule+Ligands+for+the+CBP%2FP300+Bromodomains&doi=10.1021%2Fja412434f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains</span></div><div class="casAuthors">Hay, Duncan A.; Fedorov, Oleg; Martin, Sarah; Singleton, Dean C.; Tallant, Cynthia; Wells, Christopher; Picaud, Sarah; Philpott, Martin; Monteiro, Octovia P.; Rogers, Catherine M.; Conway, Stuart J.; Rooney, Timothy P. C.; Tumber, Anthony; Yapp, Clarence; Filippakopoulos, Panagis; Bunnage, Mark E.; Muller, Susanne; Knapp, Stefan; Schofield, Christopher J.; Brennan, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9308-9319</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small-mol. inhibitors that target bromodomains outside of the bromodomain and extra-terminal (BET) sub-family are lacking.  Here, the authors describe highly potent and selective ligands for the bromodomain module of the human lysine acetyl transferase CBP/p300, developed from a series of 5-isoxazolyl-benzimidazoles.  The starting point was a fragment hit, which was optimized into a more potent and selective lead using parallel synthesis employing Suzuki couplings, benzimidazole-forming reactions, and reductive aminations.  The selectivity of the lead compd. against other bromodomain family members was investigated using a thermal stability assay, which revealed some inhibition of the structurally related BET family members.  To address the BET selectivity issue, x-ray crystal structures of the lead compd. bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compds.  The crystal structures obtained revealed two distinct binding modes.  By varying the aryl substitution pattern and developing conformationally constrained analogs, selectivity for CBP over BRD4(1) was increased.  The optimized compd. is highly potent (Kd = 21 nM) and selective, displaying 40-fold selectivity over BRD4(1).  Cellular activity was demonstrated using fluorescence recovery after photo-bleaching (FRAP) and a p53 reporter assay.  The optimized compds. are cell-active and have nanomolar affinity for CBP/p300; therefore, they should be useful in studies investigating the biol. roles of CBP and p300 and to validate the CBP and p300 bromodomains as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFzgs1DD4QZLVg90H21EOLACvtfcHk0ljjxOe9ReKVaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsLvP&md5=e5da3e96a4d234453a481c7ee5e788f2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fja412434f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja412434f%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DD.%2BA.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DSingleton%26aufirst%3DD.%2BC.%26aulast%3DTallant%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DMonteiro%26aufirst%3DO.%2BP.%26aulast%3DRogers%26aufirst%3DC.%2BM.%26aulast%3DConway%26aufirst%3DS.%2BJ.%26aulast%3DRooney%26aufirst%3DT.%2BP.%2BC.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DYapp%26aufirst%3DC.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DSchofield%26aufirst%3DC.%2BJ.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Small-Molecule%2520Ligands%2520for%2520the%2520CBP%252FP300%2520Bromodomains%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D9308%26epage%3D9319%26doi%3D10.1021%2Fja412434f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Unzue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiedmer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiliotopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevado, C.</span><span> </span><span class="NLM_article-title">Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00172</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00172" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1350-1356&author=A.+Unzueauthor=M.+Xuauthor=J.+Dongauthor=L.+Wiedmerauthor=D.+Spiliotopoulosauthor=A.+Caflischauthor=C.+Nevado&title=Fragment-Based+Design+of+Selective+Nanomolar+Ligands+of+the+CREBBP+Bromodomain&doi=10.1021%2Facs.jmedchem.5b00172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain</span></div><div class="casAuthors">Unzue, Andrea; Xu, Min; Dong, Jing; Wiedmer, Lars; Spiliotopoulos, Dimitrios; Caflisch, Amedeo; Nevado, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1350-1356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel ligands of the CREBBP bromodomain were identified by fragment-based docking.  The in silico discovered hits have been optimized by chem. synthesis into selective nanomolar compds., thereby preserving the ligand efficiency.  The selectivity for the CREBBP bromodomain over other human bromodomain subfamilies has achieved by a benzoate moiety which was predicted by docking to be involved in favorable electrostatic interactions with the Arg1173 side chain, a prediction that could be verified a posteriori by the high-resoln. crystal structure of the CREBBP bromodomain in complex with ligand 6 and also by MD simulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy4MHhgfhyu7Vg90H21EOLACvtfcHk0li7-juaKDZpzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaktLg%253D&md5=aff73b86b04fc4d7243adcba364ca6a6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00172%26sid%3Dliteratum%253Aachs%26aulast%3DUnzue%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DWiedmer%26aufirst%3DL.%26aulast%3DSpiliotopoulos%26aufirst%3DD.%26aulast%3DCaflisch%26aufirst%3DA.%26aulast%3DNevado%26aufirst%3DC.%26atitle%3DFragment-Based%2520Design%2520of%2520Selective%2520Nanomolar%2520Ligands%2520of%2520the%2520CREBBP%2520Bromodomain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1350%26epage%3D1356%26doi%3D10.1021%2Facs.jmedchem.5b00172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Picaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thanasopoulou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonards, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olzscha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteiro, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bannister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecellio, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bountra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velichko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Thangue, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouzarides, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinjha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwaller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Generation of a Selective Small Molecule Inhibitor of the CBP/P300 Bromodomain for Leukemia Therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">5106</span><span class="NLM_x">–</span> <span class="NLM_lpage">5119</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-0236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1158%2F0008-5472.CAN-15-0236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=26552700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFensrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=5106-5119&author=S.+Picaudauthor=O.+Fedorovauthor=A.+Thanasopoulouauthor=K.+Leonardsauthor=K.+Jonesauthor=J.+Meierauthor=H.+Olzschaauthor=O.+Monteiroauthor=S.+Martinauthor=M.+Philpottauthor=A.+Tumberauthor=P.+Filippakopoulosauthor=C.+Yappauthor=C.+Wellsauthor=K.+H.+Cheauthor=A.+Bannisterauthor=S.+Robsonauthor=U.+Kumarauthor=N.+Parrauthor=K.+Leeauthor=D.+Lugoauthor=P.+Jeffreyauthor=S.+Taylorauthor=M.+L.+Vecellioauthor=C.+Bountraauthor=P.+E.+Brennanauthor=A.+O%E2%80%99Mahonyauthor=S.+Velichkoauthor=S.+M%C3%BCllerauthor=D.+Hayauthor=D.+L.+Danielsauthor=M.+Urhauthor=N.+B.+La+Thangueauthor=T.+Kouzaridesauthor=R.+Prinjhaauthor=J.+Schwallerauthor=S.+Knapp&title=Generation+of+a+Selective+Small+Molecule+Inhibitor+of+the+CBP%2FP300+Bromodomain+for+Leukemia+Therapy&doi=10.1158%2F0008-5472.CAN-15-0236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy</span></div><div class="casAuthors">Picaud, Sarah; Fedorov, Oleg; Thanasopoulou, Angeliki; Leonards, Katharina; Jones, Katherine; Meier, Julia; Olzscha, Heidi; Monteiro, Octovia; Martin, Sarah; Philpott, Martin; Tumber, Anthony; Filippakopoulos, Panagis; Yapp, Clarence; Wells, Christopher; Che, Ka Hing; Bannister, Andrew; Robson, Samuel; Kumar, Umesh; Parr, Nigel; Lee, Kevin; Lugo, Dave; Jeffrey, Philip; Taylor, Simon; Vecellio, Matteo L.; Bountra, Chas; Brennan, Paul E.; O'Mahony, Alison; Velichko, Sharlene; Mueller, Susanne; Hay, Duncan; Daniels, Danette L.; Urh, Marjeta; La Thangue, Nicholas B.; Kouzarides, Tony; Prinjha, Rab; Schwaller, Juerg; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5106-5119</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The histone acetyltransferases CBP/p300 are involved in recurrent leukemia-assocd. chromosomal translocations and are key regulators of cell growth.  Therefore, efforts to generate inhibitors of CBP/p300 are of clin. value.  We developed a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, I-CBP112, that targets the CBP/p300 bromodomains.  Exposure of human and mouse leukemic cell lines to I-CBP112 resulted in substantially impaired colony formation and induced cellular differentiation without significant cytotoxicity.  I-CBP112 significantly reduced the leukemia-initiating potential of MLL-AF9+ acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo.  Interestingly, I-CBP112 increased the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin.  Collectively, we report the development and preclin. evaluation of a novel, potent inhibitor targeting CBP/p300 bromodomains that impairs aberrant self-renewal of leukemic cells.  The synergistic effects of I-CBP112 and current std. therapy (doxorubicin) as well as emerging treatment strategies (BET inhibition) provide new opportunities for combinatorial treatment of leukemia and potentially other cancers.  Cancer Res; 75(23); 5106-19. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWk5dMbmC6K7Vg90H21EOLACvtfcHk0liLG-aecsE3rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFensrzN&md5=da936fa34139ba27abc748db5f78c95e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-0236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-0236%26sid%3Dliteratum%253Aachs%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DThanasopoulou%26aufirst%3DA.%26aulast%3DLeonards%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DMeier%26aufirst%3DJ.%26aulast%3DOlzscha%26aufirst%3DH.%26aulast%3DMonteiro%26aufirst%3DO.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DYapp%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DChe%26aufirst%3DK.%2BH.%26aulast%3DBannister%26aufirst%3DA.%26aulast%3DRobson%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DU.%26aulast%3DParr%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DLugo%26aufirst%3DD.%26aulast%3DJeffrey%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DVecellio%26aufirst%3DM.%2BL.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DVelichko%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DHay%26aufirst%3DD.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DUrh%26aufirst%3DM.%26aulast%3DLa%2BThangue%26aufirst%3DN.%2BB.%26aulast%3DKouzarides%26aufirst%3DT.%26aulast%3DPrinjha%26aufirst%3DR.%26aulast%3DSchwaller%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DGeneration%2520of%2520a%2520Selective%2520Small%2520Molecule%2520Inhibitor%2520of%2520the%2520CBP%252FP300%2520Bromodomain%2520for%2520Leukemia%2520Therapy%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D5106%26epage%3D5119%26doi%3D10.1158%2F0008-5472.CAN-15-0236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Hammitzsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Mossawi, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Wit, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecellio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wordsworth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowness, P.</span><span> </span><span class="NLM_article-title">CBP30, a Selective CBP/P300 Bromodomain Inhibitor, Suppresses Human Th17 Responses</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">10768</span><span class="NLM_x">–</span> <span class="NLM_lpage">10773</span><span class="refDoi"> DOI: 10.1073/pnas.1501956112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1073%2Fpnas.1501956112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=26261308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSit7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=10768-10773&author=A.+Hammitzschauthor=C.+Tallantauthor=O.+Fedorovauthor=A.+O%E2%80%99Mahonyauthor=P.+E.+Brennanauthor=D.+A.+Hayauthor=F.+O.+Martinezauthor=M.+H.+Al-Mossawiauthor=J.+de+Witauthor=M.+Vecellioauthor=C.+Wellsauthor=P.+Wordsworthauthor=S.+M%C3%BCllerauthor=S.+Knappauthor=P.+Bowness&title=CBP30%2C+a+Selective+CBP%2FP300+Bromodomain+Inhibitor%2C+Suppresses+Human+Th17+Responses&doi=10.1073%2Fpnas.1501956112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses</span></div><div class="casAuthors">Hammitzsch, Ariane; Tallant, Cynthia; Fedorov, Oleg; O'Mahony, Alison; Brennan, Paul E.; Hay, Duncan A.; Martinez, Fernando O.; Al-Mossawi, M. Hussein; de Wit, Jelle; Vecellio, Matteo; Wells, Christopher; Wordsworth, Paul; Muller, Susanne; Knapp, Stefan; Bowness, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">10768-10773</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Th17 responses are crit. to a variety of human autoimmune diseases, and therapeutic targeting with monoclonal antibodies against IL-17 and IL-23 has shown considerable promise.  Here, the authors report data to support selective bromodomain blockade of the transcriptional coactivators CBP (CREB binding protein) and p300 as an alternative approach to inhibit human Th17 responses.  The authors show that CBP30 has marked mol. specificity for the bromodomains of CBP and p300, compared with 43 other bromodomains.  In unbiased cellular testing on a diverse panel of cultured primary human cells, CBP30 reduced immune cell prodn. of IL-17A and other proinflammatory cytokines.  CBP30 also inhibited IL-17A secretion by Th17 cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis.  Transcriptional profiling of human T cells after CBP30 treatment showed a much more restricted effect on gene expression than that obsd. with the pan-BET (bromo and extraterminal domain protein family) bromodomain inhibitor JQ1.  This selective targeting of the CBP/p300 bromodomain by CBP30 will potentially lead to fewer side effects than with the broadly acting epigenetic inhibitors currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4fYjOUV2xW7Vg90H21EOLACvtfcHk0liLG-aecsE3rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSit7jI&md5=fb9de88ecdd6441628ae1455ac11b65c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1501956112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1501956112%26sid%3Dliteratum%253Aachs%26aulast%3DHammitzsch%26aufirst%3DA.%26aulast%3DTallant%26aufirst%3DC.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DHay%26aufirst%3DD.%2BA.%26aulast%3DMartinez%26aufirst%3DF.%2BO.%26aulast%3DAl-Mossawi%26aufirst%3DM.%2BH.%26aulast%3Dde%2BWit%26aufirst%3DJ.%26aulast%3DVecellio%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DWordsworth%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBowness%26aufirst%3DP.%26atitle%3DCBP30%252C%2520a%2520Selective%2520CBP%252FP300%2520Bromodomain%2520Inhibitor%252C%2520Suppresses%2520Human%2520Th17%2520Responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D10768%26epage%3D10773%26doi%3D10.1073%2Fpnas.1501956112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Denny, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coe, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langille, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahasrabudhe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonin, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pletcher, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chekler, E. L. P.</span><span> </span><span class="NLM_article-title">Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">5349</span><span class="NLM_x">–</span> <span class="NLM_lpage">5363</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01839</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01839" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Glu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5349-5363&author=R.+A.+Dennyauthor=A.+C.+Flickauthor=J.+W.+Coeauthor=J.+Langilleauthor=A.+Basakauthor=S.+Liuauthor=I.+A.+Stockauthor=P.+Sahasrabudheauthor=P.+D.+Boninauthor=D.+A.+Hayauthor=P.+E.+Brennanauthor=M.+T.+Pletcherauthor=L.+H.+Jonesauthor=E.+L.+P.+Chekler&title=Structure-Based+Design+of+Highly+Selective+Inhibitors+of+the+CREB+Binding+Protein+Bromodomain&doi=10.1021%2Facs.jmedchem.6b01839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain</span></div><div class="casAuthors">Denny, R. Aldrin; Flick, Andrew C.; Coe, Jotham; Langille, Jonathan; Basak, Arindrajit; Liu, Shenping; Stock, Ingrid; Sahasrabudhe, Parag; Bonin, Paul; Hay, Duncan A.; Brennan, Paul E.; Pletcher, Mathew; Jones, Lyn H.; Chekler, Eugene L. Piatnitski</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5349-5363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. probes are required for preclin. target validation to interrogate novel biol. targets and pathways.  Selective inhibitors of the CREB binding protein (CREBBP)/EP300 bromodomains are required to facilitate the elucidation of biol. assocd. with these important epigenetic targets.  Medicinal chem. optimization that paid particular attention to physiochem. properties delivered chem. probes with desirable potency, selectivity, and permeability attributes.  An important feature of the optimization process was the successful application of rational structure-based drug design to address bromodomain selectivity issues (particularly against the structurally related BRD4 protein).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLWkqF-qAmdbVg90H21EOLACvtfcHk0liJM3f_SIA15A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Glu70%253D&md5=23676a973abba59088dedd5502877105</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01839%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DR.%2BA.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DCoe%26aufirst%3DJ.%2BW.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DStock%26aufirst%3DI.%2BA.%26aulast%3DSahasrabudhe%26aufirst%3DP.%26aulast%3DBonin%26aufirst%3DP.%2BD.%26aulast%3DHay%26aufirst%3DD.%2BA.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DPletcher%26aufirst%3DM.%2BT.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DChekler%26aufirst%3DE.%2BL.%2BP.%26atitle%3DStructure-Based%2520Design%2520of%2520Highly%2520Selective%2520Inhibitors%2520of%2520the%2520CREB%2520Binding%2520Protein%2520Bromodomain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5349%26epage%3D5363%26doi%3D10.1021%2Facs.jmedchem.6b01839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Romero, F. A.; Magnuson, S.; Pastor, R.; Tsui, V.; Murray, J.; Crawford, T.; Albrecht, B. K.; Côté, A.; Taylor, A. M.; Lai, K. W.; Chen, K. X.; Bronner, S.; Adler, M.; Egen, J.; Liao, J.; Wang, F.; Cyr, P.; Zhu, B.-Y.; Kauder, S.</span><span> </span><span class="NLM_article-title">4,5,6,7-Tetrahydro-1<i>H</i>-pyrazolo[4,3-C]pyridin-3-amine Compounds as CBP and/or EP300 Inhibitors</span>. WO2016086200.<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=F.+A.+Romero&author=S.+Magnuson&author=R.+Pastor&author=V.+Tsui&author=J.+Murray&author=T.+Crawford&author=B.+K.+Albrecht&author=A.+C%C3%B4t%C3%A9&author=A.+M.+Taylor&author=K.+W.+Lai&author=K.+X.+Chen&author=S.+Bronner&author=M.+Adler&author=J.+Egen&author=J.+Liao&author=F.+Wang&author=P.+Cyr&author=B.-Y.+Zhu&author=S.+Kauder&title=4%2C5%2C6%2C7-Tetrahydro-1H-pyrazolo%5B4%2C3-C%5Dpyridin-3-amine+Compounds+as+CBP+and%2For+EP300+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DF.%2BA.%26atitle%3D4%252C5%252C6%252C7-Tetrahydro-1H-pyrazolo%255B4%252C3-C%255Dpyridin-3-amine%2520Compounds%2520as%2520CBP%2520and%252For%2520EP300%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1271</span><span class="NLM_x">–</span> <span class="NLM_lpage">1298</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1271-1298&author=F.+A.+Romeroauthor=A.+M.+Taylorauthor=T.+D.+Crawfordauthor=V.+Tsuiauthor=A.+C%C3%B4t%C3%A9author=S.+Magnuson&title=Disrupting+Acetyl-Lysine+Recognition%3A+Progress+in+the+Development+of+Bromodomain+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors</span></div><div class="casAuthors">Romero, F. Anthony; Taylor, Alexander M.; Crawford, Terry D.; Tsui, Vickie; Cote, Alexandre; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1271-1298</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomains, small protein modules that recognize acetylated lysine on histones, play a significant role in the epigenome, where they function as "readers" that ultimately det. the functional outcome of the post-translational modification.  Because the initial discovery of selective BET inhibitors have helped define the role of that protein family in oncol. and inflammation, BET bromodomains have continued to garner the most attention of any other bromodomain.  More recently, non-BET bromodomain inhibitors that are potent and selective have been disclosed for ATAD2, CBP, BRD7/9, BRPF, BRPF/TRIM24, CECR2, SMARCA4, and BAZ2A/B.  Such novel inhibitors can be used to probe the physiol. function of these non-BET bromodomains and further understanding of their role in certain disease states.  Here, we provide an update to the progress in identifying selective bromodomain inhibitors and their use as biol. tools, as well as our perspective on the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgbRrKGlHaVLVg90H21EOLACvtfcHk0liJM3f_SIA15A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO&md5=260352f61301aa88aad48c0b63e6152f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01514%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DDisrupting%2520Acetyl-Lysine%2520Recognition%253A%2520Progress%2520in%2520the%2520Development%2520of%2520Bromodomain%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1271%26epage%3D1298%26doi%3D10.1021%2Facs.jmedchem.5b01514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">The (<i>S</i>) absolute stereochemistry of <b>8</b> was determined from the cocrystal structure of <b>8</b> in the CBP bromodomain. In every instance the (<i>S</i>)-enantiomer was always more potent than the (<i>R</i>)-enantiomer (data not shown). compounds <b>3</b>, <b>5</b>, <b>6</b>, <b>7</b>, and <b>9</b> were synthesized from (<i>R</i>)-tetrahydrofuran-3-ol and thus the absolute stereochemistry is unambiguously that of the (<i>S</i>)-configuration.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><div class="note"><p class="first last">Mo Ka Molecular Discovery, Perugia.</p></div><a href="http://www.moldiscovery.com/software/moka/" class="extLink">http://www.moldiscovery.com/software/moka/</a> (Accessed July 27,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Mo+Ka+Molecular+Discovery%2C+Perugia.http%3A%2F%2Fwww.moldiscovery.com%2Fsoftware%2Fmoka%2F+%28Accessed+July+27%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0li-YK1Qqc5x3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, A.</span><span> </span><span class="NLM_article-title">Ligand Efficiency: A Useful Metric for Lead Selection</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+Efficiency%3A+A+Useful+Metric+for+Lead+Selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2ea--8M1ICOEbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520Efficiency%253A%2520A%2520Useful%2520Metric%2520for%2520Lead%2520Selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Chan, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Thangue, N. B.</span><span> </span><span class="NLM_article-title">P300/CBP Proteins: HATs for Transcriptional Bridges and Scaffolds</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2363</span><span class="NLM_x">–</span> <span class="NLM_lpage">2373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=11559745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsFamt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2001&pages=2363-2373&author=H.+M.+Chanauthor=N.+B.+La+Thangue&title=P300%2FCBP+Proteins%3A+HATs+for+Transcriptional+Bridges+and+Scaffolds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">p300/CBP proteins: HATs for transcriptional bridges and scaffolds</span></div><div class="casAuthors">Chan, Ho Man; La Thangue, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2363-2373</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review with 139 refs.  P300/CBP transcriptional co-activator proteins play a central role in co-ordinating and integrating multiple signal-dependent events with the transcription app., allowing the appropriate level of gene activity to occur in response to diverse physiol. cues that influence, for example, proliferation, differentiation and apoptosis.  P300/CBP activity can be under aberrant control in human disease, particularly in cancer, which may inactivate a p300/CBP tumor-suppressor-like activity.  The transcription regulating-properties of p300 and CBP appear to be exerted through multiple mechanisms.  They act as protein bridges, thereby connecting different sequence-specific transcription factors to the transcription app.  Providing a protein scaffold upon which to build a multicomponent transcriptional regulatory complex is likely to be an important feature of p300/CBP control.  Another key property is the presence of histone acetyltransferase (HAT) activity, which endows p300/CBP with the capacity to influence chromatin activity by modulating nucleosomal histones.  Other proteins, including the p53 tumor suppressor, are targets for acetylation by p300/CBP.  With the current intense level of research activity, p300/CBP will continue to be in the limelight and, we can be confident, yield new and important information on fundamental processes involved in transcriptional control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNuaZehN-7bVg90H21EOLACvtfcHk0lgi_NZ6Ju2TVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsFamt7c%253D&md5=f4c7d310294dc7253ad9818bd52cb792</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DLa%2BThangue%26aufirst%3DN.%2BB.%26atitle%3DP300%252FCBP%2520Proteins%253A%2520HATs%2520for%2520Transcriptional%2520Bridges%2520and%2520Scaffolds%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2001%26volume%3D114%26spage%3D2363%26epage%3D2373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Sakaguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, M.</span><span> </span><span class="NLM_article-title">Regulatory T Cells and Immune Tolerance</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">787</span><span class="refDoi"> DOI: 10.1016/j.cell.2008.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1016%2Fj.cell.2008.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=18510923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFaltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=775-787&author=S.+Sakaguchiauthor=T.+Yamaguchiauthor=T.+Nomuraauthor=M.+Ono&title=Regulatory+T+Cells+and+Immune+Tolerance&doi=10.1016%2Fj.cell.2008.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory T cells and immune tolerance</span></div><div class="casAuthors">Sakaguchi, Shimon; Yamaguchi, Tomoyuki; Nomura, Takashi; Ono, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">775-787</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Regulatory T cells (Tregs) play an indispensable role in maintaining immunol. unresponsiveness to self-antigens and in suppressing excessive immune responses deleterious to the host.  Tregs are produced in the thymus as a functionally mature subpopulation of T cells and can also be induced from naive T cells in the periphery.  Recent research reveals the cellular and mol. basis of Treg development and function and implicates dysregulation of Tregs in immunol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoATufEZGfRqrVg90H21EOLACvtfcHk0lgi_NZ6Ju2TVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFaltrg%253D&md5=a0e32e258b46e4975f40d937a7c8f6d8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DSakaguchi%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DOno%26aufirst%3DM.%26atitle%3DRegulatory%2520T%2520Cells%2520and%2520Immune%2520Tolerance%26jtitle%3DCell%26date%3D2008%26volume%3D133%26spage%3D775%26epage%3D787%26doi%3D10.1016%2Fj.cell.2008.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Tanaka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, S.</span><span> </span><span class="NLM_article-title">Regulatory T Cells in Cancer Immunotherapy</span> <span class="citation_source-journal">Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1038/cr.2016.151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1038%2Fcr.2016.151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=27995907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCmtr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=109-118&author=A.+Tanakaauthor=S.+Sakaguchi&title=Regulatory+T+Cells+in+Cancer+Immunotherapy&doi=10.1038%2Fcr.2016.151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory T cells in cancer immunotherapy</span></div><div class="casAuthors">Tanaka, Atsushi; Sakaguchi, Shimon</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-118</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">FOXP3-expressing regulatory T (Treg) cells, which suppress aberrant immune response against self-antigens, also suppress anti-tumor immune response.  Infiltration of a large no. of Treg cells into tumor tissues is often assocd. with poor prognosis.  There is accumulating evidence that the removal of Treg cells is able to evoke and enhance anti-tumor immune response.  However, systemic depletion of Treg cells may concurrently elicit deleterious autoimmunity.  One strategy for evoking effective tumor immunity without autoimmunity is to specifically target terminally differentiated effector Treg cells rather than all FOXP3+ T cells, because effector Treg cells are the predominant cell type in tumor tissues.  Various cell surface mols., including chemokine receptors such as CCR4, that are specifically expressed by effector Treg cells can be the candidates for depleting effector Treg cells by specific cell-depleting monoclonal antibodies.  In addn., other immunol. characteristics of effector Treg cells, such as their high expression of CTLA-4, active proliferation, and apoptosis-prone tendency, can be exploited to control specifically their functions.  For example, anti-CTLA-4 antibody may kill effector Treg cells or attenuate their suppressive activity.  It is hoped that combination of Treg-cell targeting (e.g., by reducing Treg cells or attenuating their suppressive activity in tumor tissues) with the activation of tumor-specific effector T cells (e.g., by cancer vaccine or immune checkpoint blockade) will make the current cancer immunotherapy more effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqpJ04a1bId7Vg90H21EOLACvtfcHk0lgi_NZ6Ju2TVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCmtr7M&md5=124edc1c7d0aa3739c53ba74790437cb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fcr.2016.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.2016.151%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DSakaguchi%26aufirst%3DS.%26atitle%3DRegulatory%2520T%2520Cells%2520in%2520Cancer%2520Immunotherapy%26jtitle%3DCell%2520Res.%26date%3D2017%26volume%3D27%26spage%3D109%26epage%3D118%26doi%3D10.1038%2Fcr.2016.151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Shimizu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, S.</span><span> </span><span class="NLM_article-title">Induction of Tumor Immunity by Removing CD25 + CD4+ T Cells: a Common Basis Between Tumor Immunity and Autoimmunity</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">5211</span><span class="NLM_x">–</span> <span class="NLM_lpage">5218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=1999&pages=5211-5218&author=J.+Shimizuauthor=S.+Yamazakiauthor=S.+Sakaguchi&title=Induction+of+Tumor+Immunity+by+Removing+CD25+%2B+CD4%2B+T+Cells%3A+a+Common+Basis+Between+Tumor+Immunity+and+Autoimmunity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DJ.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DSakaguchi%26aufirst%3DS.%26atitle%3DInduction%2520of%2520Tumor%2520Immunity%2520by%2520Removing%2520CD25%2520%252B%2520CD4%252B%2520T%2520Cells%253A%2520a%2520Common%2520Basis%2520Between%2520Tumor%2520Immunity%2520and%2520Autoimmunity%26jtitle%3DJ.%2520Immunol.%26date%3D1999%26volume%3D163%26spage%3D5211%26epage%3D5218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Hori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, S.</span><span> </span><span class="NLM_article-title">Control of Regulatory T Cell Development by the Transcription Factor Foxp3</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1126/science.1079490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1126%2Fscience.1079490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=12522256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtFarsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=1057-1061&author=S.+Horiauthor=T.+Nomuraauthor=S.+Sakaguchi&title=Control+of+Regulatory+T+Cell+Development+by+the+Transcription+Factor+Foxp3&doi=10.1126%2Fscience.1079490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Control of Regulatory T Cell Development by the Transcription Factor Foxp3</span></div><div class="casAuthors">Hori, Shohei; Nomura, Takashi; Sakaguchi, Shimon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5609</span>),
    <span class="NLM_cas:pages">1057-1061</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Regulatory T cells engage in the maintenance of immunol. self-tolerance by actively suppressing self-reactive lymphocytes.  Little is known, however, about the mol. mechanism of their development.  Here we show that Foxp3, which encodes a transcription factor that is genetically defective in an autoimmune and inflammatory syndrome in humans and mice, is specifically expressed in naturally arising CD4+ regulatory T cells.  Furthermore, retroviral gene transfer of Foxp3 converts naive T cells toward a regulatory T cell phenotype similar to that of naturally occurring CD4+ regulatory T cells.  Thus, Foxp3 is a key regulatory gene for the development of regulatory T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY_22m45Ig-bVg90H21EOLACvtfcHk0lhk68FfV4m6DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtFarsbw%253D&md5=eb4ecdd3a735c2ba41703ef65fb5587d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1126%2Fscience.1079490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1079490%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DS.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DSakaguchi%26aufirst%3DS.%26atitle%3DControl%2520of%2520Regulatory%2520T%2520Cell%2520Development%2520by%2520the%2520Transcription%2520Factor%2520Foxp3%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D1057%26epage%3D1061%26doi%3D10.1126%2Fscience.1079490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatti, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brindle, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Two Histone/Protein Acetyltransferases, CBP and P300, Are Indispensable for Foxp3+ T-Regulatory Cell Development and Function</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">3993</span><span class="NLM_x">–</span> <span class="NLM_lpage">4007</span><span class="refDoi"> DOI: 10.1128/MCB.00919-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=10.1128%2FMCB.00919-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=25154413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCqtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=3993-4007&author=Y.+Liuauthor=L.+Wangauthor=R.+Hanauthor=U.+H.+Beierauthor=T.+Akimovaauthor=T.+Bhattiauthor=H.+Xiaoauthor=P.+A.+Coleauthor=P.+K.+Brindleauthor=W.+W.+Hancock&title=Two+Histone%2FProtein+Acetyltransferases%2C+CBP+and+P300%2C+Are+Indispensable+for+Foxp3%2B+T-Regulatory+Cell+Development+and+Function&doi=10.1128%2FMCB.00919-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Two histone/protein acetyltransferases, CBP and p300, are indispensable for fFoxp3+ T-regulatory cell development and function</span></div><div class="casAuthors">Liu, Yujie; Wang, Liqing; Han, Rongxiang; Beier, Ulf H.; Akimova, Tatiana; Bhatti, Tricia; Xiao, Haiyan; Cole, Philip A.; Brindle, Paul K.; Hancock, Wayne W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3993-4007, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">T-regulatory (Treg) cells are important to immune homeostasis, and Treg cell deficiency or dysfunction leads to autoimmune disease.  A histone/protein acetyltransferase (HAT), p300, was recently found to be important for Treg function and stability, but further insights into the mechanisms by which p300 or other HATs affect Treg biol. are needed.  Here we show that CBP, a p300 paralog, is also important in controlling Treg function and stability.  Thus, while mice with Treg-specific deletion of CBP or p300 developed minimal autoimmune disease, the combined deletion of CBP and p300 led to fatal autoimmunity by 3 to 4 wk of age.  The effects of CBP and p300 deletion on Treg development are dose dependent and involve multiple mechanisms.  CBP and p300 cooperate with several key Treg transcription factors that act on the Foxp3 promoter to promote Foxp3 prodn.  CBP and p300 also act on the Foxp3 conserved noncoding sequence 2 (CNS2) region to maintain Treg stability in inflammatory environments by regulating pCREB function and GATA3 expression, resp.  Lastly, CBP and p300 regulate the epigenetic status and function of Foxp3.  Our findings provide insights into how HATs orchestrate multiple aspects of Treg development and function and identify overlapping but also discrete activities for p300 and CBP in control of Treg cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI1fb6sF005bVg90H21EOLACvtfcHk0lhk68FfV4m6DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCqtbzI&md5=104de0308e0127578dca578d3ea68ed3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1128%2FMCB.00919-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00919-14%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DBeier%26aufirst%3DU.%2BH.%26aulast%3DAkimova%26aufirst%3DT.%26aulast%3DBhatti%26aufirst%3DT.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DBrindle%26aufirst%3DP.%2BK.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DTwo%2520Histone%252FProtein%2520Acetyltransferases%252C%2520CBP%2520and%2520P300%252C%2520Are%2520Indispensable%2520for%2520Foxp3%252B%2520T-Regulatory%2520Cell%2520Development%2520and%2520Function%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26spage%3D3993%26epage%3D4007%26doi%3D10.1128%2FMCB.00919-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Crawford, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audia, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duplessis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasveschuk, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawadzke, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, A. G.</span><span> </span><span class="NLM_article-title">Diving Into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">5391</span><span class="NLM_x">–</span> <span class="NLM_lpage">5402</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00264</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00264" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5391-5402&author=T.+D.+Crawfordauthor=V.+Tsuiauthor=E.+M.+Flynnauthor=S.+Wangauthor=A.+M.+Taylorauthor=A.+C%C3%B4t%C3%A9author=J.+E.+Audiaauthor=M.+H.+Beresiniauthor=D.+J.+Burdickauthor=R.+T.+Cummingsauthor=L.+A.+Dakinauthor=M.+Duplessisauthor=A.+C.+Goodauthor=M.+C.+Hewittauthor=H.-R.+Huangauthor=H.+Jayaramauthor=J.+R.+Kieferauthor=Y.+Jiangauthor=J.+M.+Murrayauthor=C.+G.+Nasveschukauthor=E.+Pardoauthor=F.+Poyauthor=F.+A.+Romeroauthor=Y.+Tangauthor=J.+Wangauthor=Z.+Xuauthor=L.+E.+Zawadzkeauthor=X.+Zhuauthor=B.+K.+Albrechtauthor=S.+R.+Magnusonauthor=S.+F.+Bellonauthor=A.+G.+Cochran&title=Diving+Into+the+Water%3A+Inducible+Binding+Conformations+for+BRD4%2C+TAF1%282%29%2C+BRD9%2C+and+CECR2+Bromodomains&doi=10.1021%2Facs.jmedchem.6b00264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains</span></div><div class="casAuthors">Crawford, Terry D.; Tsui, Vickie; Flynn, E. Megan; Wang, Shumei; Taylor, Alexander M.; Cote, Alexandre; Audia, James E.; Beresini, Maureen H.; Burdick, Daniel J.; Cummings, Richard; Dakin, Les A.; Duplessis, Martin; Good, Andrew C.; Hewitt, Michael C.; Huang, Hon-Ren; Jayaram, Hariharan; Kiefer, James R.; Jiang, Ying; Murray, Jeremy; Nasveschuk, Christopher G.; Pardo, Eneida; Poy, Florence; Romero, F. Anthony; Tang, Yong; Wang, Jian; Xu, Zhaowu; Zawadzke, Laura E.; Zhu, Xiaoyu; Albrecht, Brian K.; Magnuson, Steven R.; Bellon, Steve; Cochran, Andrea G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5391-5402</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The biol. role played by non-BET bromodomains remains poorly understood, and it is therefore imperative to identify potent and highly selective inhibitors to effectively explore the biol. of individual bromodomain proteins.  A ligand-efficient nonselective bromodomain inhibitor was identified from a 6-Me pyrrolopyridone fragment.  Small hydrophobic substituents replacing the N-Me group were designed directing toward the conserved bromodomain water pocket, and two distinct binding conformations were then obsd.  The substituents either directly displaced and rearranged the conserved solvent network, as in BRD4(1) and TAF1(2), or induced a narrow hydrophobic channel adjacent to the lipophilic shelf, as in BRD9 and CECR2.  The preference of distinct substituents for individual bromodomains provided selectivity handles useful for future lead optimization efforts for selective BRD9, CECR2, and TAF1(2) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTLnuVCIKdHbVg90H21EOLACvtfcHk0ljvtPtZVNYxfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSnsbs%253D&md5=bf92e94c5fd3ee36bd8441294ca85185</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00264%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DFlynn%26aufirst%3DE.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBeresini%26aufirst%3DM.%2BH.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DHuang%26aufirst%3DH.-R.%26aulast%3DJayaram%26aufirst%3DH.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DPoy%26aufirst%3DF.%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZawadzke%26aufirst%3DL.%2BE.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DMagnuson%26aufirst%3DS.%2BR.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DCochran%26aufirst%3DA.%2BG.%26atitle%3DDiving%2520Into%2520the%2520Water%253A%2520Inducible%2520Binding%2520Conformations%2520for%2520BRD4%252C%2520TAF1%25282%2529%252C%2520BRD9%252C%2520and%2520CECR2%2520Bromodomains%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5391%26epage%3D5402%26doi%3D10.1021%2Facs.jmedchem.6b00264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehling, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaswani, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasveschuk, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantone, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neiss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Meara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, R. J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audia, J. E.</span><span> </span><span class="NLM_article-title">Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1330</span><span class="NLM_x">–</span> <span class="NLM_lpage">1339</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01882</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01882" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1330-1339&author=B.+K.+Albrechtauthor=V.+S.+Gehlingauthor=M.+C.+Hewittauthor=R.+G.+Vaswaniauthor=A.+C%C3%B4t%C3%A9author=Y.+Leblancauthor=C.+G.+Nasveschukauthor=S.+Bellonauthor=L.+Bergeronauthor=R.+Campbellauthor=N.+Cantoneauthor=M.+R.+Cooperauthor=R.+T.+Cummingsauthor=H.+Jayaramauthor=S.+Joshiauthor=J.+A.+Mertzauthor=A.+Neissauthor=E.+Normantauthor=M.+O%E2%80%99Mearaauthor=E.+Pardoauthor=F.+Poyauthor=P.+Sandyauthor=J.+Supkoauthor=R.+J.+Simsauthor=J.-C.+Harmangeauthor=A.+M.+Taylorauthor=J.+E.+Audia&title=Identification+of+a+Benzoisoxazoloazepine+Inhibitor+%28CPI-0610%29+of+the+Bromodomain+and+Extra-Terminal+%28BET%29+Family+as+a+Candidate+for+Human+Clinical+Trials&doi=10.1021%2Facs.jmedchem.5b01882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials</span></div><div class="casAuthors">Albrecht, Brian K.; Gehling, Victor S.; Hewitt, Michael C.; Vaswani, Rishi G.; Cote, Alexandre; Leblanc, Yves; Nasveschuk, Christopher G.; Bellon, Steve; Bergeron, Louise; Campbell, Robert; Cantone, Nico; Cooper, Michael R.; Cummings, Richard T.; Jayaram, Hariharan; Joshi, Shivangi; Mertz, Jennifer A.; Neiss, Adrianne; Normant, Emmanuel; O'Meara, Michael; Pardo, Eneida; Poy, Florence; Sandy, Peter; Supko, Jeffrey; Sims, Robert J.; Harmange, Jean-Christophe; Taylor, Alexander M.; Audia, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1330-1339</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In recent years, inhibition of the interaction between the bromodomain and extra-terminal domain (BET) family of chromatin adaptors and acetyl-lysine residues on chromatin has emerged as a promising approach to regulate the expression of important disease-relevant genes, including MYC, BCL-2, and NF-κB.  Here we describe the identification and characterization of a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor that attenuates BET-dependent gene expression in vivo, demonstrates antitumor efficacy in an MV-4-11 mouse xenograft model, and is currently undergoing human clin. trials for hematol. malignancies (CPI-0610).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp40qjnYl4EZLVg90H21EOLACvtfcHk0ljvtPtZVNYxfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKjs7g%253D&md5=5e1c5aab26aa58844a9f6670a7bbd78b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01882%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DLeblanc%26aufirst%3DY.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DBergeron%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DCooper%26aufirst%3DM.%2BR.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DJayaram%26aufirst%3DH.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DMertz%26aufirst%3DJ.%2BA.%26aulast%3DNeiss%26aufirst%3DA.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%26aulast%3DPardo%26aufirst%3DE.%26aulast%3DPoy%26aufirst%3DF.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DSupko%26aufirst%3DJ.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26atitle%3DIdentification%2520of%2520a%2520Benzoisoxazoloazepine%2520Inhibitor%2520%2528CPI-0610%2529%2520of%2520the%2520Bromodomain%2520and%2520Extra-Terminal%2520%2528BET%2529%2520Family%2520as%2520a%2520Candidate%2520for%2520Human%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1330%26epage%3D1339%26doi%3D10.1021%2Facs.jmedchem.5b01882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KTX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KTX','PDB','5KTX'); return false;">PDB: 5KTX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KU3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KU3','PDB','5KU3'); return false;">PDB: 5KU3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0F','PDB','5W0F'); return false;">PDB: 5W0F</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0I','PDB','5W0I'); return false;">PDB: 5W0I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0L" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0L','PDB','5W0L'); return false;">PDB: 5W0L</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0Q" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0Q','PDB','5W0Q'); return false;">PDB: 5W0Q</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0E','PDB','5W0E'); return false;">PDB: 5W0E</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VZS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VZS','PDB','5VZS'); return false;">PDB: 5VZS</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i98"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00796">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_16204"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00796">10.1021/acs.jmedchem.7b00796</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Full experimental details and characterization for all reported compounds, BromoScan data for <b>10</b> and <b>19</b>, Cerep off-target screening data for <b>19</b>, Invitrogen kinase data for <b>19</b>, ab initio torsion scan data for <b>8</b>, PK/PD data for <b>19</b>, crystallography methods for <b>3</b>-CBP, <b>8</b>-CBP, <b>17</b>-CBP, <b>10</b>-CBP, <b>19</b>-CBP, and <b>19</b>-BRD4(1) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_001.pdf">jm7b00796_si_001.pdf (1.25 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00796/suppl_file/jm7b00796_si_002.csv">jm7b00796_si_002.csv (1.98 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes for the structures of the CBP bromodomain in complex with <b>3</b>, <b>8</b>, <b>17</b>, <b>10</b>, and <b>19</b> are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0F">5W0F</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0I">5W0I</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0L">5W0L</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0Q">5W0Q</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5W0E">5W0E</a>, respectively. PDB code for the structure of the BRD4(1) in complex with <b>19</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VZS">5VZS</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00796&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-22%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00796%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00796" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679928a6a87d3c6a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
